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O.1
NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN 
PATIENTS WITH ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC): SURVIVAL AND CLINICAL ACTIVITY BY 
SUBGROUP ANALYSIS
Naiyer A. Rizvi1, Scott N. Gettinger2, Leora Horn3, Leena Gandhi4, 
David R. Spigel5, John D. Powderly6, Rebecca S. Heist7, Richard D. 
Carvajal1, David M. Jackman4, Lecia V. Sequist7, David C. Smith8, 
Philip D. Leming9, Suzanne L. Topalian10, F. Stephen Hodi4, Ma-
rio Sznol11, Christopher T. Harbison12, Georgia D. Kollia12, Julie R. 
Brahmer10, Scott J. Antonia13  
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Background: Nivolumab, a fully human IgG4 programmed 
death-1 (PD-1) immune checkpoint inhibitor antibody, has shown 
durable clinical activity in a large phase 1 trial of patients with ad-
vanced solid tumors. For NSCLC patients in this trial, we report 
overall survival (OS) by dose and histology and clinical activity of 
patient subgroups, including PD-1 ligand-1 (PD-L1) tumor status.
Methods: Previously treated patients with advanced NSCLC 
received IV nivolumab (1, 3, or 10 mg/kg) every 2 weeks for ≤96 
weeks with tumor evaluation by RECIST v1.0. Clinical activity by 
key prognostic factors was assessed. PD-L1 tumor cell membrane 
expression was measured in a cohort of available archival patient 
specimens (n=68) by a BMS/Dako immunohistochemistry assay 
(positive expression defined as ≥5% tumor cells).
Results: Across doses and histologies, NSCLC patients (N=129, 
54% with ≥3 prior therapies) had median OS (mOS) of 9.2−14.9 
months and 1- and 2-year OS rates of 32−56% and 12−45%, re-
spectively (Table). At the 3 mg/kg dose, mOS was 14.9 months; 
1- and 2-year OS rates were 56% and 45%. Objective response 
rate was 17% (22/129); median response duration was 17 months. 
Clinical activity was observed across all patient subgroups, includ-
ing <3 and ≥3 prior therapies and with/without EGFR or KRAS 
mutations. For patients with PD-L1 (+) versus (-) tumors, mOS was 7.8 
months (95% CI: 5.6, 21.7) and 10.5 months (5.2, 21.2), respectively; 
mPFS was 3.6 months (1.8, 7.5) and 1.8 months (1.7, 2.3). Grade 3−4 
treatment-related adverse events occurred in 18/129 (14%) patients; 
most common was fatigue, reported in 4/129 (3%) patients.
Conclusion: Nivolumab continues to demonstrate an encourag-
ing survival profile and clinical activity across NSCLC patient sub-
groups with a manageable safety profile. Ongoing phase 3 trials 
are evaluating nivolumab 3 mg/kg in NSCLC patients and PD-L1 as 
a potential predictor of clinical outcomes. 
Keywords: nivolumab, immunotherapy, erlotinib, chemotherapy
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PATIENT-REPORTED OUTCOMES FROM THE LUME-
LUNG 1 TRIAL: A RANDOMISED, DOUBLE-BLIND, PLA-
CEBO-CONTROLLED PHASE III STUDY IN SECOND-LINE 
ADVANCED NSCLC PATIENTS
Anders Mellemgaard1, Jean-Yves Douillard2, Silvia Novello3, Rolf Kaiser4, Sergey 
Orlov5, Maciej Krzakowski6, Joachim Von Pawel7, Maya Gottfried8, Igor Bonda-
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Martin Reck12  
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Background: Nintedanib (N) is an oral, twice-daily angiokinase 
inhibitor targeting VEGFR-1−3, PDGFR-α/β and FGFR-1−3 as well 
as RET and Flt3. LUME-Lung 1 (NCT00805194; 1199.13) is a place-
bo (Pl)-controlled Phase III trial investigating N + docetaxel (D) in 
advanced NSCLC patients after failure of first-line chemotherapy.
Methods: Stage IIIB/IV or recurrent NSCLC patients were ran-
domised to N 200 mg bid + D 75 mg/m2 q21d (n=655), or Pl + D 
(n=659). The primary endpoint was centrally reviewed PFS anal-
ysed after 714 events; the key secondary endpoint was OS anal-
ysed hierarchically after 1121 events. Patient-reported quality of life 
(QoL) was included as a secondary endpoint and assessed on Day 
1 of each 21-day treatment cycle, at the end of active treatment, 
and at the first follow-up using the EORTC (QLQ-C30/LC13) and 
EQ-5D questionnaires. Changes of ≥10 points versus baseline were 
considered clinically significant. Analyses of cough, dyspnoea and 
pain were prespecified. Time to deterioration (TTD, first 10-point 
worsening from baseline) was analysed using a stratified log-
rank test. An exploratory analysis of all subscales/items from the 
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QLQ-C30/LC13 estimated the respective HRs for TTD using a Cox 
proportional hazards model.
Results: LUME-Lung 1 showed that N + D significantly prolonged 
PFS for all patients regardless of histology versus Pl + D (3.4 vs 
2.7 months; HR 0.79, 95% CI: 0.68−0.92; p=0.0019). For patients 
with adenocarcinoma histology who progressed within 9 months 
after start of first-line treatment, OS was significantly improved in 
the N + D group (10.9 vs 7.9 months; HR 0.75, 95% CI: 0.60−0.92; 
p=0.0073). Similar results were noted for all patients with ade-
nocarcinoma (12.6 vs 10.3 months; HR 0.83, 95% CI: 0.70−0.99; 
p=0.0359), but not in the total study population (10.1 vs 9.1 months; 
HR 0.94, 95% CI: 0.83−1.05; p=0.2720). The most common CT-
CAE Grade ≥3 AEs were diarrhoea and reversible alanine and 
aspartate aminotransferase elevations. QLQ-C30/LC13 response 
rates were high (>80%) up to treatment course 24. Adding N to D 
did not influence patient-reported TTD for cough (HR 0.90, 95% 
CI: 0.77−1.05; p=0.1858), dyspnoea (HR 1.05, 95% CI: 0.91−1.20; 
p=0.5203), pain (HR 0.95, 95% CI: 0.82−1.09; p=0.4373) or global 
health status/QoL (HR 0.95, 95% CI: 0.83−1.10). However, the 
addition of N resulted in significant deterioration in scores for 
nausea and vomiting, appetite loss and diarrhoea. The results were 
similar for adenocarcinoma patients for cough (HR 0.97, 95% CI: 
0.78−1.20; p=0.7744), dyspnoea (HR 1.04, 95% CI: 0.86−1.26; 
p=0.6813) and pain (HR 0.93, 95% CI: 0.76−1.13; p=0.4785), but 
there was a trend for improved global health status/QoL (HR 
0.86, 95% CI: 0.71−1.05). For squamous cell carcinoma patients, 
there was a trend for delayed TTD for cough (HR 0.84, 95% CI: 
0.66−1.07; p=0.1561) and a maintained global health status/QoL 
(HR 0.975, 95% CI: 0.788−1.206).
Conclusion: In second-line NSCLC patients, adding N to D signifi-
cantly improved PFS in patients of all histologies and OS in patients 
with adenocarcinoma, without detrimental effects on patient-re-
ported QoL.
Keywords: advanced NSCLC, nintedanib
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Background: PT-DC and erlotinib are approved for first-line treat-
ment of NSCLC (with tyrosine kinase inhibitors [TKIs] indicated for 
patients with EGFR mutant [EGFR MT] tumors), yet there remains a 
need for therapies with improved long-term survival. Nivolumab, 
a fully human IgG4 programmed death-1 immune checkpoint 
inhibitor antibody, demonstrated encouraging safety and survival 
outcomes and an acceptable safety profile as monotherapy in pre-
treated advanced NSCLC patients. We report interim safety and 
efficacy data from a phase 1 study evaluating nivolumab in combi-
nation with PT-DC or erlotinib in chemotherapy-naïve patients with 
advanced NSCLC.
Methods: In the 4 nivolumab plus PT-DC cohorts, patients (N=56) 
were assigned by histology to receive nivolumab 10 mg/kg IV 
Q3W plus concurrent IV gemcitabine 1250 mg/m2 + cisplatin 75 
mg/m2 (squamous [sq]) or pemetrexed 500 mg/m2 + cisplatin 75 
mg/m2 (non-sq), or nivolumab 5 or 10 mg/kg IV Q3W plus IV pa-
clitaxel 200 mg/m2 + carboplatin AUC6 (any histology), with dose 
de-escalation based on dose-limiting toxicities (DLTs). PT-DC was 
given for 4 cycles with nivolumab, with nivolumab continued until 
progression/unacceptable toxicity. In the erlotinib combination 
cohort, patients with EGFR MT NSCLC (EGFR TKI naïve or pro-
gression post TKI therapy; N=21) received nivolumab 3 mg/kg IV 
Q2W + erlotinib 150 mg PO daily until progression/unacceptable 
toxicity. Objective response rate (ORR) was assessed by RECIST 1.1.
Results: No DLTs were seen during the first 6 weeks of treatment 
with nivolumab plus PT-DC. After a median follow-up of 75 weeks, 
grade 3−4 treatment-related adverse events (AEs) were reported in 
45% of patients (25−73% across arms), including fatigue and acute 
renal failure (n=3 each). Treatment-related pneumonitis (any grade) 
was reported in 7 patients; 4 patients had grade 3−4 pneumonitis, 
managed by protocol algorithm. Across arms, ORR was 33−47% 
and progressive disease as best overall response was infrequent. 
One-year OS rates were 50−87%. In the nivolumab plus erlotinib 
cohort (N=21), only 1 patient was EGFR TKI naïve. After a median 
follow-up of 71.9 weeks, treatment-related grade 3−4 AEs (5 pa-
tients) were increased AST (n=2) or ALT (n=1), weight decrease (n=1) 
and diarrhea (n=2); 4 patients discontinued due to treatment-re-
lated AEs (diarrhea [grade 3, n=2]; increased AST [grade 3, n=1]; 
nephritis [grade 2, n=1]; flushing [grade 2, n=1]). No pneumonitis 
was observed. In this erlotinib combination cohort, ORR was 19% 
and 24-wk PFS rate was 51%; median duration of response (DOR) 
was not reached (range 60.1, 72.3+ wks). Three of 20 patients with 
acquired erlotinib resistance achieved partial response (DOR 60.1, 
64.6+, 70+ wks [2 ongoing]); 9 patients had stable disease (3/9 
ongoing). One patient had an unconventional “immune-related” 
response (ongoing). The EGFR TKI-naïve patient achieved PR (DOR 
72.3+ wks [ongoing]).
Conclusion: Nivolumab plus standard PT-DC demonstrated ac-
ceptable ORR, PFS, and 1-year OS rates in chemotherapy-naïve 
pts, with a safety profile reflecting additive nivolumab and chemo-
therapy toxicities. Nivolumab plus erlotinib may provide durable 
clinical benefit and an acceptable safety profile in TKI-refractory, 
EGFR MT advanced NSCLC, supporting further evaluation of 
nivolumab and EGFR TKI combinations in this population.
Keywords: chemotherapy, erlotinib, nivolumab, immunotherapy
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PD.1 
MK-3475 (ANTI-PD-1 MONOCLONAL ANTIBODY) FOR 
NON-SMALL CELL LUNG CANCER (NSCLC): ANTITUMOR 
ACTIVITY AND ASSOCIATION WITH TUMOR PD-L1 EX-
PRESSION
Leena Gandhi1, Gregory Lubiniecki2, Ani Balmanoukian3, Rina 
Hui4, Omid Hamid3, Naiyer A. Rizvi5, Natasha Leighl6, Matthew 
Gubens7, Jonathan W. Goldman8, Kenneth Emancipator9, Marisa 
Dolled-Filhart9, Jared K. Lunceford9, Michelle Niewood2, Kevin 
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Background: MK-3475, a humanized monoclonal IgG4 antibody 
against PD-1, has demonstrated durable antitumor activity in NS-
CLC and melanoma. Preliminary data presented at the 2013 World 
Congress of Lung Cancer showed a relationship between tumor 
PD-L1 expression and overall response to MK-3475. Here, we pres-
ent updated data on tumor PD-L1 expression and its relationship 
with overall response rate (ORR), progression-free survival (PFS), 
and overall survival (OS).
Methods: In a phase I study, 38 previously treated NSCLC patients 
received MK-3475 10 mg/kg Q3W. Tumor response was assessed 
every 9 weeks by immune-related response criteria (irRC) per in-
vestigator review and by RECIST v1.1 per independent radiologic 
review. A new tumor biopsy performed within 60 days before the 
first dose of MK-3475 was required. Tumor PD-L1 expression was 
assessed by IHC. A potential cut point for PD-L1 expression was 
determined by the Youden Index from a receiver operating charac-
terstics curve developed from the investigators’ irRC assessments.
Table. Relationship between tumor PD-L1 expression and clinical activity in patients with pretreatment tumor biopsies evaluable by IHC
PD-L1 Tumor Expression N for irRC
ORR by irRC, n 
(%) [95% CI] N for RECIST
ORR by RE-
CIST, n (%) 
[95% CI]
PFS Ratea at 
6 Months 
(95% CI)
PFS Statistics
OS Rateb at 
6 Months 
(95% CI)
OS Statistics
High (score ≥ potential cut point) 9 6 (67%) [30%, 93%] 7
4 (57%) 
[18%, 90%]
67% 
(42%-100%)
Median: 
not reached
89% 
(71%-100%)
Median: 
not reached
Low (score < potential cut point 22 0 (0%) [0%, 15%] 20
1 (5%)c 
[0%, 25%]
11% 
(3%-40%)
Median: 
2.1 months
33% 
(18%-62%)
Median: 
3.9 months
HR (95% CI) for high vs low PD-L1 
expression — — — — —
0.22 
(0.07-0.67) —
0.32 
(0.10-0.99)
One-sided 
P value 
(PD-L1 association test)
— <0.001 (Fish-er’s exact test) — —
0.009 (Fisher’s 
exact test)
0.004 (Cox 
regression) —
0.024 (Cox 
regression)
aBased on investigators’ irRC as-
sessments. 
bBased on the 31 patients with 
evaluable tumor. 
cResponse was not confirmed. 
Results: Confirmed ORR for the entire cohort of 38 patients per 
investigators’ irRC assessments was 24%, median PFS was 9 weeks, 
and median OS was 51 weeks. PD-L1 IHC score was above a po-
tential cut point in 9 patients and below a potential cut point in 22 
patients; tumor was not submitted for or staining was not evaluable 
in 7 patients. Significant associations between tumor PD-L1 expres-
sion and ORR, PFS, and OS were observed (Table).  
Conclusion: Tumor PD-L1 expression levels were associated with 
tumor response, PFS, and OS in patients with NSCLC treated with 
MK-3475. The preliminary finding of minimal anti-tumor activity 
in patients whose tumors express low levels of PD-L1 suggests that 
PD-L1 is an important biomarker for patients with NSCLC treated 
with MK-3475.
Keywords: MK-3475, immunotherapy, PD-1, PD-L1
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PD.2 
COMBINATION OF PLATINUM STANDARD FIRST FRONT 
LINE CHEMOTHERAPY AND VAXIRA VACCINE IN PA-
TIENTS WITH ADVANCED NON- SMALL- CELL LUNG 
CANCER
Amparo Macias1, Darien Toledo1, Frank Aguirre2, Eduardo Santi-
esteban2, Xitlally Popa1, Ana Maria Vazquez1, Maurenis Hernandez1, 
Zaima Mazorra1, Roberto Eduardo Gómez3, Tania Crombet1  
1Center Of Molecular Immunology, Havana/CUBA, 2Jose Ramón Tabranes Hos-
pital, Oncology Unit, Matanzas/CUBA, 3Elea Laboratories, Medical Direction, 
Buenos Aires/ARGENTINA
Background: The combination of vaccines and chemotherapy 
holds promise for cancer therapy, but the effect of cytotoxic che-
motherapy on vaccine-induced antitumor immunity is unknown. 
Vaxira is a therapeutic vaccine that induces an immune response 
against Neu- Gc containing gangliosides sulfatides and others 
antigens expressed in several tumors. Vaxira is composed by Ra-
cotumomab and aluminum hydroxide as adyuvant. Racotumomab 
is an antiidiotype murine monoclonal antibody specific to P3 Ab1 
MAb, an antibody which reacts to NeuGc-containing ganglio-
sides, sulfatides and other antigens expressed in tumors. Phase I 
trials conducted in patients with advanced melanoma, breast and 
lung cancer have demonstrated the low toxicity and high immuno-
genicity of Vaxira.
Methods: An exploratory phase I study was conducted to assess 
the feasibility of combining Vaxira vaccine with the standard first 
line chemotherapy used in advanced NSCLC patients and de-
termine the effect on Racotumomab-specific humoral immune 
responses. Twenty patients with histological confirmed NSCLC 
stages IIIB/IV were treated with cisplatin/vinblastine as standard 
first front line therapy according the treatment established in the 
Oncology Therapeutic Guidelines. Vaccination schedule consist-
ed in the administration of 1mg of Racotumomab by intradermic 
route. The first 5 doses were administered every 14 days concom-
itantly with the first line chemotherapy and the rest every 28 days. 
Vaccination was not interrupted due to disease progression, and 
continued until death or deterioration of PS. Humoral immune 
responses against Racotumomab anti-idiotype and NeuGcGM3 
antigen were measured by standard ELISA assays, and changes in 
lymphocyte cells subpopulations were measured by flow cytome-
try analyses (FACS).
Results: The distribution by clinical stage at inclusion was: 8 in 
stage IIIB, 12 in stage IV. The combination (CT plus vaccine) re-
sponses were evaluated according the RECIST Criteria, and 19 
patient achieved control disease. The 20 patients were included in 
an evaluation of survival (Kaplan Meier estimate), after a follow up 
of at least 10 months. Median survival was 12.94 months. The com-
bination was safe since the vaccination did not add toxic effects to 
the first lines of oncospecific therapy. All patients developed high 
antibody responses against Racotumomab MAb during the vacci-
nation schedule. IgM and IgG antibody specific response against 
NeuGcGM3 antigen was obtained, as in the standard not con-
comitant vaccination schedule used in other clinical trial protocols. 
Moreover, an early onset kinetics IgG isotype antibody response 
specifically for NeuGcGM3 was detected
Conclusion: The combination of Vaxira vaccine and systemic 
platinum chemotherapy has an acceptable safety profile. The 
present data suggest that chemotherapy does not inhibit Vaxira 
vaccine-mediated immune response and provide further support 
for evaluating novel combinations of chemotherapy and Vaxira 
vaccine for NSCLC and other cancers.
Keyword: NCLC Immunotheraphy Racotumomab Vaxira
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ANTIANGIOGENIC-SPECIFIC ADVERSE EVENTS (AES) IN 
PATIENTS WITH NON-SMALL CELL LUNG CANCER (NS-
CLC) TREATED WITH NINTEDANIB (N) AND DOCETAXEL 
(D)
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Background: Antiangiogenic treatments, including monoclonal 
antibodies and TKIs, have shown activity in tumours; however, their 
use is limited in part by their characteristic side effects (eg, bleed-
ing, thrombosis, perforation, cutaneous serious skin reactions, 
hypertension). N is an oral, twice-daily, triple angiokinase inhibi-
tor. Here we extend our investigation of the LUME-Lung 1 study 
(NCT00805194; 1199.13) and evaluate whether adding N to stan-
dard 2nd-line D increases the frequency of characteristic AEs often 
associated with antiangiogenic agents versus placebo (PI) + D.
Methods: LUME-Lung 1, a randomised, PI-controlled Phase III 
trial investigating N + D in patients with advanced NSCLC after 
failure of 1st-line chemotherapy, demonstrated significant PFS im-
provement regardless of histology and showed significant survival 
improvement for patients with adenocarcinoma (Ad) histology. 
The incidence and intensity of antiangiogenic-associated AEs 
according to the common terminology criteria for AEs (CTCAE 
version 3.0) were evaluated in all patients who received at least one 
dose of N, D or Pl. AEs were also categorised into special search 
categories by pooling Medical Dictionary for Regulatory Activities 
preferred terms using standardised queries and individually tailored 
searches.
Results: AEs linked to VEGF inhibition that were more frequent in 
the N vs Pl arm were bleeding (all grades: 14.1% vs 11.6%; grade ≥3: 
2.3% vs 1.8%), serious skin reactions (all grades: 13.0% vs 10.7%; 
grade ≥3: 0.8% vs 0.5%), hypertension (all grades: 3.5% vs 0.9%; 
grade ≥3: 0.6% vs 0.2%) and venous thromboembolism (all grades: 
2.8% vs 1.5%; grade ≥3: 1.2% vs 1.1%). Regarding histologic differ-
ences, more frequent bleeding was reported for N-treated squa-
mous cell carcinoma (SCC) (all grades: 17.1% vs 10.8%; grade ≥3: 
2.9% vs 2.5%) than for Ad patients (all grades: 10.9% vs 11.1%; grade 
≥3: 1.3% vs 1.5%). Conversely, more frequent venous thromboem-
bolism was reported for N-treated Ad (all grades: 2.8% vs 1.2%; 
grade ≥3: 0.9% vs 0.6%) than for SCC patients (all grades: 2.2% 
vs 2.2%; grade ≥3: 1.1% vs 1.8%). Fatal bleeding events and perfo-
rations occurred at a low frequency and were balanced between 
both arms regardless of histology.
Conclusion: We demonstrated that adding N to standard 2nd-
line D for NSCLC therapy did not greatly increase the frequency 
of characteristic AEs associated with antiangiogenic agents. The 
nature, frequency and severity of AEs were consistent with the 
underlying disease of NSCLC, concomitant chemotherapy with 
D and expected AEs of N. The antiangiogenic AE profile of N 
appears less pronounced than what has been described for other 
antiangiogenic therapies in NSCLC.
Keywords: docetaxel, NSCLC, nintedanib
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GENOMIC PROFILING BY FOUNDATIONONE OF 724 
LUNG ADENOCARCINOMA CASES REVEALS A HIGH 
FREQUENCY OF CLINICAL RELEVANT GENOMIC ALTER-
ATIONS
Siraj Mahamed Ali, Roman Yelensky, Doron Lipson, Geoff Otto, 
Geneva Young, Jie He, Paulo Campregher, Jeffrey Ross, Norma 
Palma, Phillip J Stephens, Gary A Palmer, Vincent Alan Milller  
Foundation Medicine, Inc., Cambridge/UNITED STATES OF AMERICA
Background: For the management of metastatic or relapsed lung 
non-small cell carcinoma (NSCLC), particularly lung adenocar-
cinoma (LA), rational treatment targeted therapy as guided by 
genomic characterization has resulted in improved outcomes for 
patient. As such, ALK-rearranged NSCLC is a developing paradigm 
for precision oncology. To further explore the distribution of clin-
ically relevant genomic alterations in NSCLC, genomic profiling 
via a clinical next-generation sequencing assay was performed 
on 1070 cases, and ALK rearranged cases were characterized for 
prior diagnostic testing and outcomes. For the management of 
metastatic or relapsed lung non-small cell carcinoma (NSCLC), 
particularly lung adenocarcinoma (LA), rational treatment targeted 
therapy as guided by genomic characterization has resulted in im-
proved outcomes for patient. As such, ALK-rearranged NSCLC is 
a developing paradigm for precision oncology. To further explore 
the distribution of clinically relevant genomic alterations in NSCLC, 
genomic profiling via a clinical next-generation sequencing assay 
was performed on 1070 cases, and ALK rearranged cases were 
characterized for prior diagnostic testing and outcomes.
Methods: Hybridization capture of all exons of 236 cancer-relat-
ed genes and 47 introns of 19 commonly-rearranged genes was 
applied to ≥50ng of DNA extracted from 1070 recent consecutive 
clinical FFPE NSCLC specimens and sequenced to a median depth 
of >500x. Specialized algorithms were applied to identify driver 
alterations including base substitutions, short insertions and de-
letions, copy-number alterations and genomic rearrangements at 
low mutant allele frequencies.
Results: Of NSCLC cases, 724/1070 (68%) were LA, and within 
these LA cases, alterations were identified in over 150 genes, 
including the common alterations of KRAS (28%), EGFR (23%), 
CDKN2A (20%), and STK11 (14%). Additional clinically relevant 
alterations occurred in ERBB2 (8%, composed of 5% amplifications 
and 3% short variants), MDM2 (7%), NF1 (6%), PIK3CA (5%), BRAF 
(5%), and MET (3%). Known and novel fusion events were identified 
in 10% of LA cases, including in ALK (5%), RET (3%), and ROS1 (2%). 
47 NSCLC cases harbored ALK rearrangements (4.4%); including 
lung adenocarcinomas (n=39/724), NSCLC (n=4/146), adenos-
quamous carcinomas (n=2/12), and mucoepidermoid and large 
cell neuroendocrine carcinomas (n=1/3 and n=1/23). Six cases 
harbored non-EML4 5’ fusion partners, and the remainder were 
EML4-ALK fusions. Of the 28 ALK rearranged cases previously 
tested by ALK FISH, 9 (32%) were negative on ALK FISH, and 19 
were positive. Of the 9 cases negative by FISH, 5 patients respond-
ed to crizotinib by investigator assessment, 2 patients did not, and 
the response data for the remaining 2 patients is unavailable. Of 
the 19 cases positive by FISH, 6 responded to crizotinib, and the 
response data for the remaining 13 patients is unavailable.
Conclusion: FoundationOne genomic profiling of LA cases un-
covered a high frequency of clinically relevant alterations that can 
inform targeted treatment decisions. Genomic profiling also iden-
tified NSCLC cases previously testing negative by FISH which also 
responded to crizotinib. 
Keyword: nslc, genomics, ALK, adenocarcinoma
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FACTORES PREDICTIVOS DE DESARROLLO DE METáSTA-
SIS CEREBRALES EN CáNCER DE PULMóN NO CéLULAS 
PEQUEñAS (NSCLC)
Eduardo Richardet, Maria Eugenia Pacher, Matias Cortes, Matias 
Molina, Romina Brombin, Aldo Riso, Pablo Companys, Patricia 
Hernandez, Luciana Acosta, Eduardo Cuestas, Martin Richardet 
Ionc, Cordoba, Cordoba/ARGENTINA
Background: Las metástasis cerebrales están presentes en 10 a 
30% de los pacientes con NSCLC en algún momento de la en-
fermedad. El objetivo de nuestra investigación es identificar las 
características clínico patológicas en pacientes con estadio IIIB -IV 
relacionados con el desarrollo de metástasis cerebrales.
Methods: Entre el 2000 y 2013 se analizaron en nuestro centro 
590 pacientes con NSCLC, de los cuales 190 (32,3%) eran EIIIB y 
400 (67,7%) EIV. Las variables incluidas en el análisis fueron: sexo, 
edad, histología, tabaquismo y ECOG. Se utilizó el modelo de 
regresión logística multivariado para identificar los factores rela-
cionados con las metástasis cerebrales.
Results: De la totalidad de pacientes el 12,8% (n:76) presentaron 
metástasis cerebrales. La incidencia de metástasis cerebral fue 
mayor en los hombres que en mujeres (77,7% vs 22,2%). Más 
del 80% de los pacientes presentó ECOG entre 0-1. En cuanto 
a la histología, 60.32% eran adenocarcinomas; 30% carcinomas 
escamosos, y un 9,5% carcinomas no diferenciados. 65% de los 
pacientes eran menores de 65 años de edad y 66,6% no tabaquis-
tas. En los menores de 65 años de edad se encontró mayor riesgo 
de desarrollar metástasis cerebral (HR = 0,5-IC95% = 0,6-1,16 - p 
= 0.045). La histología de adenocarcinoma se asoció con mayor 
presencia de metástasis cerebrales (OR = 2,42 - IC 95% = 1,84 a 
3,00 - p = 0.003).
Conclusion: En este estudio se observó, un porcentaje de MTS 
cerebrales del 12,8%( inferior a otras series mundiales), teniendo 
los pacientes menores de 65 años, adenocarcinoma mayor riesgo 
de desarrollar metástasis cerebrales. En relación al sexo, predo-
mina en hombres, no siendo estadísticamente significativas, con-
tradictoriamente a lo presentado por Shin Hsin Hsiao en la revista 
Lung Cancer en 2013.
Keyword: lung cancer, brain metastases
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RADIATION DOSE RESPONSE AND CLINICAL OUTCOMES 
WITH TRIMODALITY THERAPY FOR STAGE IIIA NON-
SMALL CELL LUNG CANCER
Kenneth Merrell1, Christopher Seder2, Benjamin Mou1, Zachary 
Wilson1, Christopher Hallemeier1, Kenneth Olivier1, Dennis Wigle2, 
Yolanda Garces1  
1Mayo Clinic, Radiation Oncology, Rochester/UNITED STATES OF AMERICA, 
2Mayo Clinic, Division Of Cardiovascular And Thoracic Surgery, Rochester/UNIT-
ED STATES OF AMERICA
Background: Trimodality therapy with neoadjuvant chemoradi-
ation (CRT) and surgery for stage IIIA non-small cell lung cancer 
(NSCLC) improves progression free survival. The optimal neoad-
juvant radiotherapy (RT) dose is not clearly defined. Our periop-
erative morbidity and mortality results for doses above and below 
45 Gy have been previously published. Here we present RT dose 
response and clinical outcomes.
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Methods: We reviewed 50 consecutive patients with stage IIIA 
NSCLC who underwent neoadjuvant CRT followed by surgery at 
our institution between March 1999 and June 2011. Patients were 
divided into two cohorts: group 1= RT dose < 50.4 Gy (n=25) and 
group 2=RT dose ≥ 50.4 Gy (n=25). All patients received primary 
tumor and involved mediastinal RT with platinum based concurrent 
chemotherapy. All patients underwent curative intent surgery with-
in four months of completion of CRT. Resection type was single 
lobectomy (n=38), bilobectomy (n=7), left pneumonectomy (n=2), 
right pneumonectomy (n=1), and wedge resection (n=2) with medi-
astinal sampling in all patients. Overall survival (OS), locoregional 
control (LRC) and metastasis free survival (MFS) was estimated us-
ing the Kaplan-Meier method. Univariate and multivariate analysis 
(MVA) were performed using Cox proportional hazards regression.
Results: Median patient age was 60.5 years (range, 40-76). Me-
dian follow-up was 3.0 years (range, 0.6-13). Median RT doses for 
groups 1 and 2 were 45 Gy (range, 45-50.4) and 60 Gy (range, 
59.4-70.2 Gy), respectively delivered in 1.8 to 2.0 Gy fractions. 
Median survival was 36, 42, and 30 months for all patients, group 1 
and group 2, respectively. Three- and 5-year OS was 54% and 46% 
for group 1, and 45% and 36% for group 2 (p=0.53). Rates of ypN0 
were similar between the groups (group 1=56%, group 2=48%; 
p=0.31). Five-year OS was improved with complete nodal response 
(ypN0=58% vs. ypN1-2=22%; p=0.052). One- and 3-year LRC 
was 91% and 81% for group 1, and 100% and 83% for group 2 
(p=0.73). One- and 3-year MFS was 77% and 47% for group 1 and 
76% and 44% for group 2 (p=0.49). Predictors of OS using MVA 
include ECOG PS <1 (p=0.003, HR 0.21, 95% CI 0.07-0.58) and 
complete mediastinal lymph node response (p=0.012, HR=0.29, 
95% CI 0.1-0.76).
Conclusion: Our results show similar rates of LC, OS and patho-
logic nodal response with dose above and below 50.4 Gy. Consis-
tent with previous studies, complete nodal response is associated 
with improved OS. Further studies are warranted to identify the 
optimal RT dose for trimodality therapy.
Keywords: non-small cell lung cancer, Trimodality therapy
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PALLIATIVE THERAPEUTIC OPTION IN ADVANCED NSCLC
Rodica Anghel, Irina Isacu, Alin Tarlea, Xenia Bacinschi  
Institute Of Oncology, Bucharest/ROMANIA
Background: Patients with inoperable non-small cell lung cancer 
previously treated by external beam radiation therapy have a poor 
prognosis if endobronchial obstruction persists or relapses. The 
therapeutic options are limited to controlling symptoms (dyspnea, 
cough, hemoptysia) and maintaining their quality of life. We evalu-
ated endobronchial brachytherapy as palliative treatment for these 
patients.
Methods: Between January 2009 and June 2013, 63 patients with 
stage IIIB NSCLC treated in the Radiation Therapy Department 
of the Oncological Institute of Bucharest, Romania, have been 
administered endobronchial brachytherapy for symptoms pallia-
tion. All the patients previously underwent external beam radiation 
therapy. These patients, which experienced obstructive symptoms 
and hemoptysia, were referred to brachytherapy. Endobronchial 
irradiation consisted in 2 fractions of 7.5 Gy days 1 and 8 and has 
been delivered using remote HDR afterloading brachytherapy with 
Iridium-192. The patients were evaluated prior to therapy, after 
brachytherapy, and every 2 months thereafter. The evaluation 
consisted in complete clinical examination, bronchoscopy and 
quality of life QLQ-C30 questionare, for efficacy, adverse events 
and survival follow-up.
Results: Bronchial obstruction and consequently dyspnea was 
significantly improved in 51 patients (81%) and hemoptysia dimin-
ished in 59 cases (93.6%). Quality of life was improved in 55 cases 
(87.3%). Symptoms improvement lasted for at least 3 months in 31 
cases and at least 6 months in 10 cases. The median survival for the 
entire group was 6 months from the beginning of therapy. Acute 
toxicities were mucositis, and mild hemoptysia. Grade 3-4 compli-
cations occurred in 8 patients (12.7%).
Conclusion: Endobronchial brachytherapy is a therapeutic option 
able to palliate symptoms caused by endobronchial obstruction 
with acceptable toxicity but no overall survival benefit.
Keywords: endobronchial brachytherapy, endobronchyal ob-
struction, paliative treatment
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ICOTINIB AND ICOGEN - AN INTRODUCTION TO THE 
LATIN AMERICAN ONCOLOGY COMMUNITY
Victoria Lynn Wilde, Michael Costanzo, Michael Green, Michael 
Greco, Don Zhang, Jirong Peng  
Beta Pharma, Inc, Research & Development, Princeton/UNITED STATES OF 
AMERICA
Background: Icotinib is a highly selective, first generation epider-
mal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for 
the treatment of non-Small Cell lunch cancer (NSCLC). Originally 
discovered in 2003 in the United States, icotinib completed its 
well-designed and cost-effective clinical development in China. 
Methods: In 2008, in a first of its kind, head-to-head EGFR-TKI 
clinical trial, icotinib was tested versus gefitinib in a randomized, 
double-blind, phase III non-inferiority study (ICOGEN). Patients 
received icotinib, administered orally, at 125 mg three times daily 
or gefitinib, administered orally, at 250 mg once daily, until disease 
progression or unacceptable toxicity. EGFR mutation status of 
patients was not determined prior to study and analysis was per-
formed retrospectively.
Results: From 27 centers in China, 417 NSCLC patients were re-
cruited for eligibility assessment and 399 patients were enrolled 
in the study and randomized to receive either icotinib or gefitinib. 
With a median progression-free survival (PFS) of icotinib of 4.6 
months (95% CI 3.5-6.3) versus gefitinib at 3.4 months (2.3-3.8), 
icotinib was deemed to be non-inferior to gefitinib in terms of PFS. 
Upon post-hoc analysis, the Kaplin-Meier curves showed that 
patients with EGFR mutations showed significant difference in PFS 
than those with the wild-type EGFR. Icotinib was associated with 
fewer adverse events than gefitinib when taking all grade events 
together (61% versus 70%, p = 0.046).
Conclusion: ICOGEN showed that icotinib was non-inferior to 
gefitinib in terms of progression-free survival, overall survival and 
tumor response rate. Upon successful completion of the ICOGEN 
phase III clinical trial, icotinib received marketing approval from the 
CFDA in June 2011. The Phase IV, ISAFE trial, evaluated 5,549 pa-
tients and showed icotinib has an overall response rate of 30% and 
a low adverse event rate of 31.5%. In the three years that icotinib 
has been prescribed in China, over 40,000 patients have received 
treatment. Icotinib is currently under worldwide development, with 
plans to expand to the Latin American clinic in the near future.
Keywords: EGFR, NSCLC, first-generation, Lung
 
LALCA 2014 Abstracts Journal of Thoracic Oncology   •  Volume 9, Number 9, Supplement 3, September 2014
S158 Copyright © 2014 by the International Association for the Study of Lung Cancer
LAL A 2014 Abstracts Journal of Thoracic ncolo y  •  Volu e 8, er , l  ,  
 
POSTER SESSION 1  
FRIDAY, AUGUST 22, 2014
DISPLAY TIME: 09:00 − 18:00
AUTHOR STAND BY TIME: 11:00 − 11:30 
AND 16:15 − 16:45 (NETWORKING BREAKS)
POSTER SESSION 1 - August 22, 2014 09:00-18:00 
Topic: Prevention, Early Detection, Epidemiology and Tobacco Control
P1.01
NON- SMALL CELL LUNG CANCER EPIDEMIOLOGY IN 
COSTA RICAN TERTIARY LEVEL HOSPITALS.
John E. Miranda1, Astrid Martinez2  
1Universidad De Costa Rica-Ccss, Thoracic Surgery, San José/COSTA RICA, 2Caja 
Costarricense Del Seguro Social, San Jose/COSTA RICA
Background: Lung Cancer is the most common cause of death by 
cancer around the World. Even though the Costa Rican national 
health system acknowledges the importance of the subject, the 
current National Registry of Tumors is not updated and therefore 
does not provide a database with complete information about the 
patients being diagnosed and treated for this disease. The aim of 
this study is to analyze and update the epidemiologic information 
of lung cancer in Costa Rica 
Methods: This is a retrospective, observational study in adult 
patients (≥ 18 years) with a positive biopsy for non-small cell lung 
cancer (NSCLC), from January 2006 to December 2010, who were 
diagnosed at the three main tertiary care hospitals from the Social 
Security System in Costa Rica, where most cases of NSCLC are 
treated. The information was extracted from the medical records of 
patients with the histopathological diagnosis of lung cancer. Those 
patients with incomplete data were excluded from the study, as 
well as those individuals with recurrent cancer prior to the begin-
ning of the study.
Results: A total of 304 patients were identified with a positive 
biopsy for lung cancer, from which 182 (n) had NSCLC. The median 
age of diagnosis was 66 years (26-89 years) and 66.8%(120) were 
male. A total of 120 patients (66.8%) were known smokers, with a 
median consumption of 49 pack/year. Adenocarcinoma was the 
most common histological diagnosis with 65% (119) of the cases, 
followed by Squamous 24% (44) and Indeterminate 7% (12). In only 
67% (122) of the cases the TNM classification was used correctly. 
Most of the patients were diagnosed with advanced stage disease, 
being stage IV the most common, in 53% of the cases (65/122). 
The median time elapsed between the first appointment with a 
thorax Physician and the diagnosis was of 17 days (2-585) and the 
median time elapsed between the diagnosis and the beginning of 
treatment was 11 days (0-272). By the end of this study 79% of the 
patient had died, with a median survival time after the diagnosis of 
148 days.
Conclusion: Epidemiologic characteristics of NSCLC patients in 
Costa Rica are similar to those reported in the medical literature. 
Most patients diagnosed had advanced stage disease, which im-
pacts directly in the survival time.
Keywords: Lung Cancer, Epidemiology
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ACCESS TO EGFR TESTING AT THE BRAZILIAN NATIONAL 
CANCER INSTITUTE (INCA): IMPACT OF THE REFLEX TEST-
ING STRATEGY
Tatiane Montella1, Pedro Masson Domingues1, Mauro Zukin2, Clar-
issa Serodio Baldotto2, Carlos Gil Ferreira1  
1Brazilian National Cancer Institute (Inca), Clinical Research Department, Rio De 
Janeiro/BRAZIL, 2Brazilian National Cancer Institute (Inca), Rio De Janeiro/BRAZIL
Results: From May 2011 to Dec 2013, 248 samples (74%) out of 
336 eligible patients (advanced non-squamous NSCLC) were 
screened for EGFR mutations. In the first year after the implemen-
tation of EGFR testing only 40% of the recommended patients 
were tested. This number has increased in the last 3 months of 
2013 to up to 85% EGFR tested patients. Of all tested patients (248 
cases), 55% were women and 27% were never smokers or light 
smokers. Most patients had adenocarcinoma (95%). Results were 
obtained from cytological specimen in 53 cases (21%). Sanger 
sequencing was performed in the majority of patients (81%). EGFR 
mutations were detected in 66 patients (27%). The incidence of 
mutations was higher in females (67%) and never/light smokers 
(47%). Thirty-nine patients (59%) harbored typical mutations with 
known clinical significance. Of those, 24 (61%) were in-frame de-
letions in exon 19, 9 (23%) were exon 21 L858R, 5 (13%) were exon 
20 insertions and only 1 (3%) was exon 18 G719A. We found a high 
incidence of atypical mutations of unknown clinical significance 
(27 cases, 11%). All of them were single amino acid substitutions. 
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Conclusion: This study showed an increasing implementation of 
the EGFR test at low-income country institution in the last 3 years. 
The results allowed the access to EGFR tyrosine kinase inhibitors in 
mutant patients. Furthermore, it demonstrates the feasibility and 
potential for the non-clinical selective approach. The higher fre-
quency of atypical mutations might be related to the poor quality 
biopsy material, and highlights that there are still some challenges 
to overcome in personalized medicine at Latin America countries.
Keywords: EGFR, reflex testing, advanced NSCLC, Epidemiology
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A TARGETED LITERATURE REVIEW ON ALK+ NON-SMALL 
CELL LUNG CANCER (NSCLC) EPIDEMIOLOGY, DIAGNOS-
TICS, AND ECONOMIC OUTCOMES RELEVANT TO LATIN 
AMERICA
Sanjeev Balu1, Lucía Seseña Carrillo2, Caroline Solon2, Sarah For-
man2, Oscar Camacho3, Sandeep Duttagupta2, Francesca Ange-
letti1, Rachel Beckerman2  
1Novartis Pharmaceuticals, Global Oncology, Lacan, East Hanover/UNITED 
STATES OF AMERICA, 2Cb Partners, New York/UNITED STATES OF AMERICA, 
3Novartis Pharmaceuticals, Mexico City/MEXICO
Background: There exists limited data on the epidemiology, di-
agnostics, treatment patterns, guidelines, economic burden, and 
quality of life (QoL) among patients with NSCLC and anaplastic 
lymphoma kinase (ALK)+ NSCLC, particularly in Latin America. 
The objective of this study was to perform a pragmatic literature 
review to obtain information on NSCLC and ALK+ NSCLC over the 
last 5 years in the Latin American region. 
Methods: A targeted literature search strategy was adopted. A 
bibliographic review of the literature covering all full publications/
abstracts in English, Spanish, and Portuguese languages in bio-
medical journals, scientific congresses, and publicly available data-
bases between 2009 and 2014 was conducted. The search strat-
egy included a combination of key words including ‘NSCLC’ and 
‘ALK+’ and ‘treatment’ or ‘guidelines’ or ‘diagnostics’ or ‘economic 
burden’ or ‘QoL’ in titles/abstracts. An initial search was limited to 
ALK+ NSCLC from the Latin American perspective; when no arti-
cles were retrieved, the search was broadened to all NSCLC and 
other regions. A total of 34 citations were identified and reviewed. 
The major findings are summarized and presented under several 
categories: economic burden, epidemiology and treatment guide-
lines, diagnostics, and QoL.
Results: Economic burden: There were no studies reporting on 
the economics/economic burden of ALK+ NSCLC and within Latin 
America. Seven studies were retrieved based out of the expanded 
search. Lifetime healthcare expenditures for adenocarcinoma were 
found to be US$36,771 ± 1,998 for 2012 in one study. In another, 
therapies (docetaxel, pemetrexed, and erlotinib) were estimated 
to be cost-effective/cost-saving second-line therapies compared 
with best supportive care. Epidemiology and treatment guide-
lines: Out of the 7 reviewed studies, within Latin America, two-
thirds of lung cancer patients were found to be men. Among Latin 
American women, the number of cases of lung cancer was likely 
to double in 20 years. The prevalence of lung cancer was found 
to be 13.43/100,000 people in Colombia, 21.82/100,000 people 
in Chile, 22.58/100,000 people in Brazil, 35.77/100,000 people 
in Argentina, and 9.72/100,000 people in Mexico. Diagnostics: 
Overall 10 articles were reviewed. No Latin American study was 
retrieved. The reviewed studies highlighted the challenges in ALK 
testing, including approaches to select target patients for the test, 
and issues related to ALK inhibitor resistance monitoring. QoL: 
Overall 10 articles were reviewed. The EORTC QLQ C-30 and 
EQ-5D were commonly used instruments to assess QoL. Fatigue 
(100%), loss of appetite (97%), shortness of breath (95%), cough 
(93%), and pain (92%) were some of the common symptoms. An-
other study indicated a significant impact on patients’ HRQOL 
resulting in a huge deterioration in utility scores. In another study, 
depression and anxiety were found in one-third of NSCLC patients 
and were associated with decreased HRQoL scores.
Conclusion: There was very limited data on epidemiology and 
QoL among NSCLC and ALK+ NSCLC patients within Latin Amer-
ica and no study reporting on the economic burden, guidelines, 
and diagnostics within the region. Further studies, both clinical as 
well as real-world, are warranted to establish local data within the 
region to enable decision makers with more information on future 
treatments for NSCLC and ALK+ NSCLC.
Keywords: ALK+, NSCLC, Guidelines, Epidemiology
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ETHNIC DIFFERENCES IN NON-SMALL CELL LUNG CAN-
CER (NSCLC) GENETICS.
Luis E Raez1, Jennifer Mourafetis1, Neil Abrahams1, Brian Hunis1, 
Candice Sareli1, Evelio Velis2, Mark Block1, Francisco Tarrazzi1, Dina 
Dumercy1  
1Memorial Cancer Institute, Pembroke Pines/UNITED STATES OF AMERICA, 
2Barry University, Department Of Statistics, Fort Lauderdale/UNITED STATES OF 
AMERICA
Background: Recent research has identified mutations and trans-
locations in several different genes in non-small cell lung cancer 
(NSCLC). Some of these mutations are more common in cancers 
from Asian patients than in cancers from Non-Hispanic Whites 
(NHW). We investigated if differences also exist in the profile of 
genetic mutations and translocations (EGFR, ALK, ROS-1, etc) in 
NSCLC from minority patients compared to NHW. 
Methods: Charts were reviewed for 182 pts diagnosed with 
metastatic NSCLC at Memorial Healthcare System. Results from 
molecular marker (MM) testing obtained as part of their routine 
care were recorded. The MM panels were expanded recently, so 
all markers were not available for all patients. For statistical analysis 
patients were divided into groups based on recorded ethnic back-
ground. Chi-square and Fisher’s Exact tests were used to assess 
significant associations between genetic profile and ethnicity. All 
summary statistics on time-to-event variables were calculated 
according to the Kaplan-Meier method and were compared by 
means of the log-rank test. Survival curves were constructed for 
each of the tumor stages. Adjusted hazard ratios (AHR) and 95% 
confidence intervals (95% CI) were reported based on the results 
of a multivariate Cox regression model for overall survival (OS) with 
adjustment for gender, age at diagnosis, and race. A p value 0.05 
was considered significant. SPSS® software 21 was used for statisti-
cal analyses.
Results: MM testing was requested for 182 patients and samples 
were sufficient to obtain results in 161 (88%). Of these patients, 36% 
were Hispanics (H), 58% were women and 7% were African-Amer-
ican (AA). 90% had adenocarcinoma and 83% were smokers. ALK 
translocation was present in 5% (6/125) of the patients, c-MET in 
15% (6/40), EGFR mutations [exons 19 and 21] in 25% (38/153), 
EGFR resistant mutations [exon 20] in 2% (3/153), KRAS 15% 
(17/111), ROS1 7% (3/45) and BRAF 5% (2/38). There was a signifi-
cant association (p<0.05) between smoking status and being NHW 
vs. AA; and being female vs. male. There were no significant differ-
ences in the proportions of patients in each ethnic group with each 
mutation tested. The absence of statistical significance may reflect 
a type I error due to relatively small sample size. Our rates of EGFR 
mutations are higher than usually reported as we are a referral 
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center for lung cancer.
Conclusion: These results did not demonstrate significant differ-
ences in gene expression profiles between minority patients and 
NHW presenting with lung cancer. This result may be due to insuf-
ficient sample size, so a prospective analysis is planned to obtain a 
larger data set for testing.
Keywords: molecular profiling, Ethnic Disparities, gene expression 
profiles, EGFR mutations
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THE ROLE OF 18F-FDG-PET/CT IN THYROID CANCER
Kostas Nikolaos Syrigos, Theodora Liotsou, Sophia Tsagouli, Lina 
Skoura, S Chatzioannou, G Datseris  
Sotiria General Hospital, Athens School Of Medicine, Oncology Unit Gpp,  
Athens/GREECE
Background: Differentiated Thyroid Cancer (DTC) is the most 
frequent endocrine cancer representing 1% of malignant tumors. 
Most DTCs have an exceptional prognosis if combined with early 
diagnosis and appropriate treatment, while aggressive histological 
subtypes and variants hold a worse prognosis. The aim of interna-
tional papers researched is to identify sensitivity and specificity of 
18F-Fluorodeoxyglucose-Positron Emission Tomography/ Comput-
erized Tomography (18F-FDG-PET/CT) in thyroid cancer (TC). 
Methods: Methods detecting TC in early stages and assessing 
thyroid nodules are ultrasonography (U/S), ultrasonography-guid-
ed fine-needle aspiration biopsy (USG FNA), conventional scin-
tigraphic methods (using 99mTc-pertechnetate, 99mTc-sestamibi or 
tetrofosmin), 18F-FDG-PET/CT. Once treated, a patient’s follow-up 
is necessary for several years. Ultrasonography has high sensitivity, 
whereas CT scan and magnetic resonance imaging low. The vital 
role of 18F-FDG-PET/CT is evident in patients’ improvement with 
DTC status post thyroidectomy, who present increasing thyro-
globulin (Tg) levels and a negative 131I whole-body scan (WBS). It is 
helpful in high-risk early stage patients (post thyroidectomy) with 
less differentiated, thus less iodine-avid and clinically more ag-
gressive subtypes (e.g. tall cell variant and Hürthle cell carcinoma), 
and in anaplastic carcinoma. It may define the disease’s extent in 
patients with medullary thyroid cancer (MTC) and rising postopera-
tive calcitonin levels. Nevertheless, fluoradopamine (18FDOPA) is a 
promising radiotracer.
Results: High sensitivity (up to 85%) and specificity (up to 95%) of 
18F-FDG-PET in metastatic DTC patients is reported. The integrated 
18F-FDG-PET/CT fusion imaging systems provide advantages over 
PET, related to a better anatomical localization of the hypermeta-
bolic metastatic lesions. PET’s role and PET/CT fusion imaging sys-
tems benefit patients with medullary thyroid carcinoma (MTC) and, 
as such, they have superior sensitivity to other imaging methods.
Conclusion: Dissimilar stages and histological entities of TC 
require dissimilar approaches in imaging and therapy, so the com-
bination of PET and CT was introduced. Its metabolic fusion and 
morphologic information increased diagnostic accuracy, reduced 
pitfalls and altered therapies.
Keywords: 124I imaging, negative iodine scan, thyroglobuline, 
calcitonin
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OVERALL SURVIVAL IN LUNG CANCER PATIENTS TREAT-
ED AT ONCOSALUD - AUNA.
Luis Mas1, Luis Pinillos2, Carlos Vallejos1, Claudio Jaime Flores1, 
Joseph Arturo Pinto1, Priscila Valdiviezo1, Juan Fernando Suazo1, 
Alfredo Aguilar1  
1Oncosalud -Auna, Lima/PERU, 2Radioncologia, Lima/PERU
Background: Lung cancer still remains as the principal death 
cause in many regions around the world. Unfortunately, 60 % - 
70% of patients are diagnosed in advanced. We report the overall 
survival of lung cancer patients treated at a private institution (On-
cosalud - AUNA). 
Methods: Retrospective analysis of data from lung cancer patients 
treated at Oncosalud from 2005 to 2010. Overall survival was 
determined using Kaplan- Meier method and survival curves com-
parisons were performed using the log-rank test.
Results: There were 276 evaluable patients (out of 334). Patient 
age ranged from 35 to 95 years,with a median of 69 years;56.2% 
of patients were women and44.6% were older than 70 years. More 
than 50% had an advanced stage disease. From the total group 
of patients, the 69.9% had died, the follow up median of survivors 
was 5.5 years (IC95%: 4.7 − 6.2). Overall survival median was 12.3 
months (IC95%: 9.6 − 15.0), 2 and 5 year survival rate was33.8% 
and 20.8% respectively. Overall survival presents a difference 
regarding to sex (p = 0.002) and age groups (p < 0.001). Two years 
survival rate in female patients was 45.5% and 24.8% in male. Two-
years survival rate in patients under 70 years was 38.5% and 27.7% 
in older patients.
Conclusion: Overall survival for our patients is similar to other 
series. Female patients and patients under 70 years had a relatively 
better prognostic.
Keywords: Lung Cancer, overall survival
POSTER SESSION 1 - August 22, 2014 09:00-18:00 
Topic: Prevention, Early Detection, Epidemiology and Tobacco Control
P1.08
DESIGN, IMPLEMENTATION AND PRELIMINARY RESULTS 
OF A TOBACCO CESSATION PROGRAM IN A PRIVATE 
CLINIC
José Miguel Clavero1, Nicolás Silva-Illanes2, Laura Itriago Itriago2, 
Rodrigo Gil2, Daniel Seijas2  
1Clínica Las Condes, Thoracic Surgery, Santiago/CHILE, 2Clínica Las Condes, 
Santiago/CHILE
Background: Chile faces big challenges on tobacco control. Ac-
cording to the Pan American Health Organization, around 40% of 
adult population declares smoking habits. Tobacco cessation pro-
grams have not been implemented as a national health policy. The 
aim of this study is to describe the design and preliminary results 
of a tobacco cessation program implemented in one of the largest 
private clinics in Chile. 
Methods: During 2013 a task force was established including On-
cologist, Pulmonologist, Psychiatrist, Thoracic surgeons and Epi-
demiologists. Three tobacco clinical guidelines from Spain, New 
Zealand and United Kingdom were reviewed. Recommendations 
from each clinical guideline were extracted and discussed by the 
group of specialists. Protocols and clinical pathways were designed 
taking into account the local setting.
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Results: 
A tobacco cessation program was implemented. Patient’s first 
step on the program consist in an evaluation by a nurse navigator. 
During this interview clinical information is collected and risk scor-
ing instruments are applied. After nurse interview, all patients are 
evaluated by a pulmonologist who can start treatment or derive 
the patient to the Addictions clinic. Standard treatment has three 
month extension. Treatment during this period includes face-to-
face cessation smoking support by pulmonologists and nurses, 
telephone support follow up by nurse navigators and pharmaco-
logical treatment (varenicline, bupropion or nicotine replacement 
therapy). 110 patients have been recruited in 10 month. Preliminary 
results show 52% on six month success rates. Conditional probabil-
ity of abstinence on 10 month follow up is 45% using Kaplan Meier 
statistics.
Conclusion: A tobacco cessation program in a chilean private 
clinic has had good results on quit rates at 10 month of implemen-
tation. Different coordinated interventions (pharmacological treat-
ment, face to face support and telephone support) could be good 
strategies to design programmes in similar settings. Collaborative 
work between different specialists and committed nurse navigators 
are key elements. Long term evaluation of this program is required.
Keywords: Tobacco cessation, Smoking cessation, Smoking clinic
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GENETIC VARIATION OF CHRNA3 (RS1051730) AND CHR-
NA5 (RS16969968) RECEPTORS AND THEIR ASSOCIATION 
WITH NICOTINE DEPENDENCE IN MEXICAN POPULA-
TION. 
Rebeca Perez, Esperanza Calleros  
Universidad Juárez Del Estado De Durango, Biología Molecular, Gómez Palacio/
MEXICO
Background: Smoking is a major public health problem worldwide. 
Genetic basis of susceptibility to nicotine dependence have not 
been understand. The expression and genetic variation of CHRNA3, 
CHRNA5 and CHRNAB4 receptor gene play a fundamental role in 
nicotine addiction. CHRNA3 (rs1051730) and CHRNA5 (rs16969968) 
polymorphisms are associated with the risk of developing lung 
cancer and COPD, because both diseases are closely related to 
smoking. The aims in the present work was characterize the genetic 
variation of these polymorphisms in Mexican Mestizo population 
and correlate with the level of smoking of the individuals. 
Methods: Were included 312 samples from individuals clinically 
healthy, unrelated, with parents and grandparents born in Mexico. 
The protocol was approved by the Bioethics Committee of the 
Universidad Juarez del Estado de Durango and consent informed 
was obtained of each participant. Genotyping was performed 
by PCR assay using TaqMan probes from Applied Biosystems. 
C_9510307_20 was used to CHRNA3 and C_26000428_20 to 
CHRNA5. Statistical analysis consisted of logistic regression adjust-
ed for covariates, using the STATA 11.0 program.
Results: The population was stratified in nonsmokers (38.4%) and 
smokers (61.6%), within the latter 58.8% had light smoking, 27% 
moderate and 14.2% heavy. Comparing smokers and nonsmokers 
was not found significant difference in age, however in the analysis 
by sex was found that heavy smoking was more frequently in man 
than women (p <0.001). The frequency of CHRNA3 (rs1051730) 
genotypes were: G / G (0.74), G / A (0.23) and A / A (0.03) in non-
smokers and G / G (0.72), G / A (0.27) and A / A (0.01) in smokers. 
While for CHRNA5 (rs16969968) were: G / G (0.74), G / A (0.23) 
and A / A (0.03) in nonsmokers and G / G (0.71), G / A (0.27) and 
A / A (0.02) in smokers; no significant difference was found in any 
polymorphism when was compared the genotype frequency in 
both groups (p = 0.7). However when was analyzed the group of 
smokers and stratified by smoking status found an increased risk of 
OR = 1.71 for CHRNA3 and OR = 1.79 for CHRNA5 in heavy smok-
ers, which is consistent with other reports.
Conclusion: The results suggest that carriers of the variant A in 
CHRNA3 (rs1051730) and CHRNA5 (rs16969968) polymorphisms 
are more susceptible to the effects of nicotine and these polymor-
phisms become important when the environmental factor smoking 
is present.
Keywords: Molecular epidemiology, Nicotinic receptors, Tobac-
co, Nicotine dependence
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EFFECT OF RADIATION DOSE ON QUANTITATIVE MEA-
SUREMENT OF PART-SOLID NODULE SIZE ON CT IN A 
CHEST PHANTOM
Kavita Garg  
University Of Colorado, Aurora/UNITED STATES OF AMERICA
Background: The malignancy rate of part-solid lung nodules is 
significantly higher compared to solid or nonsolid nodules. Accu-
rate measurement and change in the nodule size while minimizing 
the cumulative radiation dose from CT is important in patient 
management. The objective of this study was to assess the affect of 
dose on the accuracy of part-solid compared to solid nodule size 
measurements obtained from CT images of the chest.
Methods: Twelve synthetic nodules, four solid (spherical) and 
eight part solid (spherical and lobular) (CIRS, Norfolk, VA) were 
imbedded in the lungs of an anthropomorphic torso phantom 
(LUNGMAN, Kyoto Kagaku Co., Ltd., Kyoto, Japan). The thorax 
phantom was imaged on a Sensation 64 (Siemens Medical Solu-
tions USA, Malvern, PA) CT using a modified version of the QIBA 
recommended solid nodule protocol to include imaging at 40mAs 
(CTDIvol = 3.06mGy) and 200mAs (15.32mGy). Images were 
independently segmented by four experienced radiologists, at 
two sittings, using the INTIO ClearStart•SVMTM Segmentation and 
Volumetric Measurement System (Lung research version; INTIO, 
Inc, Broomfield, CO). Nodule diameter and volume measures were 
obtained from these segmentations (n=256 part-solid, n=128 solid). 
 
Results: The relative bias estimates for part-solid nodules were 
13.8% (16.1) for the longest diameter (1D) measure and15.5% (20.4) 
for the volume (3D) measure with the 200mAs acquisition, and 
13.6% (16.9) for 1D and 14.6% (23.7) for 3D at 40mAs. For solid 
nodules the relative bias estimates were 1.4% (5.4) for 1D and 31.6% 
(17.2) for 3D at 200mAs and 3.6% (6.5) for 1D and 36.6% (33.7) for 
3D at 40mAs. Although the relative bias of solid nodule 3D volume 
measurements were significantly higher (p <0.0001) than part-solid 
measurements in this study, there was no significant (p > .05) inter-
action between solidity and dose.  
 
Conclusion: Chest CT radiation dose did not have any affect on 
the accuracy of part-solid compared to solid nodule size measure-
ments.
Keywords: Chest CT, Pulmonary nodule size measurement, CT 
radiation dose, Part-solid nodule measurement
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LONG-TIME PROGRESSION-FREE SURVIVAL AFTER VI-
NORELBINE-BASED CHEMORADIOTHERAPY FOR NON-
SMALL CELL LUNG CANCER
Bulent Karagoz1, Rauf Gorur2, Oguz Bilgi1  
1Gata Haydarpasa Training Hospital, Medical Oncology, Istanbul/TURKEY, 2Gata 
Haydarpasa Training Hospital, Thoracic Surgeon, Istanbul/TURKEY
Background: Vinorelbine based combination chemotherapy is 
successful treatment modality for metastatic non-small cell lung 
cancer (NSCLC). It is reported that sequential chemoradiotherapy 
including vinorelbine may be an effective and safe treatment op-
tion in locally advanced NSCLC. 
Methods: We wish to present also a case that strongly supports 
effectiveness for vinorelbine-based chemoradiotherapy. 
Results: Sixty-three year old man with mass of 10 cm in upper lobe 
of right lung has been admitted to our clinic. The diagnosis was 
squamous cell carcinoma of lung. He was not a suitable candidate 
for surgery. After tree courses of ciplatin- etoposide induction 
chemotherapy, concurrently chemoradiotherapy with weekly 
vinorelbine 25 mg/m2 and 70 Gy radiotherapy was performed. 
During chemoradiotherapy, grade 2 neutropenia, grade 3 nau-
sea-vomiting, and asthenia occurred. After treatment, the patient’s 
complaints disappeared, the mass was 7 cm in second month, 4 cm 
in forth month. Then, the patient has been followed without treat-
ment. During thirteen years, the patient remained asymptomatic, 
and showed no evidence of recurrence. Although five year survival 
is less than ten percent in advanced stage lung cancer, the survival 
time is unexpectedly long in this case. 
Conclusion: Treatment schedule may have a major role to play in 
achieving long-term survival as well as clinical stage. With longer 
survival, this presented case has supported studies about effec-
tiveness of vinorelbine-based chemoradiotherapy in NSCLC. 
Concomitant vinorelbine and radiotherapy may be an option in 
selected patients with locally advanced lung cancer.
Keywords: vinorelbine, chemoradiotherapy, locally advanced lung 
cancer
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PROGNOSTIC VALUE OF THE PLEURAL INVOLVEMENT 
BEFORE AND AFTER INDUCTION TREATMENT FOR LO-
CALLY ADVANCED NON-SMALL CELL LUNG CANCER
Diego Marquez-Medina1, Antonio Martin-Marco1, Juan Carlos 
Samamé Perez-Vargas2  
1Arnau De Vilanova University Hospital, Lleida/SPAIN, 2Medical Oncology  
Department. Hospital Nacional Arzobispo Loayza Of Lima (Perú)., Lima/PERU
Background: The invasion of visceral pleura (VPI) is reported as an 
adverse prognostic factor for early Non-Small Cell Lung Cancer 
(NSCLC) in the 7th edition of the IASLC TNM classification. Half of 
NSCLC debuts in a locally advanced stage (LA-NSCLC), to whom 
induction therapy (IT) followed by consolidation surgery or radio-
therapy is becoming the standard care. We analyzed the prognos-
tic impact of pre- and post-treatment VPI in LA-NSCLC. 
Methods: We retrospectively reviewed 108 LA-NSCLC consec-
utively treated with induction platin-based chemo or chemora-
diation plus and consolidation surgery or radiation in our center 
from October-2004 to June-2012. Three patients died due to early 
surgery complications were excluded. The impact of baseline and 
post-IT minimal pleural effusion (MPE) and/or VPI over the dis-
ease-free (DFS) and overall survival (OS) was analyzed in the whole 
series. The impact of pathological VPI after IT was analyzed in 50 
resected patients.
Results: The mean age of the series was 66.7 years (47-84 years). 
Female patients were 7.4% only. Histology included 15.74% 
non-specified NSCLC, 72.22% squamous carcinomas, and 12.03% 
adenocarcinomas. Baseline stage included 18.51% cII, 39.81% 
cIIIA, and 41.66% cIII NSCLC. Treatment plan included 22.22% 
induction chemoradiation plus surgery, 33.33% induction chemo-
radiation plus consolidation radiation, 28.7% induction chemo-
therapy plus surgery, and 15.74% induction chemotherapy plus 
consolidation radiation. Five patients progressed to stage-IV during 
IT and did not undergo consolidation therapy. Baseline and post-IT 
MPE or VPI did not impact neither on DFS (p= 0.804 and p= 0.43, 
respectively) nor OS (p= 0.444 and p= 0.527, respectively) of the 
whole series. The pathological VPI did not impact neither on DFS 
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(p= 294) nor OS (p= 0.218) in the subgroup of resected patients. 
Conclusion: Baseline and post-treatment MPE and VPI do not im-
pact in the outcome of LA-NSCLC treated with induction chemo 
or chemoradiation followed by consolidation surgery or radiother-
apy in our series. These results could be biased by the small size of 
our series, or be distorted by the higher impact of other adverse 
factors such as lymph node or angiovascular involvement.
Keywords: Locally advanced, non-small cell lung cancer, induc-
tion therapy, pleura
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AN OPTIMIZED BACKGROUND-CORRECTION FOR AS-
SESSING [18F] FDG-PET  FOLLOWING LUNG CANCER STE-
REOTACTIC BODY RADIOSURGERY
Michael E. Kasper1, Charles Y. Shang1, Vindu Kathriarachchi2, Rash-
mi Benda1  
1Lynn Cancer Institute, Radiation Oncology, Boca Raton/UNITED STATES OF 
AMERICA, 2Florida Atlantic University, Biomedical Science, Boca Raton/UNITED 
STATES OF AMERICA
Background: Although [18F] FDG-PET provides helpful informa-
tion in diagnosing lung malignancies, no widely accepted SUV 
values suggest tumor recurrence after lung irradiation. This study 
investigated the effectiveness of a modified SUVmax in predicting 
the local control post lung SBRT. 
Methods: 106 analyzable FDG-PET images from 49 NSCLC 
patients who received lung SBRT are included with the follow-up 
time ranged from 14.5 weeks to 113.2 weeks. The SUVmax was 
measured within the PTV of the lesion using pretreatment PET or its 
corresponding region in post-SBRT PET. A reference SUV (SUVref) 
was derived from the mean SUV in the adjacent aorta. The ratio 
between SUVmax and SUVref was defined as the new SUVcmax.
Results: While inconsequential differences were found between 
the positive SUVmax (n =37) and the locally controlled (n =69) 
groups (p =0.086), SUVcmax of the positive group are significant 
higher (5.82 ±3.10 vs. 1.45 ±0.55, p =0.026). Respectively 85.2% 
and 96.3% of locally controlled cases post SBRT showed de-
creased values in the latter PET using SUVmax and SUVcmax. PET 
taken <24 weeks post-SBRT yield higher uncertainties. 
Conclusion: A regional background-corrected SUV indicator - 
SUVcmax of PTV demonstrated a strong correlation between low 
(<2.5-3.0) values and the predictability of the local tumor control 
after lung SBRT for NSCLC. FDG-PET images taken earlier than 24 
weeks post-irradiation contributed higher uncertainties and are not 
recommended for assessing local tumor control post lung SBRT.
Keywords: Lung SBRT Evaluation, SUV max, SUV cmax, Early 
stage Non Small Cell Lung Cancer
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SINGLE PORT VATS ANATOMICAL SEGEMENTECTOMY 
FOR EARLY LUNG CANCER IN OCTOGENARIAN
Yoo Young Chong, Seung Pyung Lim, Min Woong Kang  
Chungnam National Universitiy Hospital, Department Of Thoracic And Cardio-
vascular Surgery, Daejeon/KOREA
Background: Minimal invasive pulmonary resection for the lung 
cancer patients is one of the big issues in the thoracic oncologic 
surgery field. Video-assisted thoracoscopic surgery is very popu-
lar procedure for the thoracic surgeon. Usually, VATS anatomical 
pulmonary resection was performed with 3 or 4 ports and 4 to 5 
cm incision. With gained experience of VATS procedure, some 
surgeons perform single port VATS pulmonary resection. 
Methods: We report successful surgical treatment of single port 
VATS segmentectomy for the 83 year old early adenocarcinoma 
patient.
Results: On post-opertative 6th day, chest tube removed and 
post-operative 8th day, the patients discharge without any compli-
cation and there is no recurrence for the 1 year follow up. 
Conclusion: Sublobar pulmonary resection is one of the surgical 
options for the early lung cancer patients. Although the efficacy 
and feasibility of segmentectomy for the lung cancer still remain 
unclear, however, many reports suggest that segmentectomy is the 
good option for the early lung cancer.
Keywords: VATS, single port, segmentectomy
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CARDIOPULMONARY EXERCISE TESTING (CPET) AS PRE-
OPERATIVE TEST BEFORE LUNG RESECTION
Kostas Nikolaos Syrigos1, Anastasios Kallianos2, Aggeliki Rapti2, 
Sotirios Tsimpoukis2, Andriani Charpidou2, Ioannis Ntannos2, Elias 
Kainis2  
1Sotiria General Hospital, Athens School Of Medicine, Oncology Unit Gpp, Ath-
ens/GREECE, 2Sotiria General Hospital, Oncology Unit Gpp, Athens/GREECE
Background: Lung resection is still the only potentially curative 
therapy for patients with localised non-small lung cancer (NSCLC). 
However, the presence of cardiovascular comorbidities and un-
derlying lung disease increases the risk of postoperative compli-
cations. Various studies have evaluated the use of different preop-
erative tests in order to identify patients with an increased risk for 
postoperative complications, associated with prolonged hospital 
stay and increased morbidity and mortality. 
Methods: In this topic review, we discuss the role of cardiopulmo-
nary exercise testing (CPET) as one of the preoperative tests sug-
gested for lung cancer patients scheduled for lung resection. We 
describe different types of exercise testing techniques and present 
algorithms of preoperative evaluation in lung cancer patients.
Results: Patients without known underlying lung disease with a 
preoperative FEV1 (forced expiratory volume in one second) great-
er than 2 L generally tolerate well pneumonectomy, whereas those 
with FEV1 greater than 1.5 L are expected to tolerate lobectomy. 
Although spirometric values strongly correlate with the severity of 
obstruction, they do not provide direct information regarding the 
degree of gas exchange and cardiovascular reserve. CPET reflects 
interactions between pulmonary function, cardiovascular status 
and oxygen uptake and utilization by the peripheral tissues.
Conclusion: Overall, patients with maximal oxygen consumption 
(VO2 max) <10 mL/kg/min or those with VO2 max <15 mL/kg/
min and both postoperative FEV1 and DLCO <40% predicted are 
at high risk for perioperative death and postoperative cardiopul-
monary complications, and thus should be offered an alternative 
medical treatment option.
Keywords: Lung resection, comorbidities, oxygen consumption, 
forced expiratory volume
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PROGNOSTIC VALUE OF DEC2 AND FOXM1 EXPRESSION 
IN NON-SMALL CELL LUNG CANCER PATIENTS
María José Carlini1, David Smith2, Myriam Nuñez3, Lorena Lupinac-
ci2, Julieta Grasselli2, Gastón Boggio2, Mercedes Liliana Dalurzo2, 
María Guadalupe Pallotta2, Lydia Inés Puricelli1  
1Institute Of Oncology “Ángel H. Roffo”, Research Area, Ciudad Autónoma De 
Buenos Aires/ARGENTINA, 2Hospital Italiano De Buenos Aires, Ciudad Autóno-
ma De Buenos Aires/ARGENTINA, 3Facultad De Farmacia Y Bioquímica, Ciudad 
Autónoma De Buenos Aires/ARGENTINA
Background: FoxM1 belongs to a large family of forkhead tran-
scription factors (TF) and is associated with cell proliferation. 
Consistently, it is overexpressed in several types of cancer. On the 
other hand, reduced expression of the TF DEC2 was observed in 
several cancer types relative to normal tissue, indicating its po-
tential role as a tumor supressor. Also, in dormant tumor cells of 
head and neck squamous cell carcinoma, diminished expression 
of FoxM1 and augmented expression of DEC2 was observed in 
the network of TF relevant for quiescence, suggesting an opposed 
role of these TFs in malignant progression. The prognostic value 
of these TF in non-small cell lung cancer (NSCLC) is unknown. In 
this context, our aim was to analyze the expression of FoxM1 and 
DEC2, independently or combined, as biomarker of clinical utility 
in NSCLC. 
Methods: The expression of the TFs was assessed by immuno-
histochemistry in tumor samples of surgical specimens of NSCLC 
patients (stages I-III). Sections were coded and analyzed by two 
experienced observers without knowledge of patient evolution. 
The expression of the TFs was evaluated in the tumor cells and 
categorized according to the percentage of positive stained cells 
(score from 0 to 3, where 0 = negative, 1 ≤ 10%, 2 = 11−50%, and 3 
≥ 51%). By means of these percentages, patients were divided into 
two groups showing low or high expression by using 10% as cut-off 
value. Results were correlated with the clinicopathologic factors 
of the patients (Spearman’s rank correlation coefficient, chi-square 
test) including disease free-survival (DFS) and overall survival (OS) 
by univariate (Kaplan Meier) and multivariate analyses (Cox regres-
sion hazard model).
Results: We observed high expression of FoxM1 in 43/89 cases. 
We also detected in 39/81 cases that the infiltrating immune cells 
were positive for FoxM1. DEC2 expression was observed in 28/64 
cases. The low/high expression groups for these variables were 
not associated with the clinicopathologic parameters, including 
survival. When the analysis was performed only for those patients 
with T2 tumor size, the low expression of DEC2 was associated 
with a lower OS at five years (log-rank test, P=0.035). The multi-
variate study exhibited a borderline significance, when adding the 
covariables age, histologic type and sex (Cox test, P=0.09). Also, 
we observed a trend for patients with high expression of FoxM1 
together with low expression of DEC2 to have lower OS.
Conclusion: The expression of DEC2 is a good prognosis marker 
in NSCLC, for patients with T2 tumor size. However, it should be 
evaluated in a larger cohort of patients to ensure a more robust 
multivariate analysis. On the other hand, the combined evaluation 
of opposite expression of FoxM1 and DEC2 in a larger cohort of 
patients may reveal prognostic information and deserves further 
study.
Keywords: non-small cell lung cancer, DEC2, prognostic factor, 
FoxM1
POSTER SESSION 1 - August 22, 2014 09:00-18:00 
Topic: Early Stage NSCLC (Stage I - III)
P1.17
MULTIPLEXED MUTATION PROFILING OF ASIAN LUNG 
ADENOCARCINOMA AND SQUAMOUS CELL CARCI-
NOMA REVEALS THERAPEUTICALLY RELEVANT ALTER-
ATIONS
Sai Sakktee Krisna1, Amit Jain1, Benjamin Haaland2, Angela Maria 
Takano3, Gopalakrishna Iyer4, Minn Minn Myint Thu1, Darren Wan-
Teck Lim1, Eng Huat Tan1, Tony Kiat Hon Lim3, Daniel Shao Weng 
Tan1  
1National Cancer Centre Singapore, Department Of Medical Oncology, Singa-
pore/SINGAPORE, 2Duke-Nus Graduate Medical School, Centre For Quantita-
tive Medicine, Singapore/SINGAPORE, 3Singapore General Hospital, Depart-
ment Of Pathology, Singapore/SINGAPORE, 4National Cancer Centre Singapore, 
Department Of Surgical Oncology, Singapore/SINGAPORE
Background: The primary aim of this study was to determine the 
mutational spectrum of Non Small Cell Lung Cancer (NSCLC) 
samples using a multiplexed testing with the Sequenom LungCar-
ta. 
Methods: Formalin-Fixed Paraffin-Embedded (FFPE) tissues from 
212 resected lung adenocarcinomas (1996-2010) and 87 resected 
lung squamous cell carcinoma (1998-2010) were retrieved. DNA 
was extracted from areas that had more than 30% tumour, and an-
alyzed using the Sequenom MassARRAY LungCarta panel. Clinical 
data was collected by the Lung Cancer Consortium Singapore.
Results: Majority of lung adenocarcinoma were Stage I-III (96.7%), 
M:F (104/108) and 55.2% never smokers. One hundred and twenty 
five out of 212 (59.0%) lung adenocarcinoma cases harbored mu-
tations. Forty eight (22.6%) had 2 or more mutations; (n=35, 16.5% 
with 2 mutations; n=9, 4.2% with 3 mutations; n=4, 1.9% with 4 mu-
tations). EGFR mutations were detected in 73 (34.4%) cases. EGFR 
mutations comprised 47 (22.2%) exon 19 deletions and 22 (10.4%) 
L858R mutations, and 9 other EGFR mutations (n=1, 0.5% T790M, 
n=1, 0.5% exon 18 point mutation, n=4, 1.9% exon 20 mutations). 
Other mutations include TP53 (n=15, 7.1%), STK11 (n=12, 5.7%), 
KRAS (n=12, 5.7%), PIK3CA (n=3, 1.4%), and BRAF (Total n=7, 3.3%, 
V600E n=3, 1.4%). Two cases harbored both a sensitizing EGFR 
exon 19 deletions and a resistant exon 20 insertion mutation. Ten 
cases with EGFR mutations had a TP53 mutation (4.7%). Lung squa-
mous cell carcinoma were primarily stage I-III (93.1%), M:F (80/7) 
and 90.8% had positive smoking history. 41.4% (36/87) cases har-
bored mutations. 17 (19.5%) had 2 or more mutations; (n=12, 13.8%; 
2 mutations, n=5, 5.7%; 3 mutations). PIK3CA mutations were 
detected in 9 (10.3%) cases (n=8 exon 9; n=1 exon 20). KRAS mu-
tations were detected in 4 (4.6%) cases (n=3 codon 12; n=1 codon 
13). EGFR mutations were detected in 6 (6.9%) cases (n=4 exon 19 
point mutations; n=2 exon 20 insertions). Other mutations include 
NRF2 (n=7, 8.0%), TP53 (n=6, 6.9%) and NTRK2 (n=5, 5.7%)
Conclusion: Multiplexed mutational profiling with Sequenom 
is feasible in resected FFPE specimens, and reveals potentially 
tractable targets. e.g. 10% PIK3CA in squamous cell NSCLC. The 
prevalence of KRAS is generally low (4-6%) in adenocarcinoma 
and squamous cell cancer in the East Asian context. Co-mutations 
were found in 22.6% of lung adenocarcinoma cases and 19.5% of 
lung squamous cases − several with potential clinical implications 
(e.g. EGFR activating mutations with co-existing exon 20 mutations 
or p53 mutation).
Keywords: Sequenom, Lung Adenocarcinoma, Lung Squamous 
Cell Carcinoma, Multiplexed mutation profiling
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ELEVATED POTASSIUM LEVELS APPEAR PROTECTIVE 
AGAINST ATRIAL FIBRILLATION AFTER ROBOTIC-ASSIST-
ED VIDEO-THORACOSCOPIC PULMONARY LOBECTOMY
Emily Ng1, Frank Omar Velez-Cubian2, Maria Echavarria2, Carla 
C. Moodie2, Joseph R. Garrett2, Jacques-Pierre Fontaine2, Lary A 
Robinson2, Eric M. Toloza2  
1University Of South Florida Morsani College Of Medicine & Moffitt Cancer 
Center, Tampa/UNITED STATES OF AMERICA, 2University Of South Florida Col-
lege Of Medicine & Moffitt Cancer Center, General Surgery & Thoracic Surgery, 
Tampa/UNITED STATES OF AMERICA
Background: We sought to investigate the relationship between 
post-operative atrial fibrillation incidence and electrolyte (potas-
sium and magnesium) levels after robotic-assisted video-thoraco-
scopic pulmonary lobectomy. 
Methods: We retrospectively studied prospectively collected data 
from 208 consecutive patients who underwent robotic-assisted 
pulmonary lobectomy by one surgeon for known or suspected 
lung cancer. Postoperatively, 39 (18.75%) of these patients experi-
enced atrial fibrillation (AF) during the hospital stay. The preoper-
ative potassium levels obtained within two weeks prior to surgery 
and postoperative potassium and magnesium levels obtained 
within 24 hours after surgery were recorded. In addition, the lowest 
potassium and magnesium levels during the post-surgical hospital 
stay were also analyzed. Statistical significance (p<0.05) was deter-
mined by unpaired student’s t-test.
Results: The mean preoperative potassium level in the AF group 
(4.43) was significantly higher (p=0.024) than the mean potassium 
level in the non-AF group (4.27). Similarly, the mean postoperative 
potassium level in AF group was also significantly higher than that 
among non-AF patients (4.27 vs. 4.09, p=0.017). Though not sig-
nificantly different (p=0.15), the postoperative magnesium level in 
patients experienced AF (1.92) tended to be lower than the non-AF 
patients (1.98). Between the two groups of patient (AF vs. non-AF) 
during their entire hospital stay, no significant difference was found 
in either the lowest recorded potassium level (3.70 vs 3.75, p=0.21) 
nor the lowest recorded magnesium level (1.74 vs. 1.78, p = 0.20). 
Results were summerized in Table 1 with standard deviation (SD) 
and standard error of the mean (SEM). 
Table 1 PreOp K PostOp K PostOp Mg Lowest K Lowest Mg
Afib
Mean 4.43 1.92 1.92 3.70 1.74
SD 0.50 0.43 0.22 0.28 0.17
SEM 0.08 0.07 0.04 0.04 0.03
NonAfib
Mean 4.27 4.09 1.98 3.75 1.78
SD 0.43 0.48 0.32 0.36 0.18
SEM 0.03 0.04 0.02 0.03 0.01
P-value 0.024 0.017 0.152 0.210 0.202
Conclusion: Post-operative atrial fibrillation incidence after robot-
ic-assisted pulmonary lobectomy may inversely related to potas-
sium level both preoperatively and postoperatively, but does not 
appear to be related to hypokalemia or hypomagnesemia. Further 
studies should be conducted to evaluate the feasibility of predic-
tion or prophylactic measure of post-operative atrial fibrillation by 
electrolyte monitoring.
Keyword: robotic surgery Atrial Fibrillation
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CORRELATIONS BETWEEN THE SIMPLIFIED KINETIC 
METHOD (SKM) AND 
STANDARD UPTAKE VALUES (SUVS) OF 18F-FDG PET IN 
LUNG CANCER
Noah C Choi1, Tristen T Chun2, Marek Ancukiewicz2, Andrzej Nie-
mierko2, Alan J Fischman3  
1Massachusetts General Hospital/ Harvard Medical School, Radiation Oncology, 
Ma /UNITED STATES OF AMERICA, 2Massachusetts General Hospital/ Har-
vard Medical School, Radiation Oncology, Ma/UNITED STATES OF AMERICA, 
3Massachusetts General Hospital/ Harvard Medical School, Radiology (Nuclear 
Medicine), Ma/UNITED STATES OF AMERICA
Background: Positron emission tomography (PET) with 18F-fluo-
ro-deoxy-glucose (18F-FDG) is an effective imaging modality to 
investigate glucose metabolism in tumors, to make cancer diagno-
sis, and to monitor patients’ responses to therapeutic interventions, 
such as radiotherapy, chemotherapy and chemo-radiotherapy. 
FDG-PET analysis has been mainly qualitative due to the complex 
nature of its analytical methods. However, recent studies showed 
that qualitative interpretation of tumor response to radiotherapy 
in local-regional lung cancer and to chemotherapy in early stage 
Hodgkin’s lymphoma remains suboptimum in guiding individual-
ized therapy for eradication of local-regional tumor. In an attempt 
to shed light on the search for simplified ways to accurately mea-
sure 18F-FDG uptake in tumors, we examined the correlations be-
tween the Simplified Kinetic Method (SKM) and Standard Uptake 
Values (SUVs) in a large number of lung cancer patients. 
Methods: 18F-FDG PET scans from 86 lung cancer patients were 
analyzed in this study. Both primary tumors and lymph node me-
tastases were evaluated using regions of interest (ROIs) at 0.5cm 
x 0.5-cm and 1.0cm x 1.0-cm sizes. The SKM was correlated with 
SUV and SUVs normalized for plasma glucose, lean body mass, 
body surface area, and in combination with lean body mass and 
plasma glucose, and body surface area and plasma glucose. Coef-
ficients of determination (R2) were calculated before radiotherapy 
or chemo-radiotherapy and at different time points after the com-
pletion of radiotherapy or chemo-radiotherapy.
Results: SUVs normalized for plasma glucose, and for a combina-
tion of body surface area and plasma glucose showed strongest 
correlation with the SKM (R2>0.90) as shown in Table 1. SUV with 
no correction showed lowest correlation (R2<0.80). R2 values were 
significantly higher for SUVs measured 10-12 days after completion 
of the radiation therapy than before the radiation therapy. R2 values 
calculated from measurements obtained from 1.0cm x 1.0cm size 
ROIs were also not significantly higher than those obtained from 
0.5-cm x 0.5cm ROIs. 
Conclusion: The results of this study demonstrate that simplified 
analytical methods using SUVs, especially SUVs normalized for 
body surface area and plasma glucose, may be adequate for rou-
tine clinical applications, and could be used along with the SKM 
for research and clinical studies intended for monitoring responses 
to radiation therapy or chemo-radiotherapy in which FDG kinetics 
can be altered. However, more thorough studies using clinical 
outcomes are necessary in order to assess the true clinical applica-
bility of these quantitative methods.
Keywords: 18F-FDG PET, Response-monitoring, Simplified-kinet-
ic-method, Standard-uptake-value
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EFFECTS OF INTRA-OPERATIVE FACTORS ON THE INCI-
DENCE OF POSTOPERATIVE ATRIAL FIBRILLATION AFTER 
ROBOTIC-ASSISTED VIDEO-THORACOSCOPIC PULMO-
NARY LOBECTOMY
Emily Ng1, Frank Omar Velez-Cubian1, Maria Echavarria2, Carla C. 
Moodie3, Joseph R. Garrett3, Jacques-Pierre Fontaine3, Lary A Rob-
inson3, Eric M. Toloza3  
1University Of South Florida College Of Medicine & Moffitt Cancer Center, Gen-
eral Surgery & Thoracic Surgery, Tampa/UNITED STATES OF AMERICA, 2Univer-
sity Of South Florida, Morsani College Of Medicine, Tampa/UNITED STATES OF 
AMERICA, 3Moffitt Cancer Center, General Surgery & Thoracic Surgery, Tampa/
UNITED STATES OF AMERICA
Background: In this study, we sought to investigate the association 
between post-operative atrial fibrillation incidence and intra-op-
erative factors, such as estimated blood loss, operative time, and 
intra-operative complications, in patients who underwent robot-
ic-assisted video-thoracoscopic pulmonary lobectomy. 
Methods: Prospectively collected data from 208 consecutive 
patients who underwent robotic-assisted pulmonary lobectomy by 
one surgeon for known or suspected lung cancer were analyzed. 
Postoperatively, 39 (18.75%) of them experienced atrial fibrillation 
(AF) during the hospital stay. Estimated blood loss (EBL) during op-
eration, duration of operation, and intra-operative complications 
from all patients were collected and analyzed. Statistical signifi-
cance (p<0.05) was determined by unpaired student’s t-test.
Results: Eighteen out of 208 patients (8.7%) experienced in-
tra-operative complications during the surgery. Of which, 5 of 
them (27.8%) experienced postoperative AF, which is a slightly 
higher incidence of AF than for patients without complication in-
tra-operative complications (34 out of 190, 17.9%). In the group of 
patients who experienced postoperative AF, the mean and median 
EBL were 368ml and 200ml ,respectively, which were both higher 
(but not significantly, p = 0.08) than the mean and median EBL 
in patients without AF (266ml and 150ml, respectively). There is 
no significant difference in operative times between the patients 
with and without postoperative AF (median 225mins vs. 206mins, 
p=0.33).  
Table 1. Total patients = 208 Patient # With AF % patients with AF
Patients w/ intra-op Complication 18 5 28.8%
no intra-op complications 190 34 17.8%
Table 2 EBL (cc) Skin-to-skin Duration (mins) Total Duration (min)
Without AF
Mean 265.7 195.7 228.2
Median 150 172 206
SD 389.0 78.4 80.5
SEM 29.9 6.06 6.19
With AF
Mean 359.9 202.2 235.0
Median 200 187 225
SD 345.6 101.3 102.4
SEM 55.3 16.2 16.4
p - value 0.083 0.331 0.325
Conclusion: This study supported that the potential link between 
post-operative atrial fibrillation and intra-operative complications. 
Thought not significantly different, the patients who experienced 
postoperative AF had higher EBL and longer operative times 
during surgery.
Keyword: complications robotic Atrial Fibrillation
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EFFECT OF GENDER AND BODY HABITUS ON INCIDENCE 
OF ATRIAL FIBRILLATION AFTER ROBOTIC-ASSISTED VID-
EO-THORACOSCOPIC PULMONARY LOBECTOMY
Emily Ng1, Frank Omar Velez-Cubian1, Maria Echavarria1, Carla C. 
Moodie1, Joseph R. Garrett1, Jacques-Pierre Fontaine2, Lary A Rob-
inson2, Eric M. Toloza1  
1University Of South Florida College Of Medicine & Moffitt Cancer Center, Gen-
eral Surgery & Thoracic Surgery, Tampa/UNITED STATES OF AMERICA, 2Moffitt 
Cancer Center, General Surgery & Thoracic Surgery, Tampa/UNITED STATES OF 
AMERICA
Background: In this study, we sought to investigate the relation-
ship between post-operative atrial fibrillation incidence and either 
gender or body hiatus after robotic-assisted video-thoracoscopic 
pulmonary lobectomy. 
Methods: Prospectively collected data from 208 consecutive 
patients (99 men and 109 women) who underwent robotic-assisted 
pulmonary lobectomy by one surgeon for known or suspected 
lung cancer were analyzed. Postoperatively, 39 (18.75%) of these 
patients experienced atrial fibrillation (AF) during their hospital stay, 
of which 26 were men and 13 were women. The patients’ weight, 
height, body surface area, (BSA) and body mass index (BMI) were 
all analyzed in both AF group and non-AF group in both men and 
women. Statistical significance (p<0.05) was determined by un-
paired student’s t-test.
Results: In our series, 26% of men (26 out of 99) and 12% of 
women (13 out of 109) experienced AF post-operatively. Men 
who experienced AF were significantly taller (176cm vs. 173cm, p 
= 0.04) and heavier (91.3kg vs. 82.5kg, p = 0.02) than those who 
did not experience AF. Their BSA (2.101cm2) was also significantly 
higher (p = 0.02) than men without AF (1.983cm2), but there is no 
significant different between their BMIs (p = 0.11). In female pa-
tients, there was no significant difference in weight, height, BSA, 
nor BMI between the AF group and non-AF group. When com-
bined men and women, patients with AF have significantly higher 
height (170cm vs. 166cm, p = 0.02) weight (83.5kg vs. 75.4kg, p = 
0.01) and BSA (1.97cm2 vs. 1.86cm2, p = 0.01), but not BMI (p = 
0.30), than those without AF. Results were summerized in Table 1 
with standard deviation (SD) and standard error of the mean (SEM). 
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Conclusion: This study demonstrated the incidence of post-op-
erative atrial fibrillation was related to male sex and bigger body 
habitus. The effect of body size was more prevalent in male pa-
tients than in female patients. The effect of body size is significant 
even after both genders were combined and analyzed.
Keyword: Gender BSA Atrial Fibrillation
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NEOADJUVANT TRIPLET CHEMOTHERAPY IN LOCALLY 
ADVANCED NON SMALL CELL LUNG CANCER (NSCLC). 
AN INSTITUTIONAL EXPERIENCE
Martin Greco1, Gonzalo Recondo1, Enrique Diaz Canton1, Maximo 
De La Vega1, Florencia Perazzo1, Jorge Nazar2  
1Cemic, Medicine. Oncology, Buenos Aires/ARGENTINA, 2Cemic, Surgery, 
Buenos Aires/ARGENTINA
Background: The treatment of locally advanced, stage III NSCLC 
is controversial. In selected patients induction chemotherapy 
followed by definitive local therapy with surgery or concurrent 
chemotherapy and radiotherapy is a therapeutic option. The use of 
three drugs regimens is associated with enhanced response rates 
but considerably higher toxicity in advanced disease. The devel-
opment of new drugs and the selection of them according to initial 
histology may result in better response rates and less toxicity
Methods: The objetive of the study is to describe the response 
rate, pathologic response rate, toxicity, disease free survival and 
overall survival in a sample of selected patients with stage III NS-
CLC treated with induction chemotherapy with a 3 drug. We ret-
rospectivelly selected patients with stage III NSCLC treated at our 
institution (January 1995 to March 2013) with a three drug induction 
chemotherapy regimen. We describe patient and disease char-
acteristics at baseline and after induction therapy . We estimate 
survival curves with Kaplan-Meier method and apply Log rank test 
for comparison of survival curves.
Results: We retrospectively included 24 patients with stage III NS-
CLC. Baseline characteristics: median Age 58,5 years (46-73), male/
female 20/4, current/ever smokers 23 (96%%), PS 0 = 11 (46%) and 
PS: 1 = 13 (54%); adenocarcinoma 13 (54%), squamous cell carcinoma 
7 (29%) and poorly differentiated 4 (17%). All patients had a CT scan 
before therapy, 12 (50%) had a PET/Scan and 2 mediastinoscopy 
(8%). 15 pts had stage IIIA (62,5 %) and 9 IIIB (37,5 %). Mean number 
of courses were 3, all chemotherapy regimens contained Cisplatin 
and it was combined with mitomicin-vinorelbine (MVP) in 4 pts, 
gemcitabine-vinorelbine (GVP) 7 pts,gemcitabine paclitaxel (GPP) 7 
pts and pemetrexed Paclitaxel (PPP) 6 pts. There were one treatment 
related death, Grade 3/4 hematological toxicity in 7 pts (29%) and 
2 pts had dose reduction. Complete Radiological response in 3 pts 
( 12,5 %) and partial in 19 pts (79%) (RR 91,5%). For the 11 pts who had 
surgery (7 lobectomy and 4 Neumonectomy) 4 complete (36%) and 
6 partial pathological response were observed. In the non surgical 
patients radiation therapy was given alone in 8 cases or concurrent 
with chemotherapy in 3 cases. Site of progression were the brain in 
3 cases of the 5 who failed after locoregional therapy.The median 
overall survival was 32.5 months (2-224 month interval). The survival 
rate at 1, 3 and 5 years were 82, 72 and 47% respectively. In this small 
population we confirmed the initial stage as the principal adverse 
prognostic factor for overall survival (p0.04). Prognostic role of other 
variables could not be evaluated due to sample selection and size. 
Conclusion: In this highly selected patients sample with stage III 
NSCLC, the initial use of a three drug chemotherapy regimen was 
well tolerated, with high radiologic and pathologic response rate, 
high resectabillity rate, allowing surgery in most cases of staged 
IIIA patients. Survival rates at 1, 3 and 5 year are similar that those 
reported in phase II trials.
Keywords: Stage III, neoadyuvant chemotherapy, 3 drug regimen
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ASSESSMENT OF TUMORAL HETEROGENEITY IN NSCLC 
TREATED WITH BEVACIZUMAB: A PROSPECTIVE STUDY
Connie Yip1, Nunzia Tacelli2, Martine Remy-Jardin2, Paul Bassett3, 
Gary J.R. Cook1, David B. Landau1, Vicky Goh1  
1King’s College London, Division Of Imaging Sciences, London/UNITED KING-
DOM, 2Hospital Calmette, Department Of Thoracic Imaging, Lille/FRANCE, 
3Statsconsultancy Ltd, Buckinghamshire/UNITED KINGDOM
Background: Imaging heterogeneity may reflect biological het-
erogeneity. Changes in tumoral heterogeneity in NSCLC treated 
with chemotherapy +/- Bevacizumab in a prospective study, and 
their associations with treatment response were assessed. 
Methods: Forty patients (34 males; mean age 60 years) with 
advanced/metastatic NSCLC were treated with platinum-based 
chemotherapy (Group 1, n=23) or chemotherapy and Bevacizumab 
(Group 2, n=17), and underwent contrast-enhanced CT at baseline, 
after 1, 3 and 6 cycles of chemotherapy. Radiological response was 
assessed using both RECIST 1.1 and Crabb criteria. 63 target lesions 
were selected for heterogeneity analysis generating global and 
locoregional heterogeneity parameters using first, second, higher 
order and model based methods. Treatment response and hetero-
geneity parameters between the two treatment groups were com-
pared using Fisher’s exact and Mann-Whitney U tests. Associations 
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between heterogeneity parameters and best radiological response 
for each were assessed using univariate and multivariate logistic 
regression. A p-value <0.01 was considered statistically significant.
Results: Overall survival (OS) was similar in both treatment groups 
(median OS: 11.2 vs. 12.2 months, p=0.737). More responders were 
identified using Crabb compared to RECIST 1.1 criteria: 10 (43%) 
by Crabb and 8 (35%) by RECIST 1.1 in Group 1, and 8 (47%) and 7 
(41%) in Group 2 respectively. There was no significant difference 
in the absolute and changes in all categories of heterogeneity val-
ues between the two groups. Several locoregional heterogeneity 
parameters were associated with response (Table 1). Multivariate 
regression showed that a combination of two or more texture pa-
rameters did not improve the predictive value compared to a single 
parameter.  
Table 1: Univariate regression showing the odds of a response for a 1% 
increase in the heterogeneity values from baseline
Heterogeneity 
parameters
RECIST 1.1 Crabb criteria
Odds ratio 
(95% CI) p-value
Odds ratio 
(95% CI) p-value
Locoregional:
Short run 
emphasis 1.51 (1.14-1.99) 0.004 1.05 (1.02-1.08) 0.002
Contrast 1.13 (0.99-1.30) 0.060 1.04 (1.01-1.06) 0.003
Run percentage 0.91 (0.85-0.97) 0.003
0.93 (0.89-
0.97) 0.001
Intensity vari-
ability
0.91 (0.84-
0.98) 0.010
0.94 (0.91-
0.98) 0.001
Run length 
variability
0.88 (0.81-
0.96) 0.006
0.86 (0.77-
0.96) 0.009
Conclusion: Changes in locoregional heterogeneity parameters 
were associated with anti-angiogenic treatment response in NSCLC.
Keywords: anti-angiogenic, response, non-small cell lung cancer, 
heterogeneity
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PERCUTANEOUS RADIOFREQUENCY ABLATION OF 
LUNG CANCER: A PICTORIAL REVIEW
Apoorva Gogna  
Singapore General Hospital, Radiology, Singapore/SINGAPORE
Background: Percutaneous Radiofrequency Ablation (RFA) is a 
minimally invasive procedure where a needle electrode is passed 
into tumor tissue under imaging guidance, to cause tumoral cell 
death. Electrical current passes via the electrode tip, through the 
tumour, and is dispersed via grounding pads which are placec on 
the skin. Heating due to ionic agitation occurs at the needle tip, 
and causes cell death. The advantages compared to surgical resec-
tion include preservation of adjacent normal lung, quicker recovery 
due to the minimally invasive nature of the procedure, repeatability, 
usefulness even in post surgical patients and possiblity of treatment 
of multiple lesions. 
Methods: This pictorial essay discusses the current guidelines, 
indications, technical details, typical results and complications of 
the procedure, based on previous cases from our department. The 
advantages and disadvantages of the modality relative to other 
treatment modalities are also discussed with examples. This may 
serve as a useful reference for clinicians interested in offering the 
modality to their patients.
Results: Not applicable
Conclusion: Not applicable
Keywords: Radiofrequency ablation, Locoregional therapy
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IMAGE-GUIDED RADIOFREQUENCY ABLATION OF LUNG 
TUMOURS: EXPERIENCE AT A TERTIARY CENTRE IN SIN-
GAPORE.
Justin Kwan1, Apoorva Gogna1, Ee Cheong Chua2, Thazin Than1, 
Richard Lo Hong Guang1  
1Singapore General Hopsital, Diagnostic And Interventional Radiology, Sin-
gapore/SINGAPORE, 2National University Singapore, Medicine, Singapore/
SINGAPORE
Background: Percutaneous radiofrequency ablation (RFA) is one 
of the most widely local ablative therapies described in the liter-
ature. It is widely accepted for treatment of inoperable primary 
and secondary tumours in the liver, with recurrence rates for small 
lesions (below 3cm) being comparable with surgical resection. 
In contrast, RF ablation of lung tumours is less well described, 
although many authors have found it an excellent technique for 
treatment of otherwise unresectable lung tumours. We describe 
our experience with RFA of lung tumours in a major tertiary hospi-
tal in Singapore. 
Methods: From March 2010 to February 2014, a total of 16 pa-
tients underwent RFA of lung tumours in our institution. A single in-
ternally-cooled electrode (Cooltip, Covidien, Massachusetts, USA) 
with a burn radius of 3cm was used in all lesions. Local anaesthesia 
with conscious sedation was sufficient for 14 patients, and general 
anaesthesia was required in 2 patients. Core needle biopsy pre-
ceeded all ablations for tissue diagnosis. CT fluoroscopy was used 
for needle guidance. Follow-up CT was performed at 1 month, then 
3 monthly intervals to assess tumour response. Complete response 
was defined as no increase in size of the mass at 1 month CT fol-
low-up study or the presence of cavitation.
Results: Fifteen out of sixteen patients had histologically proven 
metastases from a GI (hepatocellular carcinoma or colorectal) or 
gynaecological primary. The biopsy results of the remaining one 
patient were inconclusive due to the presence of extensive necro-
sis but imaging features were highly suspicious of hepatocellular 
carcinoma metastases at the time of ablation. The immediate tech-
nical success rate was 100%. Five patients suffered minor compli-
cations (pneumothorax in all cases). Two of these 5 patients (40%) 
required an additional CT-guided aspiration procedure which was 
performed within 1 week of the initial ablation. The other 3 cases of 
pneumothorax resolved spontaneously. No patient required chest 
tube placement. No peri-procedural mortality or major compli-
cations occurred. Average tumour size ablated was 1.9 cm (range 
0.8-3.8 cm). More than 1 lesion was ablated in four patients (25%) 
(maximum 3) with only one lesion ablated per session. A total of 
25 lesions were ablated. Mean follow up period was 20 months 
(range 1 to 35 months). Ten patients (63%) had no evidence of local 
recurrence at the treatment site. One patient (6%) developed new 
lung metastases at the 3 month follow-up scan. The remaining 5 
patients (31%) developed local and distant tumour progression 
eventually leading to death. Mean time to local recurrence was 10 
months (range 1 to 24 months).
Conclusion: RFA appears to be an attractive treatment option for 
patients with metastatic lung disease with excellent technical suc-
cess rate and relatively minor, expected procedural-related com-
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plications. Despite relatively small numbers, initial data is promising 
with 63% having no evidence of local recurrence or overall pro-
gression of disease. Further research is required to validate our 
data as well as to understand the potential role of RFA in palliative 
patients.
Keywords: Radiofrequency ablation, Treatment of lung metastases
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TULUNG REGISTRY: DATA ANALYSIS OF PATIENTS WITH 
NON-SQUAMOUS NSCLC TREATED WITH BEVACIZUMAB 
IN THE CZECH REPUBLIC
Libor Havel1, Jana Krejci1, Zbynek Bortlicek2  
13rd Medical Faculty Charles University, Hospital Bulovka, Department Of Pneu-
mology And Thoracic Surgery, Praha/CZECH REPUBLIC, 2Masaryk University, 
Institute Of Biostatistics And Analysis, Brno/CZECH REPUBLIC
Background: We conducted a systematic review of data from 
patients reported in the TULUNG registry (data cut-off 31-Mar-14). 
The TULUNG registry is Czech national oncology registry which 
prospectively collects data from all NSCLC patients treated with 
new targeted therapies in Czech Republic. 
Methods: Analysis was performed on a group of patients with 
non-squamous NSCLC with good performance status (PS 0-1), 
treated with bevacizumab in our clinic. Since 2009 we used beva-
cizumab for treatment in 66 patients. The total number or patients 
treated with bevacizumab reported in TULUNG registry to data 
cut-off is 134 with full record.
Results: In our group of patients 48.5% were female; the median 
age at bevacizumab treatment initiation was 59 years (range 32-76). 
The majority of patients were smokers and ex-smokers (36.4% and 
30.3% respectively) and 86.4% of tumors were adenocarcinomas 
by histology. 92.4% patients were at the metastatic stage at the 
initiation of bevacizumab treatment, 6.1% of patients were in stage 
IIIb and only 1.5% of patients in stage IIIa (UICC6). The perfor-
mance status was split between ECOG PS0 and PS1 (50% in both 
groups) at the initiation of the bevacizumab treatment. Majority of 
patients received bevacizumab treatment in the first line (98.2%). 
Two main chemotherapy regimens were used; carboplatin+pa-
clitaxel (73.7%) and cisplatin+gemcitabine (24,6%). In our group 
of 66 patients analyzed, bevacizumab therapy was terminated in 
53 (80.3%) patients at data cut-off. The most frequent reasons for 
termination were disease progression, in 52.8% and death, in 11.3% 
of patients. Treatment with bevacizumab is ongoing in 13 (19.7%) 
patients. In 53 of patients with terminated treatment, the median 
duration of treatment was 21.1 weeks (95% CI 1.0 − 60.0). Response 
assessment showed CR in 1.9%, PR in 35.8% and SD in 41.5% of 
patients. Median progression free survival was 6.9 months (95% 
CI 5.6 − 8.2), median overall survival 17.6 months (95% CI 12.7 − 
22.5). 1-year survival from bevacizumab treatment initiation was 
70.1%. Adverse events were reported in 10.6% of patients, the most 
frequently reported adverse events were thromboembolic events 
(7.1%) and anemia (1.8%). Tromboembolic events were observed in 
6 patients, none of these was fatal. We didn t´ observe any severe 
episode of bleeding event. 
Conclusion: Therapy with bevacizumab in non-squamous NSCLC 
was active and very well tolerated. In eligible patients with PS 0-1; 
only 3 patients (5.7%) had to discontinue bevacizumab therapy due 
to safety reasons. In patients with completed bevacizumab therapy 
79.2% disease control rate was reached with a median survival of 
approximately 17,6 months from initiation of first line therapy with 
bevacizumab.
Keyword: NSCLC, non-squamous, bevacizumab
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CLINICAL OUTCOMES IN ERLOTINIB-TREATED PATIENTS 
WITH ADVANCED NON-SMALL-CELL LUNG CANCER 
(NSCLC) HARBORING VERY RARE EPIDERMAL GROWTH 
FACTOR RECEPTOR (EGFR) MUTATIONS
Pedro Masson Domingues1, Tatiane Montella1, Clarissa Serodio 
Baldotto2, Mariana Siqueira2, Mauro Zukin2, Carlos Gil Ferreira1  
1Brazilian National Cancer Institute (Inca), Clinical Research Department, Rio De 
Janeiro/BRAZIL, 2Brazilian National Cancer Institute (Inca), Rio De Janeiro/BRAZIL
Background: The most described EGFR mutations are deletions 
in exon-19 and L858R in exon-21. They constitute approximately 
50-90% of total EGFR mutations. Their clinical characteristics 
and sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKI) are 
well-known. Recently, despite the lower frequency (less than 10%) 
G719X in exon-18, T790M and insertions in exon-20, and L861Q 
in exon-21 were described as other categories of EGFR mutations 
with distinct features and EGFR-TKI sensitivity. Meanwhile, several 
other mutations have been reported and characterized as novel 
mutations. However, the clinical benefit of EGFR-TKI in patients 
with these very rare mutations remains unclear. This study aims to 
describe the clinical outcomes in a cohort of Erlotinib-treated pa-
tients with very rare EGFR mutations. 
Methods: We retrospectively analyzed 50 patients with advanced 
NSCLC treated with Erlotinib at the Brazilian National Cancer Insti-
tute from May 2011 to February 2014. Mutational status was per-
formed before treatment exposure using either Cobas® platform 
or Sanger sequencing. All samples were formalin-fixed paraffin 
embedded (FFPE). Thirteen patients with very rare mutations had 
their medical records reviewed. The best response was considered 
as the best outcome the assistant physician registered in the med-
ical chart.
Results: Twenty six patients harbored EGFR mutations with a 
known clinical significance (G719X in exon-18; deletions in exon-19; 
T790M and insertions in exon-20; L858R and L861Q in exon-21), 
11 were EGFR wild-type and 13 patients selected for analysis had 
a very rare EGFR mutation. Of the very rare mutations patients 8 
(62%) were women and 11 (84%) had adenocarcinoma. Ten (77%) 
were current or former smoker, 3 (21%) were never smokers. Sanger 
sequencing was performed in most of cases 13 (93%). Regarding 
treatment, 3 patients received Erlotinib as first-line, 7 as sec-
ond-third line, and 3 as maintenance. When EGFR-TKI was started 
most patients had PS≤2 (92%). The best response documented 
was stable disease in 4 (31%) cases. All other 9 (69%) cases had 
progressive disease. Median time for treatment failure (TTF) was 
3.5 months. Median Overall Survival (OS) was 17.5 months. In Five 
cases the mutations have never been described before (E697K, 
I706V, T710I, exon-18; T751I exon-19; D761M/V765M, exons19-20). 
TTF and OS were similar in patients harboring never described 
versus previously described rare mutations (TTF: 3.4 v 2.7 months, 
P=0.41; OS: 13.4 v 17.5 months, P=0.56; respectively). Only one 
patient received Erlotinib for more than 6 months (T710I, exon-18). 
Since direct sequencing did not used both forward and reverse 
traces and all samples were FFPE the possibility that some of these 
very rare mutations are artifactual should be considered. 
Conclusion: Patients with very rare EGFR mutation derived little 
clinical benefit and had a short TTF with EGFR-TKI treatment. The 
TTF in this cohort was similar to historical data from wild-type 
EGFR patients or unselected population treated with EGFR-TKI. 
Moreover, concerns to artifactual mutation must be raised. There-
by, in this subset of patients the proper use of EGFR-TKI should be 
reevaluated.
Keywords: Uncommon EGFR mutations, EGFR TKI sensitivity, 
Very rare EGFR mutations, Advancer NSCLC
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TOTAL OCCLUSION OF TRACHEA DUE TO PRIMARY TRA-
CHEAL SQUAMOUS CELL CARCINOMA WITH RESPIRA-
TORY ARREST
Min Woong Kang1, Yoo Young Chong1, Sang Do Lee2, Seung 
Pyung Lim1  
1Chungnam National Universitiy Hospital, Department Of Thoracic And Cardio-
vascular Surgery, Daejeon/KOREA, 2Chungnam National Universitiy, Department 
Of Physiology, College Of Medicine, Daejeon/KOREA
Background: Primary tracheal tumors are rare, composing only 
0.2% of thoracic cancers. Of all primary tracheal tumors, 80% 
are malignant. Regardless of the histology type, however, tracheal 
tumors patients can present with catastrophic airway obstruction 
that can cause fatal complications. Therefore, prompt action and 
appropriate treatment is important for positive outcome. We re-
port a case in which ECMO effectively substituted the lungs during 
emergent tracheal tumor resection, whose result was successful. 
Methods: A 68-year-old female patient visited the emergency 
ward after suffering from sudden onset dyspnea and coughing for 
three days. Chest CT revealed that large mass within 1cm proximal 
to the carina was almost completely obstructing the endotracheal 
lumen. After admission, cardiac arrest was occurred and we imme-
diately preformed extracorporeal cardioplulmonary resuscitation 
with veno-veno ECMO and emergency operation. 
The plural cavity was approached via 5th ICS from posterolateral 
thoracotomy. The location of tumor was identified using broncho-
scopic light and made incision on trachea. We utilised bronchial 
blocker to obstruct both main bronchus to prevent tumor dissem-
inate and then excised the tumor with trachea. The tracheal was 
anastomosed with 4-0 prolene interrupted suture.
Results: ECMO was weaned 3 days post-operation, and she extu-
bated 5 days after the operation. As histologic type was squamous 
cell carcinoma, adjuvant therapy was required. She was transferred 
to IM for chemotherapy for complete remission. Currently, she is 
followed up in outpatient clinic without recurrence after 10 cycles 
of adjuvant radiotherapy.
Conclusion: ECMO can serve a critical role in both responding to 
respiratory failure and facilitating tranchea tumor resection when 
possibly fatal obstruction of the endotranchea lumen is present.
Keywords: ECMO, tracheal mass
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MONO INSTITUTIONAL EXPERIENCE IN NON SMALL 
LUNG CANCER WITH EML4-ALK REARRANGEMENT
Pablo Jose Perez Mesa1, Maria Guadalupe Pallotta1, Paola De La 
Iglesia2, Lorena Lupinacci1, Mercedes Liliana Dalurzo2  
1Hospital Italiano De Buenos Aires, Oncology, Buenos Aires/ARGENTINA, 2Hos-
pital Italiano, Department Of Pathology, Buenos Aires/ARGENTINA
Background: The fusion oncogene EML4-ALK was first described 
in 2007, when a small inversion in the short arm region of chromo-
some 2 was found , wich resulted in a chimeric protein with tyro-
sine kinase and oncogenic activity in vitro and in vivo. Soon EML4-
ALK was found in a small proportion of patients with non-small cell 
lung carcinoma (about 5%), mainly in adenocarcinoma histology 
and never or light smokers. The importance of ALK traslocation lies 
in two facts:, a subgroup of patients with different lung cancers in 
terms of tumor origin and evolution, on the other hand, these pa-
tiens can be treated on an individual basis by specific inhibitors of 
ALK as Crizotinib, oral agent capable of dual inhibition of tyrosine 
kinase activity of ALK and MET / HGF receptor. 
Methods: During the last 12 months 1749 new patients were eval-
uated in Oncology section of Hospital Italiano of Buenos Aires, of 
which 10% were diagnosed with lung cancer (175 cases), with 50% 
of adenocarcinomas. During the past 20 months EML4-ALK rear-
rangement was analyzed in 95 cases of lung cancer in our center 
by FISH. Patients were analyzed by sex, age, smoking, diagnosis 
stage, metastatic sites, treatment response and time on specific 
inhibitors.
Results: Of 95 cases, the EML4-ALK rearrangement was found 
in 4 patients (4.2%), all diagnosed with adenocarcinoma, 2 of 
them male, mean age 53 years (26-82 years), 2 patients were 
nonsmokers and two having less than 1 pack / year, 3 patients with 
metastatic disease at diagnosis and one with stage 3B; the most 
common metastatic site was bone, followed by liver and brain 
metastases. The 4 patients started treatment with Crizotinib, 3 of 
them presented clinical benefit (stable disease or partial response) 
and an average treatment time of 15.6 months, to date 3 patients 
keep treatment.
Conclusion: The EML4-ALK rearrangement is a rare condition, 
which is usually seen in patients with adenocarcinoma and no his-
tory of smoking; although our experience with the use of specific 
inhibitors is limited, this treament appear to be a well tolerated 
treatment with prolonged clinical responses
Keyword: EML4-ALK
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P53 DENDRITIC CELL VACCINE IN SMALL CELL LUNG 
CANCER
Alberto Alejandro Chiappori1, Scott Antonia1, Charles Williams1, 
Mary Pinder-Schenck1, Tawee Tanvetyanon1, Jhanelle Gray1, Eric 
Haura1, Ben Creelan1, Soner Altiok1, Germaine Gonzalez-Vazquez1, 
Dung-Tsa Chen1, Dmitry Gabrilovich2  
1Moffitt Cancer Center, Thoracic Oncology, Tampa/UNITED STATES OF AMERI-
CA, 2Wistar Institute, Philadelphia/UNITED STATES OF AMERICA
Background: p53 mutations cause protein overexpression in 
≥ 90% of SCLC, and p53-overexpressing cells are killed by an-
ti-p53 cytotoxic T lymphocytes (CTLs) without affecting normal, 
non-overexpressing cells. Thus, p53 is a good antigenic target 
to prime a tumor-specific CTL response. Dendritic cells (DCs), 
are potent antigen presenting cells that can be cultured from 
patient’s peripheral blood mononuclear cells (PBMCs). We 
tested a DC-vaccine (V) transfected with the p53 gene in SCLC 
(NCT00617409). Previously we demonstrated: (1) V was safe and 
induced immune responses (IR ~ 40-50%), (2) lack of IR was related 
to immunosuppressive myeloid derived suppressive cells (MDSCs), 
(3) a high rate of objective tumor regressions was seen in patients 
treated with chemotherapy after vaccination, particularly if a posi-
tive IR was obtained and (4) ATRA reduces the number of MDSCs 
and enhances IR. 
Methods: ES-SCLC patients were enrolled. After 4-6 cycles of 
platinum/etoposide, patients required stable disease or better, 
ECOG PS 0, 1 and adequate organ function. Prophylactic cranial 
irradiation (PCI) was permitted. Patients were randomized 1:1:1 to: 
Arm A (control), Arm B: (V only), or Arm C (V plus ATRA). DCs were 
infected with an adenoviral construct encoding the full length p53 
gene. V consisted of 2-5 × 106 autologous DCs expressing p53. 
Injections were intra-dermally, biweekly x3. Patients without dis-
LALCA 2014 Abstracts Journal of Thoracic Oncology   •  Volume 9, Number 9, Supplement 3, September 2014
S171Copyright © 2014 by the International Association for the Study of Lung Cancer
J r l f r cic c l     l  8, r , l t , t r 
ease progression (PD) received 3 more V monthly. Arm C patients 
received ATRA (150 mg/m2 x 3 days) before V. Upon PD, all patients 
received paclitaxel. Objective response (OR) to paclitaxel in each 
arm was the primary objective. Using a two-stage design (for each 
arm), if ≥ 3 responses were observed in the first 9 patients, 14 addi-
tional patients were accrued to stage two.
Results: 54 patients were enrolled during stage one, 18, 19 and 17 
in arms A, B and C respectively. Median age (range) = 62 (43-74). 
Male/female = 31/23, ECOG PS 0/1 = 14/40. Median and total 
number of V administered was 3 (range 0-6) and 114. V related 
adverse events (AEs) were mild without any grade 3-4 AEs. Positive 
IR was seen in 3/14 (21.4%) and 7/15 (46.7%) patients in arms B and 
C respectively. ATRA decreased MDSC numbers two-fold. OR to 
V was observed in 3/36 patients. OR to paclitaxel (or other second 
line treatment) was seen in 1/11, 2/12 and 3/14 patients for arms 
A, B and C respectively. Only arm C moved to stage two. Overall 
survival (OS) was superior in patients achieving a positive vs nega-
tive IR (370 vs. 337 days respectively). However OS in V groups was 
numerically inferior compared to control (A=541.5 days, B=328 
days, C=316 days; p=0.5062).
Conclusion: V administration is safe. IR was observed in 21.4% 
(arm B) and 46.7% (arm C). Only arm C met stage two require-
ments (accrual just completed). ATRA reduced the number of 
MDSC and enhanced IR. Positive IR translated in better OS. How-
ever, OS was numerically inferior in both V arms (p-value not signif-
icant). Better IR is likely needed to improve patient outcomes.
Keywords: p53, dendritic cell, vaccine, SCLC,, p53, dendritic cell, 
vaccine, SCLC
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PREDICTION OF PROGNOSIS FOR SMALL CELL LUNG 
CANCER BASED ON GENOME-WIDE METHYLATION 
ANALYSES WITH SURGICAL MATERIALS AND ROBUST 
CLUSTERING METHODS
Yuichi Ishikawa1, Yuichi Saito1, Genta Nagae2, Noriko Motoi1, Ma-
koto Nishio1, Sakae Okumura1, Hiroyuki Aburatani2  
1Japanese Foundation For Cancer Research, Pathology, Tokyo/JAPAN, 2University 
Of Tokyo, Tokyo/JAPAN
Background: The CpG island methylate phenotype (CIMP) dis-
plays characteristic alterations of promoter DNA methylation in 
colorectal cancers, glioblastoma and breast cancers, although 
there has been no report about any CIMP of SCLC. We investigat-
ed whether DNA methylation profiles can provide useful molecular 
subtyping of SCLC in terms of etiology and prognosis of SCLC.
Methods: We analyzed 28 fresh frozen samples from pure SCLC 
patients and 13 noncancerous lung tissues. All patients under-
went surgical lung resection at the Cancer Institute Hospital, nine 
patients among them were treated with chemotherapy before 
surgery. After genomic DNA was treated with sodium bisulfite, 
bisulfite-converted genomic DNA was analyzed using Illumina’s 
Infinium HumanMethylation27 BeadChip. And, total RNA was 
extracted from twenty-five SCLC tumor samples and mRNA ex-
pression of these samples were analyzed by Agilent’s SurePrint G3 
Human CGH Microarray. Next, we matched these two data sets by 
Gene Symbol, and identified fifty-five most differentially methylat-
ed CpG sites (corresponding to 46 genes) with a FDR p value cut 
off of 0.05. Gene ontology analysis was performed using DAVID 
Bioinformatics Resources.
Results: We selected a total of 1741 most differentially methylated 
CpG sites (s.d. > 0.20) across the 28 SCLC tumor tissues in each 
DNA methylation platform, after an elimination of the probes re-
lated with the X- and Y- chromosome. Unsupervised hierarchical 
clustering of methylation data from SCLC samples reveals two 
major subgroups with different prognosis: the 5 years disease-free 
survival (DFS) rate of patients in cluster 1 (11.1%) was lower than that 
of patients in cluster 2 (61.57%) (p = 0.001). By multivariate analysis 
for DFS, both postoperative chemotherapy and cluster 1 were a 
significant prognostic factor (p = 0.002 and 0.002; respectively). 
Next, among 1220 genes with methylation and expression data 
both available, the CpG sites were ranked on the basis of the 
spearman’s correlation coefficient between cluster 1 and cluster 2 
into an ascending order. Finally, we identified that fifty-five CpG 
sites were nagetively correlated and found that apoptosis pathway 
was a most differentially expressed.
Conclusion: By comprehensive DNA methylation profiling, two 
distinct subgroups with different molecular and clinical phenotype 
were identified to evoke a CIMP of SCLC. We found some pro-
moter markers in the apoptosis pathway could make a difference 
between the two groups, and we hope that our data can contribute 
to provide a useful resource for the construction of therapeutic 
strategy and the development of a new chemotherapeutic agent. 
Keyword: SCLC, epigenetics, methylation, genome-wide
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“TRADITIONAL” SMALL CELL LUNG CARCINOMA?
Margarida Felizardo1, Susana Simoes1, Antonio Bugalho1, Rosa 
Madureira1, Paulo Calvinho2, Sofia Furtado1  
1Hospital Beatriz Angelo, Pneumologia, Loures/PORTUGAL, 2Hospital Pulido 
Valente, Cirurgia Toracica, Lisboa/PORTUGAL
Background: Small cell lung carcinoma (SCLC) is traditionally 
considered a homogeneous disease that hasn t´ suffered major 
systemic therapeutic advances in the last 30 years. Recently, sever-
al studies have launched new insights concerning the identification 
of SCLC subgroups, similar to non-small cell lung cancer (NSCLC). 
We present a case-report with an “atypical” presentation that 
raised histological doubts and therapeutic guidance uncertainties. 
Methods: Male patient, 87 years-old, former smoker (70 packs 
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per-year) and with an history of overlap syndrome. Due to moderate 
hemoptysis he performed a thoracic CT scan that showed the pres-
ence of a nodular 19mm solid lesion in the RUL (right upper lobe), 
but no lesions in the left lung and no mediastinal lymph nodes or 
pleural effusion. He was submitted to a flexible bronchoscopy that 
showed a hemorrhagic mass occluding the left upper lobe bronchus 
(LULB). Transbronchial biopsies under fluoroscopy guidance were 
attempted in the right upper lobe bronchus (RULB) but they were 
negative for neoplastic tissue. Rigid bronchoscopy with mechanical 
debulking and argon-plasma coagulation was able to restore the 
patency of B1+B2 and B3 as well as that of the lingula. Pathology 
revealed a SCLC (synaptophysin +, CD45 and p63 negative, Ki67 su-
perior to 80%). Bronchoscopic evaluation of the previous endoscop-
ic treatment only revealed mucosa irregularity at the entrance of the 
LULB. New biopsies corroborated the diagnosis of SCLC. A PET-CT 
scan showed increased uptake in the RUL (SUV max 2.3), and SCLC 
staged IV M1a was assumed without a histological confirmation of 
RUL nodular lesion. Chemotherapy (Qt) with etoposide + platinum 
was initiated and well tolerated (without side effects or complica-
tions). Post Qt CT evaluation showed no abnormalities apart from 
the previously mentioned 19mm RUL lesion. Three months later, a 
thoracic CT showed local progression of the disease to the LULB 
and endoscopic treatment (mechanical debulking and argon-plas-
ma) was performed followed by endoluminal brachytherapy 30 
Gy/6F both with good results and tolerance. After six months, a 
chest CT showed progression of the disease with an increase in the 
RUL lesion (30.1mm) and a bulky lymph node in station 7 (21mm 
short-axis). Transcarinal needle aspiration of lymph node 7 con-
firmed the initial diagnosis (SCLC). Given the PS1 the same Qt regi-
men was restarted. We are currently awaiting imaging reassessment.
Results: not applicable
Conclusion: In the present case, disease presentation and tumor 
progression made us consider the possibility of a subgroup of 
“combined SCLC” with mixed histology. This differentiation may 
justify the clinical behavior, response rate and progression time 
that are quite different from “traditional” SCLC. The identification 
of SCLC subgroups is of the utmost importance and promotes the 
debate for the cellular basis of this tumor.
Keywords: SCLC, combined, subgroups
POSTER SESSION 1 - August 22, 2014 09:00-18:00 
Topic: SCLC, Mesothelioma, Thymoma
P1.33
NINTEDANIB PLUS PEMETREXED/CISPLATIN FOLLOWED 
BY MAINTENANCE NINTEDANIB FOR UNRESECTABLE 
MALIGNANT PLEURAL MESOTHELIOMA—AN INTERNA-
TIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CON-
TROLLED PHASE II STUDY
Claudia-Nanette Gann1, Martin Reck2, Natasha Leighl3, Anna 
Nowak4, Nick Pavlakis5, Sanjay Popat6, Jens Benn Sørensen7,  
Martha Mueller8, Ute Von Wangenheim8, Giorgio Scagliotti9  
1Boehringer Ingelheim Pharma Gmbh & Co. Kg, Ingelheim, Biberach/GERMANY, 
2Lung Clinic Grosshansdorf, Department Of Thoracic Oncology, Grosshansdorf/
GERMANY, 3Princess Margaret Cancer Centre, University Of Toronto, Depart-
ment Of Medicine, Toronto/CANADA, 4The University Of Western Australia, 
School Of Medicine And Pharmacology Qeii, Medical Centre Unit, Crawley/
AUSTRALIA, 5Royal North Shore Hospital, Department Of Medical Oncology, 
Sydney/AUSTRALIA, 6The Royal Marsden Hospital Nhs Foundation Trust, London 
And Surrey/UNITED KINGDOM, 7National University Hospital, Department Of 
Oncology, Copenhagen/DENMARK, 8Boehringer Ingelheim Pharma Gmbh & 
Co. Kg, Biberach/GERMANY, 9University Of Turin, S. Luigi Hospital, Department 
Of Clinical And Biological Sciences, Torino/ITALY
Background: Malignant pleural mesothelioma (MPM) is a rare 
cancer originating from multipotent mesothelial cells capable of 
differentiating into epithelial, sarcomatoid, or biphasic (mixed) 
neoplasms. The only approved 1st-line chemotherapeutic regimen 
for unresectable MPM is combination pemetrexed/cisplatin (Pem/
Cis), which extends overall survival (OS) to only one year, illustrat-
ing a need for improved treatment. In the present study, we investi-
gate the efficacy and safety of nintedanib (N) combined with Pem/
Cis for the treatment of unresectable MPM. N is an oral, twice-dai-
ly angiokinase inhibitor targeting most prominently vascular endo-
thelial growth factor receptors 1−3, platelet-derived growth factor 
receptors α/β, and fibroblast growth factor receptors 1−3, as well 
as Src and Abl kinase signalling, which are involved in regulating 
angiogenesis, growth and metastasis of malignant tumours. These 
signalling pathways are also implicated in the pathogenesis and 
maintenance of MPM. In the LUME-Lung 1 study (NCT00805194; 
1199.13), we demonstrated that N can be co-administered with 
docetaxel to safely and significantly increase survival in adenocar-
cinoma patients (pts) with non-small cell lung cancer. 
Methods: In this study (NCT01907100; 1199.93), a total of 86 
pts—at least 18 years of age and with ECOG score of 0 or 1 and 
histologically confirmed epithelioid or biphasic MPM—will be ran-
domised in a 1:1 ratio to receive up to 6 cycles of 1st-line combina-
tion Pem (500 mg/m2)/Cis (75 mg/m2) on day 1 followed by N (200 
mg bid) or placebo (Pl) from days 2 to 21. Pts who do not develop 
progressive disease (PD) will continue to receive maintenance 
treatment with either N or Pl until PD, unmanageable toxicity, with-
drawal of consent or death. As of 14 April 2014, 40 pts were en-
rolled in the trial; since October 2013, 33 pts had been randomised 
to treatment. The primary endpoint is progression-free survival. 
Secondary endpoints include OS and baseline change in forced 
vital capacity as a measure of pulmonary function. Frequency and 
severity of adverse events will also be evaluated as a measure of 
safety, and exploratory analyses of genotypes and their association 
with treatment response and biomarkers will be performed.
Results: Not applicable
Conclusion: Not applicable
Keywords: mesothelioma, nintedanib
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PLATELET PARAMETERS IN LUNG CANCER PATIENTS
Bulent Karagoz1, Ahmet Alacacıoğlu2, Oğuz Bilgi1, Hakan Demirci3, 
Alpaslan Özgün1, Alev Akyol Erikçi4, Ozkan Sayan5, Bahattin Yıl-
maz6, Emin Gökhan Kandemir7  
1Gata Haydarpasa Training Hospital, Medical Oncology, Istanbul/TURKEY, 2Katip 
Celebi University Ataturk Training Hospital, Medical Oncology, Izmir/TURKEY, 
3Gata Haydarpasa Training Hospital, Internal Medicine, Istanbul/TURKEY, 4Emsey 
Hospital, Hematology, Istanbul/TURKEY, 5Medipol Hospital, Hematology, Istan-
bul/TURKEY, 6Samsun Ondokuz Mayis University, Medical Oncology, Samsun/
TURKEY, 7Memorial Hospital, Medical Oncology, Istanbul/TURKEY
Background: The platelet indices have been investigated in several 
clinical settings. Mean platelet volume (MPV) is altered in myocar-
dial infarction, diabetes mellitus, and inflammatory diseases. Plate-
let distribution width (PDW) is also different in several conditions 
from in healthy subjects as well as MPV. These platelet parameters 
have not been exactly demonstrated in cancer patients. We inves-
tigated platelet indices (platelet count, MPV, PDW, and plateletcrit) 
in lung cancer patients and compare in between stages. 
Methods: In this retrospective study, 71 lung cancer patients and 
39 healthy subjects were enrolled into the study. Automated blood 
counter had been used to complete blood count.
Results: Platelet count and PDW were higher in lung cancer pa-
tients compared with healthy subjects while MPV was not different. 
Among patients with lung cancer, PDW in small cell lung cancer 
(SCLC) patients was higher than in non-small cell lung cancer (NS-
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CLC) patients. Platelet indices were not different in between stage 
III and IV NSCLC patients and in between limited and extensive 
disease SCLC.
Conclusion: This study suggests that platelet might play roles 
in cancer biology. Ongoing research will lead to our increasing 
knowledge about platelets in this situation.
Keywords: Lung Cancer, plateletcrit, platelet distribution width, 
mean platelet volume
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CONVOLVULUS ARVENSIS CRUDE ALKALOIDS EXTRACT 
INDUCES APOPTOSIS THROUGH MICROTUBULES DE-
STRUCTION IN MICE CHO(CHINA HAMSTER) CELL LINE
Ibrheem Hade Mohameed  
Deayla Univ., Biology, Baghdad/IRAQ
Background: This study evaluated the ability of crude alkaloids 
extracted from the leaves of Convolvulus arvnsis to distract the 
microtubule network of mice cell line (CHO), which is an invasive 
metastasis cell line. This assessment was carried out using the im-
munostaining technique. The extract was able to distract the mi-
crotubules of the cells under investigation after 60 min of exposure 
in a concentration as little as 20 µg/ml. when DAPI staining used, 
the cells apoptosis was not detected in this concentration and time. 
The apoptotic cell have been observed when the concentration of 
the alkaloid extract elevated up to 80 and 100 µg/ml during the 
mentioned exposure time. The cells were capable of recovering 
there native microtubules constriction after 12 hr of the alkaloid 
removal from the media. The extract concentration of 1mg/Kg/Bw 
efficiently inhibited CHO cell line tumor growth in vivo to 97.14% in 
mice after three weeks treatment compared to untreated control 
animals. 
Methods: The plat used in these experiments was gathered from 
general local gardens in Baghdad (Figure 1). Plant specimens 
(leaves, stems and flowers) were taken to the College of Science, 
Botany Department, University of Dayala and was identified by 
botanist doctor Khazal D. Wady as Convolvulus arvinsis , Family 
Convolvulaceae 
Results: The cell line under investigation was described to be an 
invasive and metastasis cell line (17). The cell line metastasis was 
tested in vivo, this was emphasized when the tumor cell injected 
in the right leg of a group of mice. The tumor cells were able to 
develop a secondary bone tumor in the right femur of the injected 
animals only after one week of the injection time (Figure 1, A, B, C.). 
The aggressiveness of the CHO cells was substantial, the tumor 
cells was able to induce ascites tumor aggressively after two days 
of intraperitoneal injection (Figure 1, D). Bright field microscope 
and fluorescent microscope The used fluorescent dye stains the 
cell nuclei with green color.The microtubule of untreated control 
cells (Figure 3) showed a network regularly distributed along the 
whole cell content. microtubule network (Figures 4 and 5). The 
network of cytoplasm microtubules at the lowest concentration 
used (20 µg/ml) was clearly and obviously thinned down, and the 
treatedcell individual microtubules fibers had a destructed and 
granulated wavelike shape.
Conclusion: The invasive CHO cells showed changes in the ar-
rangement of their microtubules at a concentration of Convolvulus 
arvensis leaf crude alkaloids extract as low as 20 µg/ml concen-
tration after 60-min of exposure time. Its damage increased with 
increment of the alkaloids extract concentration. Increasing expo-
sure dose may reduce the exposure time; disruption of the micro-
tubules was also time-dependent. The extract was able to reduce 
tumor growth in vivo up to 95% of control untreated animals and 
inhibit tumor growth in the treated mice to 97.14% compared to 
control untreated animals.
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FUNCTIONALITY OF PMNS IN LP07 LUNG TUMOR
Romina Alejandra Karas1, Elisa Bal De Kier Joffé2, Slovodanka Klein1, 
Miriam Diament1  
1Instituto De Oncología “Ángel H. Roffo”, Departamento De Bioterio Y Cáncer 
Experimental, Ciudad De Buenos Aires/ARGENTINA, 2Instituto De Oncología 
“Ángel H. Roffo”, Área De Investigación, Ciudad De Buenos Aires/ARGENTINA
Background: Circulating tumor cell adhesion is a complex pro-
cess involving multiple cell-cell interactions, activating cells and 
promoting the release of inflammatory factors. Mice bearing 
LP07 lung adenocarcinoma show some characteristics similar to 
those present in patients with non small cell lung cancer, such as 
paraneoplastic syndromes (cachexia, leukocytosis at expense of 
neutrophils and hypercalcemia). In vivo treatment with Indometh-
acin (10ug/mL oral) reverses these effects. PMNs of tumor bearing 
mice promote in vitro tumor cells invasion and migration. The 
intravenous co-inoculation of both cells increased the number of 
lung metastatic nodules. Our goal was to determine whether LP07 
tumor altered the functionality of PMNs, and if treatment with 
Indomethacin reversed this effect. 
Methods: not applicable
Results: LP07 cells (3x105 cells/0.2 ml) were inoculated sc into 
normal BALB/c mice, which were treated or not with Indomethacin 
in the drinking water from day 0. When the tumor volume reached 
500 mm3, PMNs were obtained either from peritoneal cavity (thio-
glycolate 3%) or from peripheral blood (Ficoll-Triyosom µ 1090). By 
FACS we analyzed PMNs adhesion molecules, finding that LP07 
tumor induced the differentiation and activation of PMNs, and that 
Indomethacin treatment partially reversed this effect. The tumor 
increased cells expressing CD11blo-hi-Gr1lo-hi, CD11b+, Gr1+ (Ly6-G) 
(p<0.001) and reduced those expressing CD62L+ (p<0.05). We also 
found that the tumor increased NADPH oxidase activity (Colori-
metric Assay) in PMNs (p<0.001), and that this effect decreased 
with Indomethacin treatment (p<0.01). Similar results were ob-
served with the activity of the enzymes MPO (Chemiluminescence 
dependent luminol) and MMP-9 (Zymography) in PMNs of tumor 
bearing mice (p <0.001). When analyzing SOD enzyme activity 
(Fluorescence assay) it was observed that tumor presence did not 
alter the rate of H2O2 production in PMNs, and that treatment with 
Indomethacin decreased those values (p <0.01). Interestingly, while 
the tumor also decreased iNOS enzyme activity (Griess reaction) 
in PMNs (p<0.001), treatment with Indomethacin did not reverse it. 
Furthermore, we observed that the tumor increased in vitro survival 
of PMNs after incubation at 37ºC for 20 hours whit medio alone 
(Colorimetric Assay) (p<0.001) by reducing apoptosis (DAPI-IP; 
p<0.001). When we incubated the PMNs of normal mice for 20 
hours at 37ºC with LP07 conditioned media the survival were 
increased (p<0.001) and the apoptosis were reduced (p<0.0001). 
In the same samples we observed that PMNs of tumor bearing 
mice formed extracellular networks (Neutrophil extracellular trap, 
NETs), composed of DNA and several cytoplasmic and nuclear 
components. LP07 conditioned media increased the formation of 
NETs by PMNs from tumor bearing mice either treated or not with 
Indomethacin, while PMNs from normal mice never formed NETs 
in presence or absence of LP07 conditioned media.
Conclusion: In conclusion, in this tumor model, during tumor 
progression it exist an association between PMNs and LP07 tumor 
cells. The tumor releases factors that can modulate the PMNs, 
both activating and differentiating them, increasing their survival, 
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and promoting the formation and release of NETs, events that 
probably facilitate tumor progression. In vivo Indomethacin treat-
ment interferes with the activation of PMNs, affecting the expres-
sion of adhesion molecules and the production of ROS.
Keywords: Polymorphonuclear, Neutrophil extracellular trap, 
inflammation, Lung Adenocarcinoma
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BIM DELETION POLYMORPHISMS IN COLOMBIAN PA-
TIENTS WITH NON-SMALL CELL LUNG CANCER WHO 
CARRIERS EGFR MUTATIONS (CLICAP)
Andrés Felipe Cardona Cardona1, Oscar Arrieta2, Niki Kara-
chaliou3, Ana Drozdowskyj3, Ana Giménez Capitan4, Miguel Angel 
Molina4, Claudio Martín5, Hernán Carranza1, Carlos Vargas1, Jorge 
Otero1, Leonardo Rojas6, Mauricio Cuello7, Rafael Rosell4  
1Instituto De Oncología; Fundación Santa Fe De Bogotá, Medical Oncology, Bo-
gotá/COLOMBIA, 2Instituto Nacional De Cancerologia, Experimental Oncolgy 
Lab, Mexico City/MEXICO, 3Pangaea Biotech, Barcelona/SPAIN, 4Instituo Cat-
alan De Oncología, Hospital Germans Trias I Pujol, Barcelona/SPAIN, 5Instituto 
Fleming, Buenos Aires/ARGENTINA, 6Hospital Universitario San Ignacio; Centro 
Javeriano De Oncología, Medical Oncology, Bogotá/COLOMBIA, 7Hospital De 
Clínicas - Udelar, Montevideo/URUGUAY
Background: Germline alterations in the proapoptotic protein Bcl-
2-like 11 (BIM) can have a crucial role in diverse tumors. To deter-
mine the clinical utility of detecting BIM deletion polymorphisms 
(par4226 bp/ par363 bp) in EGFR positive non-small-cell lung 
cancer (NSCLC), we examined outcomes of patients (pts) with and 
without BIM alterations. 
Methods: We studied 72 NSCLC pts with EGFR mutation who 
were treated with erlotinib between January 2009 and January 
2013. BIM deletion was analyzed by PCR in formalin-fixed paraf-
fin-embedded (FFPE) tissues of tumor biopsies. We retrospectively 
analyzed clinical characteristics, response rate, toxicity, and out-
comes among patients with and without BIM deletion (del).
Results: BIM deletion was present in 11 pts (15.3%). There were no 
significant differences between pts with and without BIM del in 
clinical characteristics or type of EGFR mutation; however, pts with 
BIM del had a worse overall response rate to erlotinib (36.4% vs. 
70.5% for pts without BIM del; p=0.041) as well as a significantly 
shorter progression-free survival (PFS) (8.2 vs. 17.6 months for pts 
without BIM del; p=0.031) and overall survival (OS) (12.4 vs. 32.9 
months for pts without BIMdel; p=0.001). Multivariate Cox regres-
sion analysis showed that BIM deletion was an independent indica-
tor of shorter PFS (HR 3.0; 95%CI 1.2-7.6; p=0.01) and OS (HR 3.4; 
95%CI 1.4-8.3; p=0.006).
Conclusion: The incidence of BIM del found in pts from Colombia 
is similar to that previously described in Asia; this alteration is asso-
ciated with a poor clinical response to erlotinib and represents an 
independent prognostic factor for pts who had NSCLC with EGFR 
mutations.
Keywords: BIM deletion, Non-small-cell lung cancer, EGFR- 
mutations
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THERE IS CORRELATION BETWEEN INFECTION WITH THE 
HUMAN PAPILLOMA VIRUS (HPV) AND SQUAMOUS CELL 
CARCINOMAS OF PRIMARY LUNG?
Liliana Fernandez1, Mauricio Velasquez2, Luz Fernandz Sua3  
1Fundacion Valle Del Lili, Medicina Interna- Neumologia, Cali/COLOMBIA, 2Fun-
dacion Valle Del Lili, Cirugia De Torax, Cali/COLOMBIA, 3Fundacion Valle Del Lili, 
Patologia, Cali/COLOMBIA
Background: Squamous cell carcinoma (SCC) is a malignant 
epithelial tumor of the bronchial epithelium. It is the second non-
small cell lung cancer frequency. We know that smoking is one of 
its main causes and the role of human papillomavirus (HPV) has 
not yet been demonstrated. It is known the loss of the function of 
p16INK4a gene located on chromosome 9p21 (CDKN2A locus) 
which encodes two tumor suppressor proteins, p16INK4a and 
p14ARF. P16INK4a suppressor protein (p16) inhibits dependent 
kinases 4 and 6 cyclin D1 (CDK4 / 6, cyclin D1), whose function is 
to regulate the activity of the retinoblastoma protein (Rb) by phos-
phorylating it. The loss of (p16) function generates Rb inactivation 
by hyperphosphorylation and therefore premature dysregulation 
and cell cycle progression, but has not been shown for production 
of viral oncoproteins infection (HPV) Squamous cell carcinoma of 
the lung. 
Methods: Retrospective, descriptive and not interventional Study 
in 24 patients diagnosed with (CCE) primary pulmonary monitoring 
between 2009-2013 in our institution. Tumor tissue microarrays 
(TMAs) were performed, the (p16) protein was evaluated with 
(Clone E6H4 ™) murine monoclonal antibody in BenchMark team 
Autostainer (Ventana ®). Family 16 (HPV) in the BenchMark auto-
mated equipment Autostainer (Ventana ®) was studied by in situ 
hybridization with Inform HPVIII iView Blue+ protocol. 
Results: The median age was 67 ± 14 years, there was a predomi-
nance of males (62.5%), 91.7% had pulmonary mass with cavitation 
in 33.3% and located in the left lower lobe in 50%, 54.2% were 
smokers, 45.8% had hemoptysis, 75% received cancer treatment. 
41.7% of tumors were positive for the protein expression of p16 
gene, these 53.85% were smokers. The study by in situ hybridiza-
tion demonstrated the presence of HPV in 4.1% of tumors.
Conclusion: The presence of overexpression of (p16) in (CCE) is 
related pulmonary genetic instability and cell cycle alterations. 
HPV infection studied by in situ hybridization demonstrates the 
viral infection; suggesting that they might try another causal factor 
and that may be related to alterations in the cell cycle, proliferation 
/ progression, genetic instability, the production of viral oncopro-
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teins E6 and E7, thus favoring oncogenic transformation. But unlike 
cervical cancer do not correlate for themselves, the expression of 
p16 protein with the presence of (HPV).
Keywords: Human Papilloma Virus HPV, squamous cell carcino-
ma, Lung Cancer, P16
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HUMAN LUNG ADENOCARCINOMA CELLS SENSITIVE 
AND RESISTANT TO 5-AMINOLEVULINIC ACID-BASED 
PHOTODYNAMIC THERAPY
Haydee Fukuda1, Maria Julieta Teijo2, Alcira Batlle2  
1Centro De Investigaciones Sobre Porfirinas Y Porfiras (Cipyp, Conicet-Uba), 
Departamento De Quimica Biologica, Facultad De Ciencias Exactas Y Naturales, 
Uba, Caba/ARGENTINA, 2Cipyp (Conicet-Uba), Buenos Aires/ARGENTINA
Background: Photodynamic therapy (PDT) is an approved anti-
cancer treatment modality that eradicates tumor cells by the pho-
tochemical generation of reactive oxygen species (ROS) following 
absorption of visible light by a photosensitizer, which is selectively 
taken up by malignant cells. 5-Aminolevulinic acid (ALA) is the 
biological precursor of Protoporphyrin IX, the only endogenous 
photosensitizer. Generation of cells resistant to the treatment is an 
undesired effect. 
Methods: ALA-PDT was performed in A549 human lung adeno-
carcinoma cells growing as monolayers. Cells were incubated with 
1 mM ALA for 3 h followed by irradiation with a bank of two fluo-
rescent lamps (Osram L36W/10) for different times, and within 1 h 
analyzed for PDT-induced events (MTT assay). The surviving cells 
were harvested 24 h after treatment and replaced. After 12 cycles 
of treatment, ALA-PDT resistant cells were obtained (C-12 cells). 
Endogenously generated porphyrins were extracted from the cells 
and quantified spectrophotometrically.
Results: After incubation with ALA, C-12 cells accumulated 
50% less porphyrins than the parental control cells: 9,5±0,7 ng 
porph/105 cells in C-12; 19,9±1,2 ng porph/105 cells in control cells. 
Photosensitization with exogenous PpIX (5uM, 3 h incubation 
time) induced partial recovery of sensibility to PDT in the C-12 cells 
(surviving cells after 10 min irradiation: 39,5 % control cells with 
ALA-PDT; 27,5 % control cells with PpIX-PDT; 100 % C-12 cells 
with ALA-PDT; 75 % C-12 cells with PpIX-PDT). The low sensitivity 
of C-12 cells to PpIX-PDT was not due to PpIX level, as both cell 
types uptake similar amount of porphyrins (80,6±4,8 ng porph/105 
C-12 cells; 77,1±,2,2ng porph/105 control cells). Moreover, both 
parental and resistant cells showed similar cell morphology (ac-
complished with toluidine blue and Hoechst staining) and ability to 
migrate (wound healing assay). In the resistant C-12 clone, as result 
of photodynamic treatment, mitochondrial depolarization without 
cytochrome c release and caspase-3 activation was observed, 
and expression of the anti-apoptotic protein Bcl-2 was detected 
by means of WB assays. The nuclear factor NFkB is a well known 
oxidative stress-induced transcription factor, so, it is relevant to 
surviving after PDT. We analyzed the expression of IkB and p65 
subunit of NFkB in the cytosolic and nuclear fractions of parental 
and C-12 cells after ALA-PDT treatment. IkB was detected in the 
parental cells. In the resistant C-12 cells NFkB was observed after 
all the treatments, and the pattern of IkB expression was similar to 
the parental cells.
Conclusion: These results suggest that NFkB activation is an event 
related to a long term effect of ALA-PDT. When cells are subjected 
to a single PDT treatment, NFkB is activated only with subletal dos-
es lower than DL50.
Keyword: human adenocarcinoma cells, PDT
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USEFULNESS OF MOLECULAR METHODS FOR THE DIAG-
NOSIS OF MALIGNANT PLEURAL EFFUSIONS
Leila Antonangelo1, Débora Cristina Batista Rosolen2, Vera Luiza 
Capelozzi3, Francisco Suso Vargas3, Giorgio Bottura2, Ana Rosa 
N Dutra2, Vanessa Martins4, Annelise C. W. Lopes2, Lisete Ribeiro 
Teixeira3  
1Lim 03, Pathology Department, University Of Sao Paulo Medical School, Sao 
Paulo/BRAZIL, 2Hospital Das Clínicas Fmusp, São Paulo/BRAZIL, 3Pleura Labora-
tory, Pulmonary Division, Heart Institute (Incor), University Of Sao Paulo Medical 
School, Sao Paulo/BRAZIL, 4Faculdade De Medicina Usp, São Paulo/BRAZIL
Background: Malignant neoplasms represent an important cause 
of pleural effusion. The diagnosis of malignant pleural effusion 
(MPE) is based on the finding of tumor cells in the pleural fluid or 
tissue. However, the cytological examination of the pleural fluid 
(PF) failure to detect malignant cells in approximately 40-50% of 
cases, depending on tumor histological type, stage and primary 
site, besides the techniques used for the cytological preparation 
and the skill of the cytologist. Blinded pleural biopsy adds little 
positivity for cases of MPE with suspicious or negative cytology. 
Considering that most patients with advanced disease and pleural 
metastases have no clinical conditions for more invasive diagnostic 
procedures, it is evident the importance of pleural fluid cytology 
for the diagnosis of MPE. The combination of ancillary methods 
increases the diagnostic power of the cytological examination. In 
this context, it is well known that most tumor cells has abnormal 
DNA content - are aneuploid cells, which can be demonstrated by 
various techniques, as DNA ploidy by flow or static cytometry and 
fluorescence in situ hybridization (FISH) . The aim of this study was 
to detect chromosomal aberrations by adapting two commercial 
FISH probes and the UroVysion kit (used for diagnosis of bladder 
cancer) in order to identify malignant pleural effusions (MPE) in 
samples of pleural fluid. 
Methods: 221 samples of PF corresponding to 82 confirmed cases 
of MPE, 51 cases of benign pleural effusions (BPE) and 67 cases 
with suspicious cytology for malignancy were analyzed by FISH 
using commercial probes for chromosomes 11 and 17 (α-satellite 
spectrum Aquarius Cytocell ® Probes, UK). The assessment of 
DNA abnormalities with the UroVysion kit (Abbott Molecular, Unit-
ed States) which is based on centromeric probes for chromosomes 
3, 7, 17 and 9q21 were evaluated in 16 cases of confirmed MPE and 
5 samples of BPE, respectively.
Results: By using FISH probes for chromosomes 11 and 17 was 
possible to identify the 82 confirmed cases of MPE with positive 
cytology. Of the 51 cases with negative cytology, three were positive 
for malignancy in pleural biopsy guided by VATS and demonstrated 
aneuploid by FISH. Of the 67 cases with suspicious cytology, 43 
were confirmed as malignant by histology and by FISH. Only one 
case with suspicious cytology, but classified as BPE showed positive 
FISH. The remaining cases (n=23) showed no histological, radiolog-
ical, clinical or genetic evidence of malignancy. With the UroVysion 
kit, all the 16 cases of MPE with positive cytology showed aneuploid 
cells above the cutoff value established for malignancy.
Conclusion: The two sets of probes were able to detect aneu-
ploidy in most cases of MPE with low rate of false positives and 
false negatives. Despite the promising results, a larger number of 
cases with suspicious cytology should be evaluated to confirm 
the usefulness of these tests for the diagnosis of malignant pleural 
effusion.
Keywords: Pleural Effusions, FISH, Lung Cancer, Cytology
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MUCOEPIDERMOID CARCINOMA OF THE THYMUS AND 
MYASTHENIA GRAVIS. IS THERE AN ASSOCIATION?
Wen Ling Woo, Nikolaos Panagiotopoulos, Lasha Gvinianidze, 
David Lawrence  
Uclh University College London Hospitals, Cardiothoracic Surgery, London/
UNITED KINGDOM
Background: Mucoepidermoid carcinoma of the thymus rep-
resents a rare malignant neoplasm of the anterior mediastinum with 
less than 30 cases described in the literature. From our experience 
in only one case mucoepidermoid carcinoma fo the thymus pre-
sented with symptoms of Myasthenia Gravis. 
Methods: Review of the literature was performed to identify the 
different presenting symptoms of the mucoepidermoid carcinoma 
of the thymus and the potential association with myasthenia gravis.
Results: Mucoepidermoid carcinomas are most commonly found 
in salivary glands as first described by Stewart et al. in 1945. Primary 
mucoepidermoid carcinoma of the thymus is a are entity and there 
is no apparent association with other conditions or paraneoplastic 
syndromes. There has been only one reported case of combined 
mucoepidermoid carcinoma of the thymus and Thymoma in a 
background of myasthenia gravis. In general, presenting symptons 
include exertional dyspnea, chest pain others remain asymptomat-
ic and are incidentally found to have an anterior mediastinal mass 
on routine chest radiography.
Conclusion: There is no clear association of mucoepidermoid 
carcinoma fo the thymus and myasthenia gravis. This rare type of 
thymic tumour should always be considered in the differential di-
agnosis for anterior mediastinal masses. As it is difficult to achieve 
a diagnosis based on radiological findings alone, early surgical 
excision in recommended.
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DO MORE WITH LESS: MAXIMIZING SMALL LUNG SPECI-
MENS FOR MOLECULAR TESTING
Marileila Varella-Garcia1, M D Rumery1, Ross Camidge2, Kimi 
Kondo3, Derek Linderman2, Robert C Doebele2, Patrick Chesnut1, 
Natalie J Thomas1, Qing Ren1, Paul A Bunn2, Wilbur Franklin1, Dara 
L Aisner1  
1University Of Colorado, Pathology, Aurora/UNITED STATES OF AMERICA, 2Uni-
versity Of Colorado, Medicine, Aurora/UNITED STATES OF AMERICA, 3Universi-
ty Of Colorado, Radiology, Aurora/UNITED STATES OF AMERICA
Background: Non-small cell lung cancer (NSCLC) is often diag-
nosed on the basis of small samplings, including biopsies and fine 
needle aspirates (FNA). Although these specimens are primarily in-
tended to confirm a suspected diagnosis of lung cancer, a growing 
imperative is their utilization for molecular studies to help deter-
mine optimal therapy. Optimizing utilization of small samples is of 
importance to practitioners and patients, in an effort to reduce the 
time to molecular results and reduce the need for repeat sampling 
specifically for molecular analysis. We report our experience in the 
molecular diagnosis laboratory of the University of Colorado. 
Methods: We reviewed the methodological strategies to preserve 
tissue for testing as well as to make use of very small specimens 
applied to specimens from more than two thousand patients tested 
in the last two years and selected the first 75 lung cancer cases 
subjected to the “molecular priority’ testing for this study.
Results: Most specimens (72%) were submitted at disease pro-
gression. Core biopsies were prevalent (52%) followed by FNA 
(16%) and a combination of both (19%). Specimens were originated 
mostly from lung (52%), liver (13%), and lymph node (13%). Acquisi-
tion method was predominantly interventional radiology (89%) and 
bronchoscopy (8%). Success rate was similar when indication was 
initial disease or progression (~80%) and was positively correlated 
with the number of tumor cells present in the sample. The success 
rate was only impacted when the number of tumor cells was <50. 
We identified a set of strategic approaches that were categorized 
in two groups, (a) adaptable to routine practice and (b) requiring 
specialized handling methods. Among the successful approaches 
consideredy adaptable to routine practice, the most critical for 
improving the success rate of molecular testing were the improve-
ment in fixation workflow over the weekends, the minimization of 
decalcification in bone biopsies, and the minimization of block 
re-facing. Among the strategies that required specialized handling 
the highlights were for embedding each biopsy in an individual 
block, using smears for molecular testing, performing manual 
microdissection for tumor enrichment, limiting IHC testing, and 
customizing slide preparation (double cut). Examples of obstacles 
and potential solutions for managing small specimens in routine 
practice will be provided.
Conclusion: In the event that sampling must be performed spe-
cifically for molecular analysis, multiple steps can be performed by 
the pathology laboratory to maximize available tissue for molec-
ular studies. Main logistical issues are the timing of biopsies, sam-
pling of bony metastases, implications of performing a procedure 
specifically for molecular analysis, and constraints of specimen 
release. Strong emphasis is placed on the need for effective com-
munication throughout the multidisciplinary lung cancer team.
Keywords: resection, molecular diagnosis, biopsy, fine needle 
aspirate
POSTER SESSION 1 - August 22, 2014 09:00-18:00 
Topic: Pathology
P1.45
IMMUNOHISTOCHEMISTRY AS A PREDICTOR OF EGFR 
MUTATIONS: A RETROSPECTIVE CASE-CONTROL STUDY
Luis Corrales-Rodriguez1, Jad Abbas2, Allan Ramos-Esquivel1, Mon-
ica Araya3, Ana Maria Casco4  
1Hospital San Juan De Dios-Ccss, Medical Oncology, San Jose/COSTA RICA, 
2Hospital San Vicente De Paul-Ccss, Pathology, Heredia/COSTA RICA, 3Hospital 
San Juan De Dios-Ccss, Pathology, San Jose/COSTA RICA, 4Hospital Mexi-
co-Ccss, Pathology, San Jose/COSTA RICA
Background: Histological differentiation in NSCLC has been ad-
dressed recently due to the importance regarding prognosis and 
treatment options. Immunohistochemistry has helped differentiate 
those tumors with unclear histological characteristics aiding pa-
thologists determine the histological subtype in NSCLC. Within 
these subtypes, adenocarcinoma has been found to be linked with 
more frequency to EGFR mutations. Encountering EGFR mutations 
in NSCLC has permitted patients to benefit from targeted therapy 
addressing this alterations. Immunohistochemistry has not helped 
diagnose the EGFR mutations, and the diagnosis of these has been 
done through more elaborate and expensive testing. 
Methods: We conducted a retrospective analysis of patients from 
two central Costa Rican hospitals diagnosed with NSCLC between 
2011-2013. All patient’s tumor samples included for analysis must 
had immunohistochemical testing (at least TTF1 and CK7) as well as 
EGFR mutation analysis. Gender, mutation status, histological dif-
ferentiation, and immunohistochemistry testing was obtained. 
Results: Samples from 116 different patients were obtained. 53.4% 
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of patients were male and the median age of patients was 64.2 
± 13.6 years. 98.3% of patients had an adenocarcinoma. EGFR 
mutations were positive in 35.3% of samples with Exon 19 mutation 
being the most frequent mutation seen (48.8%) followed by Exon 
21 mutation (31.7%). Table 1. Clinical and immunohistochemical 
characteristics of the sample population 
Variable EGFR mutation positive
EGFR mu-
tation neg-
ative
p value
Male Gender (%) 20 (48.8) 42 (56) 0.29
Age (years) 64.6 ± 12.8 63.9 ± 14.1 0.78
Immunohistochemistry(%) 
CK7 + CK5/CK6 + CK20 
+ p63 + TTF1 + 
39 (95.1) 1 (2.4) 
4 (9.8) 2 (4.9) 35 
(85.4) 
70 (93.3) 1 
(1.3) 2 (2.7) 1 
(1.3) 52 (59.3) 
0.36 0.74 
0.04* 0.34 
0.02* 
 
*statistically significant
Conclusion: Given that EGFR mutation status is needed to deter-
mine the best treatment option for patients, EGFR mutation anal-
ysis should be done in all non-squamous NSCLC. In our sample, 
CK5/CK6 positive tumors was associated with EGFR mutations, 
but unfortunately the number of patients tested for CK5/CK6 was 
low. Positivity of TTF-1 was statistically associated with EGFR mu-
tation positive analysis. Eventhough immunohistochemistry may 
aid to determine which patients are EGFR mutation positive, all 
non-squamous NSCLC should continue to be tested using direct 
DNA sequencing.
Keywords: EGFR, Immunohistochemistry, TTF1, mutation
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PLACEMENT OF FIDUCIAL MARKERS FOR RADIATION 
THERAPY VIA ENDOBRONCHIAL ULTRASOUND. 
Christopher Parks1, Patricia Thompson2, Rabih Bechara1  
1Georgia Regents University/Cancer Treatment Centers Of America, Pulmonary, 
Newnan/UNITED STATES OF AMERICA, 2Cancer Treatment Centers Of Ameri-
ca, Medical Oncology, Newnan/UNITED STATES OF AMERICA
Background: Currently radiation therapy is a valuable treatment 
for patients with advanced stage or non operable cancer which 
involves the lungs or mediastinum. This therapy can involve consid-
erable mortality with damage to adjacent structures. To minimize 
the risk fiducial markers can be placed to help to guide treatment. 
Currently these markers are placed either by a transcutaneous 
approach which has a high risk of pneumothorax or via navigation-
al bronchoscopy which may not be available at all institutions. We 
describe a technique for the successful placement of markers via 
the use of endobronchial ultrasound. 
Methods: 10 consecutive patients who were scheduled to under-
go radiation therapy were selected. After consultation with the ra-
diation oncologist as to the proper locations for marker placement, 
the patients were brought to the endoscopy suite. There using 
standard procedures the patients were sedated by an anesthesiol-
ogist and an Olympus linear bronchoscope was inserted through 
the patients mouth into the airway. Using the linear ultrasound, the 
target lesion was identified. A fiducial marker was preloaded into 
a standard 21 gauge Olympus EBUS needle. This needle was then 
passed under direct visualization into the lesion. A guide wire was 
advanced expelling the marker into the lymph node. Its position 
was then confirmed immediately by ultrasound and finally by plan-
ning computed tomography prior to therapy. Patients were moni-
tored for bleeding and pneumothorax.
Results: A total of 23 markers were successfully placed. There was 
no bleeding or pneumothorax
Conclusion: EBUS appears to be a safe and effective method for 
placing fiducial markers.
Keywords: Interventional, EBUS, Radiation
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ENDOBRONCHIAL ULTRASOUND-GUIDED TRANSBRON-
CHIAL NEEDLE ASPIRATION BIOPSY COMPLICATED WITH 
MEDIASTINITIS
Margarida Felizardo1, Antonio Bugalho1, Paulo Calvinho2, Susana 
Simoes1, Sofia Furtado1  
1Hospital Beatriz Angelo, Pneumologia, Loures/PORTUGAL, 2Hospital Pulido 
Valente, Cirurgia Toracica, Lisboa/PORTUGAL
Background: Endobronchial Ultrasound-Guided Transbronchial 
Needle Aspiration (EBUS-TBNA) is a minimally invasive technique 
frequently used for the evaluation of mediastinal adenopathy and 
staging of lung cancer. 
Methods: We report the case of a male patient, 68 years old, for-
mer smoker of 50 packs per-year, with ischemic cardiomiopathy, 
high blood pressure, diabetes mellitus and moderated CPOD. In 
a routine thoracic CT scan (motivated by his COPD) a spiculated 
pulmonary nodule with 10mm was detected, in the periphery of 
the right upper superior lobe (RUSL). This nodule was staged as 
a cT1aN0M0 with a SUV of 3.55 by PET-CT scan. In November 
2013, the patient underwent a right upper lobectomy with medi-
astinal lymphadenectomy (4R, 7 and right hilar lymph nodes). The 
specimen pathology showed an adenocarcinoma (CK7 +; TTF1+; 
CK5 neg) and staged as pT1aN0Mx. The patient remained under 
oncological follow-up without adjuvant treatment and in March 
2014 the CT scan showed an increase of the mediastinal lymph 
nodes at stations 4R (22x15mm) and 7 (30x19mm) This situation 
was reported to the thoracic oncological board who decided to 
perform EBUS-EBNA in order to clarify the nature of these lymph 
nodes. The cytological description was one of a granulomatous 
foreign body reaction (the surgeon used Surgicel® as a bleeding 
controller at these stations). Ten days after the EBUS-EBNA he 
was admitted in the emergency room with an intense non pleuritic 
thoracic pain, located in the anterior chest wall, although without 
fever. The patient was diagnosed with mediastinitis by CT scan and 
submitted to a mediastinoscopy in order to drain stations 4R and 7. 
The fibrosis was intense and only station 4R was drained. Two days 
after the mediastinoscopic drainage the patient presented signs of 
septic shock and station 7 was drained by right posterior thoracot-
omy. Twenty days after the procedure the patient was discharged 
from the hospital free of symptoms and with no identification of the 
responsible microorganism. 
Results: not applicable
Conclusion: EBUS-TBNA is considered to be a safe procedure 
with extremely low rates of complications. Our case report alerts 
physicians to the risk of this rare but life-threatening complication 
following this technique.
Keywords: EBUS-TBNA, mediastinitis, complication, septic
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CHORIOCARCINOMA (CCM) METASTATIC TO THE LUNG 
IN POSTMENOPAUSAL WOMAN PRESENTING AS ENDO-
BRONCHIAL LESIONS, SEVERE HEMOPTYSIS AND RESPI-
RATORY FAILURE: CASE REPORT
Liliana Fernandez1, Laura Isabel Varela2, Luz Fernanda Sua3  
1Fundacion Valle Del Lili, Medicina Interna- Neumologia, Cali/COLOMBIA, 
2Fundacion Valle Del Lili, Oncologia, Cali/COLOMBIA, 3Fundacion Valle Del Lili, 
Patologia, Cali/COLOMBIA
Background: CCM is a malignant germ cell tumor characterized 
by a proliferation of syncytial cells and cytotrophoblasts, and by 
secretion of β-human chorionic gonadotropin (β-hCG). It can be 
divided into two types, gestational and non-gestational. CCM in 
postmenopausal woman is very rare. Treatment is based on classi-
fication into risk groups defined by the stage and scoring system. 
The overall cure rate with treatment is currently 90 %. We describe 
a case with predominantly pulmonary manifestations, in a 54 years 
old woman, 30 years after her last pregnancy, 20 years after an 
abortion and 10 years after her last period, without any manifesta-
tion of pelvic disease. 
Methods: We review the clinical history data.
Results: A 54 years old woman, pregnancies 4, para 3, abortion 1, 
with a history of pneumonia and empyema one year before admis-
sion, who continued with persistent pulmonary infiltrates and me-
diastinal lymphadenopathy requiring an open biopsy interpreted as 
lung cancer type adenocarcionoma. One month before admission 
she starts hemoptysis with a severe event in the last 24 hours with 
respiratory failure and need for invasive mechanical ventilation. 
The CT scan shows multiple nodular pulmonary lesions, mediasti-
nal lymphadenopathy and endobronchial masses. The new biopsy 
reports CCM, which is confirmed by chorionic gonadotropin 
levels at 280,000 units. An endoscopic resection was performed 
achieving stabilization of the acute clinical manifestations. She has 
three sons, the youngest is 30 years old, also had an abortion 20 
years ago, her menopause came at 45 years and had no abnormal 
bleeding. The pelvic examination and the abdominal and pelvic 
MRI were normal. We wanted to assess whether this was a primary 
or metastatic neoplasm, so we searched for the Y chromosome 
sequence by PCR on biopsy: SRY, DYS19, DYS392, DYS439 were 
positive. With this information we assumed that it was a CCM with 
metastases to lung whose origin could be in the previous pregnan-
cy or abortion in a patient without evidence of active pelvic disor-
ders. She started chemotherapy, she has had decrease in lung and 
mediastinal lesions with the chorionic gonadotropin levels close to 
normal today.  
Conclusion: This is a case of a CCM after a latency period of at 
least 20 years in postmenopausal woman confirmed by the pres-
ence of Y chromosome specific sequences by PCR in the biopsy. 
Treatment with chemotherapy for high-risk gestational trophoblas-
tic disease risk with etoposide, methotrexate and dactinomycin, 
followed by cyclophosphamide and vincristine was successful.
Keywords: respiratory failure, choriocarcinoma, hemoptysis, en-
dobronchial intervention
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MALIGNANT PRIMARY PULMONARY HEMANGIOPERI-
CYTOMA/SOLITARY FIBROUS TUMOR (HPC/SFT) WITH 
EXTENSIVE ENDOBRONCHIAL INVOLVEMENT: A CASE 
REPORT
Liliana Fernandez1, Laura Isabel Varela2, Luz Fernanda Sua3  
1Fundacion Valle Del Lili, Medicina Interna- Neumologia, Cali/COLOMBIA, 
2Fundacion Valle Del Lili, Oncologia, Cali/COLOMBIA, 3Fundacion Valle Del Lili, 
Patologia, Cali/COLOMBIA
Background: (HPC/SFT) is a rare mesenchyme neoplasm; rep-
resent less than 1% of vascular tumors. It originates from the cells 
that surround endothelial tissue. The most common sites were the 
head and neck, lower extremities and retroperitoneum; its primary 
localization in the lung and endobronchial is extremely rare. Are 
considered malignant when they have more than four mitoses per 
high power field, cellular atypia, necrosis and hemorrhage. We 
report the case of a patient with a malignant primary pulmonary 
(HPC/SFT) with extensive endobronchial involvement.
Methods: We review the clinical history data.
Results: This is a woman of 40 years old with a history of dyspnea, 
chest pain and hemoptysis, who was a lung mass in the right hemi-
thorax with loss of volume and endobronchial lesions evident on 
the CT. In biopsies taken by bronchoscopy diagnosis was inconclu-
sive, then open biopsy was carried in which document (HPC) with 
high mitotic activity and necrosis. Figure 1 shows CT, endobronqui-
al lesions and endoscopic resection. She was not surgical candi-
date for the extension of the disease, and their oncologist decided 
start chemotherapy with doxorubicin and ciclofosfamide in the 
ICU make possible to retire mechanical ventilation support, after 
she started bevacizumab plus temozolamide with excellent clinical 
and radiological response. For the management of endobronchial 
lesions therapeutic bronchoscopy was done using electrocautery 
and argon plasma coagulation, with permeability of the airway 
and control of episodes of hemoptysis. Endobronchial lesions 
subsequently progressed and she died one year after diagnosis. 
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Conclusion: HPC/SFT is a rare tumor; surgical resection is the 
treatment of choice. Chemotherapy with doxorubicin-based 
schemes has been used with ifosfamide or gemcitabine and 
docetaxel, with only a modest disease control. Combination 
therapy with temozolomide and bevacizumab appears to provide 
clinical benefit with a low rate of major toxicities. Interventional 
pulmonology offers an effective palliative treatment to reduce 
symptoms, the risks of bleeding and improve the quality of life
Keywords: metastatic malignancies, respiratory failure, hemangio-
pericytoma/solitary fibrous tumor, interventional pulmonology
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PLEURAL METASTASIS OF MELANOMA ACHIEVED LONG 
TERM SURVIVAL AFTER COMBINATION OF INTERFERON 
AND CHEMOTHERAPY
Bulent Karagoz1, Ahmet Ozet2  
1Gata Haydarpasa Training Hospital, Medical Oncology, Istanbul/TURKEY, 2Gazi 
University, Medical Oncology, Ankara/TURKEY
Background: Pleural metastases from melanoma are not common 
and prognosis of metastatic melanoma is poor. Pre-targeted treat-
ment era, the combination of interferon-α (IF- α) plus chemothera-
py had been used and have generally short response duration. 
Methods: Herein, we present a melanoma case with pleural me-
tastases achieved long-term durable complete response (CR) IF-α 
plus chemotherapy and IF-α maintenance therapy and had lower 
Regulatory T (Treg) cells.
Results: A fifty-year old woman was admitted to the hospital with 
malignant melanoma in left shoulder. In twenty-eighth month of 
adjuvant IF-α treatment, pleural and skin recurrences occurred. 
Lactate dehydrogenase (LDH) level was 660 U/L. The percentage 
of CD4+CD25+ Treg cells was 2.4% in CD4+ lymphocytes. The 
IF-α plus chemotherapy and IF-α maintenance were administered. 
After six courses chemotherapy, CR was achieved. Vitiligo and 
hypothyroidism occurred. The patient has remained in CR for ap-
proximately 7 years until second pleural metastases was detected 
and death.
Conclusion: The patient has positive prognostic factors such as 
induction of autoimmunity, small tumor volume, mild elevated LDH 
level, and lower Treg cell percentage. She survived long term with 
CR after IF-α treatment with concurrent chemotherapy and main-
tenance. IF-α plus chemotherapy may be a treatment option for 
metastatic melanoma in selected cases who cannot reach to new 
targeted drugs.
Keywords: pleural metastasis, melanoma, interferon, chemotherapy
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EVEROLIMUS PLUS OCTREOTIDE LAR IN PATIENTS WITH 
LUNG CARCINOIDS
Dan Granberg1, Nicola Fazio2, Ashley Grossman3, Stephen Sale-
tan4, Ashok Pannnerselvam5, Edward Wolin6  
1Department Of Medical Sciences, Uppsala University, Department Of Endocrine 
Oncology, Uppsala/SWEDEN, 2European Institute Of Oncology, Milan/ITALY, 
3Oxford Centre For Diabetes, University Of Oxford, Oxford/UNITED KING-
DOM, 4Novartis Pharmaceuticals Corporation, Florham Park/UNITED STATES 
OF AMERICA, 55Novartis Oncology Biometrics And Data Management, Florham 
City/UNITED STATES OF AMERICA, 6Cedars-Sinai Medical Center, Los Angeles/
UNITED STATES OF AMERICA
Background: Metastatic lung carcinoids are rare neoplasms. The 
therapeutic effects of medical treatments have so far been disap-
pointing. Possible alternatives include temozolomide and peptide 
receptor radionuclide treatment with 177Lutetium-DOTA-Octreo-
tate. In the RADIANT-3 study, everolimus was shown to prolong 
progression-free survival in patients with pancreatic neuroendo-
crine tumors, which also belong to the foregut tumors. 
Methods: A subanalysis was performed from the phase 3, ran-
domized, placebo-controlled RADIANT-2 study, evaluating the 
efficacy and safety of everolimus plus octreotide long-acting 
repeatable (LAR) in the included patients with low- to interme-
diate-grade advanced lung carcinoids. Patients were randomly 
assigned to everolimus 10 mg once daily plus octreotide LAR 30 
mg every 28 days (n = 33) or placebo plus octreotide LAR 30 mg 
every 28 days (n = 11). The primary end point was progression-free 
survival (PFS). Secondary end points included objective response 
rate, overall survival, change from baseline in biomarker levels, and 
safety outcomes.
Results: Median PFS was 13.63 months in the everolimus plus oc-
treotide LAR arm compared with 5.59 months in the placebo plus 
octreotide LAR arm. More patients receiving everolimus plus oct-
reotide LAR (67%) experienced minor tumor shrinkage (not partial 
response as per RECIST [Response Evaluation Criteria in Solid 
Tumors]) than those receiving placebo plus octreotide LAR (27%). 
Most frequently reported adverse events (AEs) included stomatitis, 
rash, diarrhea and asthenia, which was consistent with the overall 
RADIANT-2 trial and the safety profile of everolimus.
Conclusion: This exploratory subgroup analysis of the RADI-
ANT-2 trial indicates that the combination of everolimus plus 
octreotide LAR has antitumoral activity in patients with advanced 
lung carcinoids, and improves median PFS by 2.4-fold compared 
with placebo plus octreotide LAR. These clinically significant ob-
servations support that everolimus treatment regimens need to 
be further studied in this patient population. An ongoing 3-arm 
randomized trial is currently comparing everolimus, pasireotide 
and the combination of everolimus plus pasireotide in patients with 
advanced typical and atypical lung carcinoids.
Keywords: lung carcinoid, new treatment, everolimus
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THE IMPACT OF PLEURAL CATHETER POSITION ON THE 
SUCCESS OF BEDSIDE PLEURODESIS
Ricardo Mingarini Terra, Pedro Henrique Xavier Nabuco De Arau-
jo, Rodrigo Caruso Chate, Paulo Pego-Fernandes  
Thoracic Surgery, Heart Institute (Incor), University Of Sao Paulo Medical School, 
Sao Paulo/BRAZIL
Background: To investigate the impact of the pleural catheter po-
sition on the success of bedside pleurodesis, residual pleural space 
after effusion‘s drainage and acumulation of effusion pos pleurod-
esis in patientes with recurrent malignant pleural effusions (RMPEs).
Methods: We retrospectively analysed 80 patients with RMPEs 
treated with pleurodesis (talc or silver nitrate slurry) at our hospital 
between June 2009 and September 2013. The position of the 
pleural catheter (14 Fr pigtail) was categorized as posterolateral 
(PL), anterior (A), fissural (F) and subpulmonary(SP) based on the 
location of the fenestrated portion of the cateter visualized at chest 
CT. Pleurodesis was considered successful when no additional 
pleural procedure was necessary. The pleural volume on CT was 
measured after drainage of the pleural effusion and one month 
after that. We used that data to calculate the residual pleural space 
after effusion drainage and the accumulation of effusion pos pleu-
rodesis. 
Results: A total of 80 patients (61 female, 19 males, mean age 60.5 
years) were included. The median Karnofsky Performance Status 
index was 60. In 45 patients we used talc and in 35 silver nitrate. 
The primary neoplasm was breast in 40 patients, lung in 20, ovary 
in 9, colon, prostate, kidney and indeterminate in 2 and thyroid, 
stomach and pancreas in 1. The position of the pleural catheter 
was posterolateral in 17 cases, anterior in 20, fissural in 10 and 
subpulmonary in 33. Successful pleurodesis was achieved in 71 
patients (88.8%), with a similar distribution between groups (88.2 
% in PL, 85% in A, 90% in F and 90.9% in SP, p=0.928). The mean 
initial pleural volume was 379 ml (171-775), there was no significant 
difference between the groups (460 (185-643.7.2) in PL, 340 
(91.6-1067) in A, 296.2 (91.97-678.87) in F and 367 (189.5-763) in 
SP, p=0.703). The mean difference between one month and initial 
pleural volumes was 38 ml (-344-247), there was no significant 
difference between the groups (69.5 (-217-218.5) in PL, 93.3 (-457-
256.6) in A, -15.35 (-322.32-334.12) in F and -4 (-282.85-333.85) in 
SP, p=0.995). 
Conclusion: In this study, the success of bedside pleurodesis, the 
residual pleural space after effusion drainage and the acumulation 
of effusion after pleurodesis were not affected by the position of 
the pleural catheter. Regardless the pleural catheter position, bed-
side pleurodesis could be used to palliate the symptoms in patients 
with RMPEs.
Keywords: recurrent malignant pleural effusion, pleurodesis, 
Chest CT, pleural catheter
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PREDICTORS OF HOSPITAL DISCHARGE IN CANCER PA-
TIENTS WITH PERICARDIAL EFFUSION WHO UNDERGO 
SURGICAL PERICARDIAL DRAINAGE
Ricardo Mingarini Terra, Thamara Kazantzis, Leticia Leone Lau-
ricella, Pedro Henrique Xavier Nabuco De Araujo, Alberto Jorge 
Monteiro Dela Vega, Benoit Bibas, Paulo Pego-Fernandes  
Thoracic Surgery, Heart Institute (Incor), University Of Sao Paulo Medical School, 
Sao Paulo/BRAZIL
Background: Pericardial effusion (PE) is a complication of late-
stage cancer and operative pericardial drainage is its standard 
treatment. However, in many patients PE is an end-of-life event 
and some never leave the hospital despite the procedure. The 
main objective of this study was to identify predictors of hospital 
discharge in patients with cancer who coursed pericardial effusion 
and underwent operative pericardial drainage. We also looked at 
predictors of ICU discharge and overall survival and also factors 
that might be associated with paradoxical hemodynamic instability 
(PHI). 
Methods: Retrospective study carried out in a tertiary cancer cen-
ter. We included all patients with known malignancy who coursed 
with PE and underwent surgical pericardial drainage from 2010 
to 2014. Patients who underwent previous pericardial drainage or 
only needle pericardiocentesis were excluded from the study. 
Results: Out of the 90 patients included in this study, fifty one 
were discharged from hospital (56%). Renal failure and pulmonary 
embolism negatively influenced the chances of hospital discharge 
[OR 0,247; p=0,039 and OR 0,293; p=0.089, respectively]. On 
the other hand, patients who received recent chemotherapy were 
more likely to leave the hospital (OR 3,9; p=0,009). 55 patients 
(61%) were discharged from ICU. Renal failure was the main deter-
minant of that (OR 0,284 (p=0,047)). Mean survival was 138.2 days 
(95% CI 84,48-189,90), influenced only by ECOG status (OR 1,258; 
p=0,047). PHI occurred in 6 patients and all of them died within 30 
days after surgery. In our series, we could not identify predictors 
for PHI.
Conclusion: In this study we demonstrated that almost half of 
cancer patients admitted with PE requiring drainage never leave 
the hospital. Renal failure and pulmonary embolism are strong 
predictors of in-hospital death. PHI remains a serious condition 
with causes unknown.
Keywords: pericardial effusion, pericardial drainage, hospital 
discharge, overall survival
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WEB-BASED THORACIC SURGERY ONLINE COURSE: 
INCREASING ACCESS, CONNECTING PEOPLE AND DE-
CREASING INEQUALITIES. FEASIBILITY RESULTS.
Ricardo Mingarini Terra, Pedro Henrique Xavier Nabuco De Arau-
jo, Alessandro Wasun Mariani, Alberto Jorge Monteiro Dela Vega, 
Paulo Pego-Fernandes  
Thoracic Surgery, Heart Institute (Incor), University Of Sao Paulo Medical School, 
Sao Paulo/BRAZIL
Background: Access to knowledge, information and quality edu-
cation is a huge issue in many countries. Web-based technologies 
are considered powerful resources to spread knowledge and are 
supposed to improve access to better education. Nevertheless, 
very few initiatives have evaluated feasibility and efficiency of these 
methods in the field of thoracic surgery. The purpose of this study 
was to evaluate the implementation and feasibility of an exclusively 
on-line thoracic surgery course. 
Methods: We designed an 8-month on-line course based on an 
open-source learning software (MOODLE) focusing on thoracic 
oncology. It was divided in fifteen 2-week modules, each of them 
including activities as cornerstone articles reading, forum discus-
sion, and recorded classes. Grading was based in gamification, 
students accumulated points according to tasks they completed. 
We gave particular importance to forum discussion, which was an 
evidence-based clinical scenario discussion.
Results: So far, 2 editions of the course were completed (2012 
and 2013). Overall, 40 people enrolled, 21 in 2012 and 19 in 2013, 
most of them residents (31) from all over the country. 60% of them 
finished the course and were approved (drop-out rate was around 
35%). Website use varied a lot over the time and some topics were 
very popular as staging and treatment or early lung cancer. Most 
students said they spent 3 to 4 hours per week on course activities. 
The study hours were evenly distributed over the day but predom-
inated on Sunday, Monday and Tuesday. Student satisfaction with 
the model was high, all those who answered the end-of-course 
survey rated it as good or excellent. 
Conclusion: This preliminary analysis showed that the online learn-
ing model is feasible even when using free online tools. Despite the 
high drop-out rate, we were able to provide education to students 
from all over the country and their satisfaction rate was high.
Keywords: e-learning, thoracic surgery, Online Course, thoracic 
oncology
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UNDERREPRESENTATION OF HISPANICS IN LUNG CAN-
CER CLINICAL TRIALS: URGENT NEED TO UNDERSTAND 
THEIR BETTER OUTCOMES
Jorge Arturo Rios1, Goetz H Kloecker1, Cristian Daniel Rios-Perez2, 
Neal E Dunlap3  
1University Of Louisville School Of Medicine, Division Of Hematology/Oncology, 
Louisville/UNITED STATES OF AMERICA, 2Universidad Peruana Cayetano He-
redia, Lima/PERU, 3University Of Louisville School Of Medicine, Department Of 
Radiation Oncology, Louisville/UNITED STATES OF AMERICA
Background: Patients of Hispanic ethnicity have better lung can-
cer survival rates despite lower socio-economic status and more 
advanced stages at diagnosis compared to other ethnic groups. 
There is increasing evidence that not only socio-economic factors 
but also genetic differences might play an important role on this 
“Hispanic Paradox”. Further insight into this paradox requires a bet-
ter understanding of the impact of Hispanic ethnicity on the me-
tabolism of drugs and their efficacy in this ethnic group. A critical 
step to this goal is to ensure adequate representation of this ethnic 
group in clinical trials. We aimed to study the degree of underrep-
resentation of hispanics in lung cancer trials. 
Methods: We conducted a systematic review of all the lung can-
cer trials registered with the US National Institute of Health (NIH). 
We included in our analysis all registered trials that reported results 
to the NIH, regardless of whether they were published or not. 
Results: Of 370 trials with results reported, 150 (40.5%) reported 
race and/or ethnicity and were analyzed. A total of 85,880 patients 
were enrolled in these trials. Hispanics represented 0.32% of all 
the patients included in these studies. The degree of participation 
of hispanics was similar on phase I (0.41%), II (0.57%) and III/IV 
(0.30%) clinical trials. When compared to other ethnic groups with 
reportedly different outcomes in lung cancer (Asians, 10.26%), we 
observed significant difference on the participation of each ethnic 
group in clinical trials (p<0.001).
Conclusion: Despite the increasing evidence that better lung can-
cer outcomes in patients with Hispanic ethnicity might be related 
to differences in genetic background and drug-efficacy in this 
group, they are significantly underrepresented in the clinical trials 
conducted to date. Strategies to ensure accrual of this group to 
clinical trials to better understand the differences in outcomes are 
required.
Keywords: Clinical Trials, Hispanic ethnicity, Disparities, Outcomes
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THORACIC ONCOLOGY CLINIC: OUR FIRST 200 CASES. 
SAN JOSÉ, COSTA RICA.
Raquel Rojas Vigott, Luis Ugalde Gamboa, Jose Rojas Solano  
Ccss, San Jose/COSTA RICA
Background: Lung Cancer has been gaining increasing interest 
in our country, because there is a higher number of cases and the 
capacity to make a diagnosis and give opportunities of treatment 
to the patients. As we realized, this is a complex pathology, and 
heterogeneous disease. For that reason, we decided three years 
ago, to organize a multidisciplinary approach for lung cancer pa-
tients and to obtain our own statistics.
Methods: We reviwed 200 cases (files) and followed the patients 
during the last 3 years. (Retrospective study)
Results: We have attended 200 patients with the diagnosis of 
lung cancer. The average age of diagnosis was 63 years old. (From 
33 to 92 years old) 10% of our patients were fewer 45 years old. 
62% were males and 38% females. 68% of our lung cancer pa-
tiens had Adenocarcinoma histology, 17% squamous cell and 10% 
Small Cell Lung Cancer. 59% were people who used to smoke. 
41% were people who have never smoke. 69% were stage IV, 16% 
stage III (A,B) and 15% Stage I. From patients in stage IV, 73% of 
them, recieved some medical treatment (chemotherapy or target 
therapy). Of the patients in stage IV, who received some treatment, 
85% received chemotherapy and 15% target therapy. 88% of the 
patoients who received chemotherapy, completed 4 cycles. We 
tested 100 patients who had adenocarcinoma for EGFR mutation. 
26% of the patients with adenocarcinoma had EGFR (+) 53% exon 
19, 7% exon 20, 34% exon 21 and 4% a patient with both : exon 20 
and 21. 9 patients have received treatment with Erlotinib. 6 of them 
have accomplished at least 10 months os PFS, and at least 1.5 years 
of OS. 
Conclusion: We understand that lung cancer is a complex disease 
and we are getting our first results of the multidisciplinary work 
in our hospital. We are so motivated to continue working in this 
particular cancer and to understand the profile of our patients. The 
majority of the patients are in stage IV, nevertheless, the major part 
of them, have the opportunity to received some medical treat-
ment. Testing for EGFR is now a routine exam for every patient with 
adenocarcinoma. Analysis of new targets (ALK) is our concern and 
we are working on that. We are analizing the actual data in relation 
to OS and PFS.
Keywords: Lung Cancer, Costa Rica, Epidemiology, 200 cases
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EVALUATION OF HOSPITALIZATION TRENDS IN LUNG 
CANCER PATIENTS WITH HYPONATREMIA
Haseeb A Kazi1, Madhusmita Behera2, Conor Steuer2, Taofeek 
Owonikoko2, Rathi Pillai2, Suresh S Ramalingam2, Fadlo R Khuri2  
1Emory University School Of Medicine, Department Of Medicine, Atlanta/UNIT-
ED STATES OF AMERICA, 2Emory University School Of Medicine, Department 
Of Hematology/Oncology, Atlanta/UNITED STATES OF AMERICA
Background: Hyponatremia is a common inpatient diagnosis and 
prognostic factor in lung cancer. We evaluated hospitalization data 
by age categories in lung cancer patients with hyponatremia. 
Methods: Using the Healthcare Cost and Utilization Project 
(HCUP) Nationwide Inpatient Sample (NIS) database, we reviewed 
patients with any concurrent diagnosis of lung cancer and hypo-
natremia from years 2006 to 2010. The total number of patients 
was subcategorized by age to compare less than 70 years old, 
between ages 70 and 80 and greater than 80 years (eldest group). 
Demographics extracted include length of stay (LOS), cost of 
hospitalization, mortality, sex, race, household income quartiles, 
severity of illness, teaching and urban hospital status, and number 
of concomitant comorbidities. Comorbidities were compared to 
LOS and cost of hospitalization in each age category.
Results: Out of 570,304 hospitalizations related to lung cancer, 
hyponatremia was observed in approximately 8%. Of these, 51% 
(24,222) were less than age 70 (median age 61), 34% (15,798) be-
tween ages 70 and 80 (median age 75), and 15% (7151) greater than 
age 80 years (median age 84). Mortality rate was 12.1% (2932), 11.1% 
(1752) and 10.5% (752) with increasing age by categories as men-
tioned. The percentage of female patients, 44.2% (10703), 50.3% 
(7947) and 55.8% (3990) increased with older age groups. Median 
LOS was 6 days in all groups. Median hospitalization charges were 
$30,790 for age <70, $30,216 for 70-80 years and $27,223.50 for 
>80 years. Severity of illness in each category was comparable. The 
<70 age group had the greatest percentage (29.5%) in the bottom 
median household income quartile and the age >80 group had the 
greatest percentage (26.2%) in the top median household income 
quartile. As the number of comorbidities in each age category in-
creased, there were higher hospitalization costs and longer LOS.
Conclusion: Hyponatremia contributes to hospitalizations in a 
significant subset of lung cancer patients and is associated with a 
mortality of nearly 12%. There was a higher cost and longer LOS 
with an increasing number of comorbid conditions.
Keywords: hyponatremia, Lung Cancer, inpatient
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FREE CIRCULATING DNA LEVELS IN INDIVIDUALS WITH 
LUNG CANCER RISK AND CHARACTERIZATION OF COPY 
NUMBER ALTERATIONS.
Carolina Andrea Tamayo1, Ulises Urzúa1, Marcos Chahuan2, Rosana 
Miranda3, Mónica Campos2, Alcides Zambrano4, Hugo Benítez4, 
Pedro Marín4, Lionel Gil1, Marta Adonis1  
1Cetecancer, Faculty Of Medicine, University Of Chile, Santiago/CHILE, 2Hospital 
San Borja Arriarán, University Of Chile, Santiago/CHILE, 3Hospital Barros Lucos 
Trudeau, Santiago/CHILE, 4Hospital Regional De Antofagasta, Antofagasta/
CHILE
Background: Lung cancer (LC) is the leading cause of cancer-re-
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lated mortality worldwide and in Antofagasta region, and the 
second cause of cancer mortality in Chile. The high mortality of LC 
has been associated to diagnosis in advances stages. In this con-
text, new technologies for early detection are clearly important. 
Free circulating DNA (fcDNA) in serum or plasma has been de-
scribed as a promising cancer marker. A high concentration as well 
as genetic and epigenetic alterations of fcDNA has been associat-
ed to various types of cancer. This work has proposed to determine 
the levels of fcDNA in a population with high risk of LC and also to 
characterize its Copy Number Alterations (CNAs), some of which 
can be frequently found in solid tumors, including LC tumors. 
Methods: Volunteers enrolled in an early detection project (CeTe-
Cancer), were classified as LC free subjects (C), Pre Neoplastic Le-
sions (PNL) and Lung Cancer (LC), according to results of Quantita-
tive Automatic Cytology (QAC) in sputum specimen, DR70 tumour 
marker, and Autofluorescence Bronchoscopy (AFB). fcDNA was 
isolated from serum of the three groups of volunteers, quantified 
by qPCR and amplified. The amplified fcDNA was co-hybridized 
against genomic DNA from total blood, using microarray-HGC.
Results: LC volunteers showed higher fcDNA levels than C and 
PNL volunteers. Four recurrent and significant deletions were 
detected in 2p, 7q, 11q and 17p in LC volunteers. Non significant 
alterations were detected in PNL. Genes located in segments with 
CNAs were related in immune response, xenobiotic metabolism 
and oxidative phosphorilation and associated to , cell proliferation, 
cell cycle regulation, apoptosis, differentiation and cellular adhe-
sion and migration, all functions relevant to neoplastic progression.
Conclusion: Molecular characteristic of fcDNA suggest that its 
might be used as biomarker associated to malignancy of LC, as a 
non invasive and complementary tool for the diagnosis of LC.
Keywords: Lung Cancer (LC), Early Detection, Pre Neoplastic 
Lesions (PNL), Free circulating DNA (cfDNA), Copy Number Alter-
ations (CNAs), Biomarker
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CONTRIBUTION OF THE PERUVIAN COMMISSION 
AGAINST TOBACCO (COLAT PERU)
Abel Limache-García1, Luis Pinillos-Ashton2, Carmen Barco-Ol-
guin1, Carlos Farias-Alburqueque1  
1Comisión De Lucha Antitabaquica Perú, Lima/PERU, 2Comisión De Lucha Antita-
baquica, Lima/PERU
Background: Smoking is a public health problem; tobacco use is re-
sponsible for one in three cancer related deaths. The tobacco indus-
try has developed different strategies to increase its consumption, 
false and immoral advertising and the creation of a group of unreal 
social responsibility. In Peru before 1985 the tobacco consumption 
was allowed everywhere, more the 95% of teenagers ignored the 
risk of smoking and there was not awareness of tobacco as a public 
health problem. The Peruvian commission against tobacco was 
created in 1985 and the first step was to create awareness of the 
problem through social mobilization. We organized concerts, long 
walks, bicycle and running events, musical festivals, planting of 1000 
trees in one minute. We coordinated with the Ministry of Education 
to include in the school curricula information about “The Pleasure 
of not Smoking”. We coordinated with governmental institutions 
to create cessation programs, informative campaigns and through 
advocacy actions, like a meeting of past Ministers of Health; we 
promoted laws to prohibit smoking in public places. In 2004-2005, 
two events helped tobacco control, Peru signed the Framework 
Convention on Tobacco Control and a Multisectorial Coalition 
against Cancer was created with the participation of the public and 
non public sector, our Commission integrated the Coalition and pro-
moted a new law according the Framework Convention. The actual 
law prohibits smoking in public places (100% free from smoke), the 
graphic warnings are in both sides of the pack, and other regulatory 
standards according Convention Tobacco Control. Currently the risk 
of smoking is known, there is respect for non-smokers and the law is 
complied. The day of non-smokers was established (May 31th) and 
the opinion leaders are engaged. Now we are working to eliminate 
all the tobacco publicity, increase the tobacco taxes and improve 
cessation services. Health and Tobacco control for all and by all. 
Methods: Not applicable
Results: Not applicable
Conclusion: Not applicable
Keywords: tobacco, control, social movilization
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LUNG CANCER IN BRAZIL: TRENDS AND GENDER  
DIFFERENCES
Maria Teresa Ruiz Tsukazan1, Álvaro Vigo1, Carlos Barrios2, Jayme 
De Oliveira Rios3, Ricardo Nery Da Silveira3, Arthur Vieira3, Gabriel 
Menna Barreto Schwarcke3, José Antônio Figueiredo Pinto3  
1Ufrgs, Epidemiology, Porto Alegre/BRAZIL, 2Pucrs, Famed- Oncology, Porto 
Alegre/BRAZIL, 3Pucrs, Famed- Thoracic Surgery, Porto Alegre/BRAZIL
Background: The objective of this study is to describe the trends 
of histology and age in patients with non-small cell lung cancer 
(NSCLC) treated with lung resection according to gender. The his-
tology of lung cancer is changing in developed countries and there 
is still little information available for developing countries. 
Methods: Data collected by reviewing medical records of all pa-
tients (N=817) with NSCLC treated with lung resection between 
1986 and 2010 in a university hospital of Southern Brazil. Differ-
ences in histology, stage and type of surgery were analyzed by sex 
and period (1986-1990, 1991-2000 and 2001-2010). Analyses were 
performed at significance level of 5%.
Results: Most patients were males (70%), and the main histologic 
types found were squamous cell carcinoma (44.2%) and adeno-
carcinoma (40%). While the mean age at surgery was 52.7 years 
for women and 57.3 years for men in the first period, it was 60.1 for 
women and 63.9 for men in the last period (p<0.001), indicating 
that even though the overall age increased in both genders it was 
approximately 3.1 years higher for men (p<0.001), in spite of the 
period. The proportion of histologic types were different by gen-
der (p<0.001), showing that overall squamous cells carcinoma was 
more frequent in men (49.4%) than in women (32.3%), and the op-
posite occurred for adenocarcinoma (37.3% versus 45.6% for men 
and women, respectively). Analyses by period showed squamous 
cells carcinoma declined from around 40% in the two first periods 
to 29% in 2001-2010 for men, virtually equaling the proportion of 
adenocarcinoma in the last period. The proportion of adenocar-
cinoma in women increased from 22% in the first period to 36% 
in the last decade. Considering all NSCLC patients, females with 
adenocarcinoma represented 9.4% in the first period, 12.5% in the 
second and 16.8% in last period.
Conclusion: As seen in developed countries, the rates of lung 
cancer in females are rising over the last three decades, but have 
not yet surpassed male rates. Adenocarcinoma is consistently the 
most frequent histological type in women. In men, the squamous 
cell rate is decreasing, approaching the adenocarcinoma rate.
Keywords: Lung Cancer, Histology, Epidemiology, Gender
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EPIDEMIOLOGIC PROFILE OF PATIENTS WITH ALK/EML4 
MUTATION IN A PRIVATE CLINIC
Maria Fernanda Simões, Camila Pinto Barone, Eldsamira Mascar-
enhas  
Núcleo De Oncologia Da Bahia, Salvador/BRAZIL
Background: The identification of specific molecular alterations 
in non small cell lung cancer (NSCLC) is critical for the therapeutic 
choice, with benefit of using molecular targeted therapy in these 
cases. One of these changes is ALK (Anaplasic Lymphoma Kinase) 
mutation. Activation of ALK in NSCLC involves rearrangements of 
genes, resulting, for example, in ALK-EML4 fusion. Patients with 
NSCLC and ALK-EML4 fusion have specific features: adenocarci-
noma histological type, little/no exposure to smoking and young 
age. ALK is present in about 5% of all cases of NSCLC and is very 
important investigate the rearrangement, especially in patients with 
this characteristics. Regarding treatment, molecular target therapy 
with kinase inhibitors, such as Crizotinib, showed an increase in 
progression-free survival (PFS), response rate and improved quality 
of life in patients with advanced disease compared to chemother-
apy with Pemetrexed or Docetaxel. This study aims to describe the 
profile of patients with ALK mutation in treatment in a private clinic. 
Methods: Descriptive, observational, retrospective study was 
conducted through analysis of medical records of four patients 
with ALK positive NSCLC undergoing treatment in a private 
clinic in Salvador-Brazil, Núcleo de Oncologia da Bahia. Ana-
lyzed seas following variables: sex, race, date of birth, tobacco 
exposure, date of diagnosis, histological type of lung cancer, 
staging, number of lines of chemotherapy, type of chemother-
apy and survival.
Results: Among the four patients with NSCLC with ALK/
EML4 mutation, all were diagnosed in the period 2010-
2013 (Table 1). Were three females and one male, and as 
skin color, two patients were black, one white and one 
brown. At diagnosis, the mean age was 38 years (32-51). 
 
Regarding histological type, all patients had adenocarcinoma and 
were diagnosed with stage IV NSCLC already. Patients underwent 
an average of 3 (2-5) different chemotherapies and survival was 35 
months (8-60) and only one patient died yet this study. Pemetrexed 
was done in three patients until disease progression, in a period 
between 2 months to 3 years. Subsequently, these patients used 
Crizotinib, with time use and drug response ranging from 7 months 
to 2 years and 6 months. Only one patient didn’t use the target 
therapy because he showed good clinical response to first-line 
chemotherapy.
Conclusion: The epidemiologic profile found was compatible 
with the literature because patients had adenocarcinoma, were 
young (mean age 38 years) and never smoked. As for treatment, it 
was observed that use of Crizotinib improved PFS rates compared 
to chemotherapy with Pemetrexed, a rate of 24.5 months versus 
13 months, respectively. In conclusion, patients with NSCLC with 
ALK-EML4 mutation have great benefit with the use of targeted 
molecular therapy.
Keywords: Non Small Cell Lung Cancer, ALK mutation
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EFFECT OF TARGETED THERAPY IN THE OVERALL SUR-
VIVAL IN PATIENTS WITH LUNG CANCER.
Alfredo Aguilar1, Luis Mas1, Luis Pinillos2, Claudio Flores1, Joseph 
Arturo Pinto1, Priscila Valdiviezo1, Juan Fernando Suazo1, Carlos 
Vallejos1  
1Oncosalud -Auna, Lima/PERU, 2Radioncologia, Lima/PERU
Background: Incorporation of target therapy (TT) had improved 
the survival of advanced lung cancer patients. Here we report the 
experience in a Peruvian Private Institution. 
Methods: Retrospective study of a database of lung cancer pa-
tients clinically managed at Oncosalud-Auna (Lima, Peru) between 
2005-2013 that were treated with the Chemotherapy and TT 
(TT-group) or conventional chemotherapy (only-chemo group). 
Targeted therapy included Bevacizumab, Crizotinib, Erlotinib, Afa-
tinib, Cetuximab, Gefitinib. Overall survival was analyzed with the 
Kaplan- Meier method and survival curves comparisons were done 
using the log-rank test.
Results: From 120 patients with evaluable treatment, 51 had re-
ceived TT. Age ranged from 36 to 82 years, with a median of 66 
years in patients treated with TT and 67 years for the only-chemo 
group. Fifty percent and 36.4% of female and male patients, re-
spectively, received TT; 46.4% y 33.3% of patients under and over 
70 years received TT,respectively. The proportion of patients who 
received TT do not present significant difference in relation to sex 
and age group (p>0.05). Fifty one percent and 62.3% of patients 
died in the TT group and the only chemo group, respectively. The 
median of survival in the TT group was 36 months (CI95%: 24.1 − 
47.9) and in the only-chemo group was 14.8 months (CI95%: 11.3-
18.2). Two-years overall survival was 61.2% vs 35.3% for the TT and 
only-chemo groups respectively (p=0.004)
Conclusion: Targeted therapy improved the prognosis in lung can-
cer patients when is compared with conventional chemotherapy 
treatment.
Keywords: Lung Cancer, overall survival, Target therapy
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EARLY EXPERIENCE WITH THORACOSCOPIC RESECTION 
OF SMALL PULMONARY NODULES WITH PRE-OPERATIVE 
LIPIODOL MARKING.
José Miguel Clavero1, Andrés O´brien2, David Lazo1, Antonio Piot-
tante3  
1Clínica Las Condes, Thoracic Surgery, Santiago/CHILE, 2Clínica Las Condes, 
Radiology, Santiago/CHILE, 3Clínica Las Condes, Pathology, Santiago/CHILE
Background: With the extensive use of Chest CT and recent rec-
ommendations for lung cancer screening, an increasing number 
of small pulmonary nodules are detected. Several protocols of 
follow-up of solid and sub-solid nodules have been published, with 
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a biopsy generally recommended for nodule growth or increments 
in the solid/sub-solid ratio. Biopsies can be obtained trough CT 
guided TTNA, Bronchoscopy or VATS. TTNA has complications 
like hemo and pneumothorax, a NPV of 65-70% and false nega-
tive of 9-10%. Bronchoscopic biopsy is more sensitive in central 
and larger lesions. Electro-magnetic navigation bronchoscopy is 
a promising technique for small and peripheral lesions but still has 
high costs and is not widely spread. Identification of small nodules 
during VATS is difficult, especially when located deep in the lung 
parenchyma and in GGO lesions. Different techniques have been 
used for preoperative marking of pulmonary nodules, with dif-
ferent rates of complications and identification failure, including: 
radiotracers, dyes, hook and contrast materials. We describe our 
early experience with Thoracoscopic resection of small pulmonary 
nodules with pre-operative Lipiodol marking. 
Methods: We include the first 6 patients (4 men and 2 women) 
managed with this technique in Clínica Las Condes between June 
2012 and February 2014. Mean age was 69 years old (Range 56-
92). Indications for VATS resection were: bilateral solid nodules 
in a patient with a renal carcinoma and toxicity to Sunitib, a solid 
nodule in patient with colon cancer history, increase in the solid/
sub-solid ratio in a sub-solid nodule, 2 growing nodules: one solid 
and one GGO and a hipermetabolic solid nodule. Lipiodol mark-
ing was done under CT guidance (Siemens Somatom Definition 
AS, 64 rows, 120 kV, 82 mA, 1mm slice thickness). A 23G needle 
was advanced to close proximity of the nodule; 0,4 ml of lipiodol 
+ 0.3 ml methylen blue in 5/6 patients were injected and adequate 
marking controlled under CT. Average nodule size was 11 mm 
(range 3-16). In 5 patients one nodule was marked and in one pa-
tient 2 (total 7 nodules).
Results: Lipiodol marking was done in an average of 204 min 
before surgery (144-330). There were no complications related to 
the procedure. All nodules were easily detected during VATS and 
were completely resected. Surgeries were metastasectomies in 
2 patients, 2 non-anatomic resections with large margins, one S2 
anatomic segmentectomy and one Lobectomy. We had no mor-
tality or complications; mean hospital stay was 3 days (2-4). Final 
Pathology showed a hamartoma and a renal cancer metastasis (not 
marked) in one patient, one colon metastasis, 2 invasive adenocar-
cinoma and 3 adenocarcinomas in situ. No pathologic alterations 
related to lipiodol were observed, with no limitations to the histo-
logic or inmunochemistry study.
Conclusion: In our early experience, pre-operative lipiodol mark-
ing of small pulmonary nodules was safe and reliable, allowing tho-
racoscopic identificaction and resection of all the targeted nod-
ules. No complications related to the marking procedure and no 
alterations in the pathology analysis were observed. This technique 
allowed us to complete all the surgical procedures by minimal inva-
sive technique with the consequent benefits to the patients.
Keywords: thoracic surgery, Early stage NSLC
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PATTERNS OF MEDIASTINAL NODAL METASTASIS AFTER 
ROBOTIC-ASSISTED PULMONARY LOBECTOMY FOR 
NON-SMALL CELL LUNG CANCER:  RETROSPECTIVE 
ANALYSIS OF 159 CONSECUTIVE CASES.
Eric M. Toloza1, Frank Omar Velez-Cubian2, Emily Ng3, Carla C. 
Moodie1, Joseph R. Garrett1  
1Moffitt Cancer Center, Thoracic Oncology, Tampa/UNITED STATES OF AMERI-
CA, 2University Of South Florida Morsani College Of Medicine & Moffitt Cancer 
Center, Surgery, Tampa/UNITED STATES OF AMERICA, 3University Of South 
Florida Morsani College Of Medicine & Moffitt Cancer Center, Tampa/UNITED 
STATES OF AMERICA
Background: We sought to determine the patterns of mediastinal 
lymph node (LN) metastasis found after robotic-assisted vid-
eo-thoracoscopic pulmonary lobectomy for non-small cell lung 
cancer (NSCLC).
Methods: We retrospectively analyzed prospectively collected 
data for all patients who underwent robotic-assisted pulmonary 
lobectomy for NSCLC by one surgeon over 34 months. Clinical 
stage was determined by history & physical examination, comput-
erized tomography, positron-emission tomography, brain imaging 
studies, and/or endobronchial ultrasonography. Pathologic stage 
was based on intraoperative findings and final pathology. The pul-
monary lobe resected and any mediastinal lymph nodes involved 
by metastasis were noted.
Results: Of 159 NSCLC patients studied (mean age 67.6+0.8yr; 
range 39-86yr), most commonly resected histologies were adeno-
carcinoma (63.5%), squamous cell carcinoma (20.8%), and neuro-
endocrine carcinoma (8.2%). Tumors were located in the right lung 
in 106 patients and in the left lung in 53 patients. The three most 
common anatomic locations were right upper lobe (RUL; 42.1%), 
left upper lobe (LUL; 24.5%), and right lower lobe (11.3%). The fre-
quencies of stage-2 disease were similar for left lung cancers com-
pared to right lung cancers, but the frequency of stage-3 disease 
was higher for left lung cancers (28%) compared to that for right 
lung cancers (20%). Stations 2R, 4R, 7, 10, and 11 were most fre-
quently assessed during mediastinal LN dissection. Mediastinal LN 
involvement was highest in stations 5 (9/55), 4R (11/104), 2R (7/102) 
and 7 (9/141). Level 4R LNs were most frequently found to be posi-
tive with right lung cancers, while level 5 LNs were most frequently 
positive with left lung cancers. Of stage-3 right lung cancers, 80% 
were RUL lung cancers, while 57% of stage-3 left lung cancers 
were LUL lung cancers. 
Conclusion: After robotic-assisted video-thoracoscopic lobecto-
my with mediastinal LN dissection, mediastinal LN involvement is 
most commonly found with right side cancers and with upper lobe 
predominance. The patterns of mediastinal LN involvement assists 
in guiding the surgeon to perform a more complete LN dissection 
for more accurate staging.
Keywords: NSCLC, Lymph Nodes, Robotic Lobectomy, Metastasis
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THE EFFICACY OF PLATINUM-BASED ADJUVANT CHEMO-
THERAPY ACCORDING TO EGFR MUTATION IN THE SUR-
GICALLY RESECTED LUNG ADENOCARCINOMAS
Jin Hyoung Kang1, In-Ho Kim1, Jung Oh Kim2, Tae-Jung Kim3, Sook 
Hee Hong1, Eun Kyoung Jeon1, Kyo-Young Lee4, Sook Hwan Sung5, 
Jae Kil Park5, Seung Joon Kim6, Young Kyoon Kim6, Hoon-Kyo Kim7 
1Seoul St. Mary’S Hospital, Departments Of Internal Medicine, Division Of 
Medical Oncology, Seoul/KOREA, 2Seoul St. Mary‘S Hospital, Seoul/KOREA, 
3Yeouido St. Mary’S Hospital, Departments Of Pathology, Seoul/KOREA, 4Seoul 
St. Mary’S Hospital, Departments Of Pathology, Seoul/KOREA, 5Seoul St. Mary’S 
Hospital, Departments Of Thoracic Surgery, Seoul/KOREA, 6Seoul St. Mary’S 
Hospital, Departments Of Internal Medicine, Division Of Pulmonology, Seoul/
KOREA, 7St. Vincent‘S Hospital, Departments Of Internal Medicine, Division Of 
Medical Oncology, Seoul/KOREA
Background: The activating mutations of epidermal growth factor 
receptor (mutEGFR) in lung adenocarcinomas (LAC) are present 
in the frequency of 10~50%. Large body of evidence exist that 
LAC pts. with mutEGFR show relatively favorable response to 
platinum-based cytotoxic chemotherapy. In present study, we 
evaluated whether mutEGFR could be a biologic predictor for the 
outcome of LAC pts. receiving platinum-based adjuvant chemo-
therapy (PBAC) following surgical resection
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Methods: We reviewed the EGFR mutation data (exon 19 and 21) 
screened by direct sequencing in 98 LAC pts. receiving surgical 
resection. We did statistical analysis for the influence of PBAC on 
survival according to the EGFR mutational status.
Results: Of 98 pts. 26 pts. received PBAC but 72 pts. did not. 
Clinical characteristics are as follows; F:M =45:53, stage I 48, II 
23, III 27. The mutEGFR was found in 39 pts. (39.8%). PBAC did 
not provide longer survival, when compared with no PBAC group 
(HR 0.988, P=0.982). The survival benefit of PBAC was also ex-
amined after stratification according to EGFR mutations. PBAC 
demonstrated a tendency to prolong survival in LAC pts. harboring 
mutEGFR with no statistical significance (HR 0.165, P=0.086). Con-
versely, PBAC had negative impact on survival for the pts. with wild 
type EGFR but no statistical significance (HR 2.143, P= 0.213)
Conclusion: Our data suggest that PBAC tend to prolong survival 
for LAC pts. with mutEGFR. We extend the study to larger cohort 
to confirm that PBAC has meaningfully beneficial effect on survival 
for LAC pts. with mutEGFR.
Keywords: non small cell cancer, adjuvant chemotherapy, EGFR 
mutation
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MULTIPLE SYNCHRONOUS PRIMARY ADENOCARCINO-
MA ORIGINATED TYPE 1 CCAM IN YOUNG WOMAN.
Yoo Young Chong1, Min Woong Kang1, Seung Pyung Lim1, Sang Do 
Lee2  
1Chungnam National Universitiy Hospital, Department Of Thoracic And Cardio-
vascular Surgery, Daejeon/KOREA, 2Chungnam National Universitiy, Department 
Of Physiology, College Of Medicine, Daejeon/KOREA
Background: Congenital cystic adenomatoid malformation 
(CCAM) of the lung is a rare condition with the potential for malig-
nant transformation. Several cases that presented with malignant 
changes have been reported. However, there was no report of 
multiple adenocarcinomas originated from CCAM. 
Methods: We report case of 33-year-old female, who underwent 
a bilobectomy for a cystic lung lesion that was a type 1 CCAM 
associated with multiple malignant transformation.
Results: Pathologic specimen shows the resected cystic lesion 
with multiple foci of adenocarcinoma.
Conclusion: We report first case of multiple adenocarcinomas 
originated from CCAM. Careful examination and en bloc resection 
of affected lesion is important in CCAM
Keywords: CCAM, Adenocarcinoma
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VIDEO-ASSISTED VERSUS OPEN LOBECTOMY: ANALYSIS 
OF THE OCCURRENCE OF CLINICAL COMPLICATIONS, 
LENGTH OF STAY AND OVERALL SURVIVAL.
Ricardo Mingarini Terra, Alberto Jorge Monteiro Dela Vega, Pedro 
Henrique Xavier Nabuco De Araujo, Alessandro Wasun Mariani, 
Leticia Leone Lauricella, Paulo Pego-Fernandes  
Thoracic Surgery, Heart Institute (Incor), University Of Sao Paulo Medical School, 
Sao Paulo/BRAZIL
Background: The use of video-assisted lobectomy for the treat-
ment of non-small cell lung cancer is increasingly common in the 
literature and there are still questions about its advantages over the 
use of the open technique especially in regard to postoperative 
management. This study aimed to evaluate whether video-assisted 
lobectomy was associated with lower rates of clinical complica-
tions, shorter length of stay and higher overall survival. 
Methods: A retrospective study of patients undergoing pulmonary 
lobectomy for treatment of lung January 2009 to October 2012 
cancer. Included only patients who presented themselves as good 
candidates for both techniques. Presents the comparison regard-
ing age, sex, comorbidities, performance, intraoperative compli-
cations, postoperative complications, length of hospitalization, 
length of stay with chest tube, length of stay in ICU, staging, overall 
survival and disease-free survival. Patients who had other associat-
ed procedure during the same operation, except mediastinoscopy, 
were excluded. Logistic regression models were performed to 
obtain adjusted odds ratio related to clinical complications (includ-
ing arrhythmia, pneumonia, decompensated COPD) and surgical 
(eg alveolar fistula> 7 days, empyema, subcutaneous emphysema) 
in both groups, generalized linear models to compare the adjusted 
basis of length of stay and Cox regression models for overall sur-
vival and disease-free survival.
Results: We analized167 patients of whom 87 were women and 
80 men with a mean age of 65 years. Those who underwent 
open lobectomy were 116 cases and 51 underwent video-assisted 
surgery. There were 6 cases of conversion. Pathological staging 
showed that 63 patients (37.7%) were stage IA, 47 (28.1%) stage IB, 
15 (9%) stage IIA , 15 (9%) stage IIB, 25 (15%) stage IIIA and 2 (1,2%) 
stage IV. The variables that were associated with a higher incidence 
of clinical complications were peripheral artery disease (p=0.004), 
smoking (p=0.013) and age (p<0.001). Nevertheless, video-as-
sisted lobectomy was also associated with lower rate of clinical 
complications as setting for these variables and pathological stage. 
There were differences between the two techniques with respect 
to length of stay (p=0.027), but not to overall survival (p=0.961) 
when done adjusting for comorbidities, age and staging.
Conclusion: Our study showed that video-assisted lobectomy is 
associated with lower rates of clinical complications, and shorter 
length of stay as expected of a technique that was born with the 
objective to improve post-operative recovery, however the result 
of similar survival in both groups leads us to believe that the choice 
of technique has no impact on the oncological treatment.
Keywords: Video-assisted thoracic surgery, Lobectomy, Non-
small-cell lung cancer
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ENDOBRONCHIAL ULTRASOUND TRANSBRONCHIAL 
NEEDLE ASPIRATION IN THE EVALUATION OF THE MEDI-
ASTINUM: SAFETY EVALUATION
Kostas Nikolaos Syrigos1, Ioannis Kokkonouzis2, Ioannis Lampadi-
tis2, Elias Kainis2, Andriani Charpidou2  
1Sotiria General Hospital, Athens School Of Medicine, Oncology Unit Gpp, Ath-
ens/GREECE, 2Sotiria General Hospital, Oncology Unit Gpp, Athens/GREECE
Background: Evaluation of mediastinal lymph nodes is of para-
mount importance for accurate staging in lung cancer and often 
dictates optimal treatment. Mediastinoscopy is considered the 
„gold standard“ for sampling lymph nodes, but it is an invasive, 
costly technique that requires general anesthesia. Newer staging 
techniques have emerged. Endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS-TBNA) is a minimally in-
vasive technique that permits accurate and adequate sampling of 
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mediastinal and hilar lymph nodes under direct, real-time visual-
ization of lesions. The aim of this review is to evaluate the safety 
profile of this increasingly performed procedure. 
Methods: A detailed search was conducted through bibliographic 
databases (Pubmed Central, Medline) using combinations of the 
terms „complications or adverse events“, „endobronchial ultra-
sound transbronchial needle aspiration“ and „medastinum or me-
diastinal lymph nodes“.
Results: Fifty-five studies were retrieved reporting the presence 
or absence of complications following EBUS-TBNA. Eighteen of 
these focused specifically on safety issues. Complication rates 
ranged from 0.15% to 1.44% in meta-analyses, large retrospective 
reviews and nationwide surveys. The results of smaller studies were 
heterogeneous, but overall few adverse events have been report-
ed. Case reports have also been included in the review.
Conclusion: So far, based on data from well-structured studies, 
originating from experienced medical centers, EBUS-TBNA is a 
safe technique with rare complications. On the other hand, some 
studies have raised issues mainly on the infectious and traumatic 
complications of this technology, and although data are not suffi-
cient, these issues must be put under consideration. Nevertheless, 
overall EBUS remains a safe procedure.
Keywords: endobronchial ultrasound (EBUS), Lung Cancer, safety, 
mediastinum lymph nodes
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THE EFFECT OF POSTOPERATIVE ATRIAL FIBRILLATION 
ON THE HOSPITAL COURSE IN PATIENTS UNDERGOING 
ROBOTIC-ASSISTED VIDEO-THORACOSCOPIC PULMO-
NARY LOBECTOMY
Emily Ng1, Frank Omar Velez-Cubian2, Maria Echavarria1, Carla 
C. Moodie2, Joseph R. Garrett2, Jacques-Pierre Fontaine2, Lary A 
Robinson2, Eric M. Toloza2  
1University Of South Florida Morsani College Of Medicine & Moffitt Cancer 
Center, Tampa/UNITED STATES OF AMERICA, 2University Of South Florida Col-
lege Of Medicine & Moffitt Cancer Center, General Surgery & Thoracic Surgery, 
Tampa/UNITED STATES OF AMERICA
Background: In this study, we sought to investigate the effect of 
post-operative atrial fibrillation incidence after robotic-assisted vid-
eo-thoracoscopic pulmonary lobectomy on comorbid postopera-
tive complications, chest tube duration, and hospital length of stay. 
Methods: We retrospectively analyzed prospectively collected 
data from 208 consecutive patients who underwent robotic-assist-
ed pulmonary lobectomy by one surgeon for known or suspected 
lung cancer. Postoperatively, 39 (18.75%) of these patients experi-
enced atrial fibrillation (AF) during their hospital stay. The presen-
tations of postoperative complications other than AF, chest tube 
duration, and hospital length of stay were analyzed in patients with 
AF and without AF postoperatively. Statistical significance (p<0.05) 
was determined by unpaired student’s t-test.
Results: Of patients with postoperative AF, 46% also had other 
concurrent postop complications, while only 31% of patients 
without AF experienced complications. The average number of 
postoperative complications experienced by patients with AF was 
significantly higher than that experienced by those without AF 
(0.92 vs. 0.44, p = 0.001). The mean (9.8 days) and median (8 days) 
hospital lengths of stay in the AF patients were significantly longer 
than those without AF, whose mean and median hospital stays 
were 6.1 days and 4 days, respectively. A similar result was also 
seen with chest tube duration, with the mean and median chest 
tube duration in AF patients (9.6 days and 6 days, respectively) 
were significantly higher than those in patients without AF (5.6 days 
and 4 days, respectively). Results were summerized in Table 1 with 
standard deviation (SD) and standard error of the mean (SEM). 
Table 1 with AF without AF p-value
Complication per patients 0.92 0.44 0.001
SD 1.22 0.80
SEM 0.20 0.06
Length of stay (Days) <0.05
Mean 9.77 6.12
Median 8 4
SD 6.67 4.63
SEM 1.07 0.36
Chest Tube duration (days) 0.003
Mean 9.62 5.63
Median 6 4
SD 14.34 5.81
SEM 2.30 0.45
 
Conclusion: This study demonstrated the association between 
the incidence of atrial fibrillation and a more complicated hospital 
course. Further studies were needed to evaluation whether con-
founders were involved in these associations.
Keyword: Postoperative Complication Atrial Fibrillation
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INFLAMMATORY MYOFIBROBLASTIC TUMOUR OF THE 
LUNG - A REACTIVE LESION OR A TRUE NEOPLASM?
Lasha Gvinianidze, Nikolaos Panagiotopoulos, Wen Ling Woo, 
David Lawrence  
Uclh University College London Hospitals, Cardiothoracic Surgery, London/
UNITED KINGDOM
Background: Inflammatory myofibroblastic tumour represents a 
rare category of lung tumours first described in 1937. We present 
the approach and different aspects of management for these rare 
inflammatory pseudotumours. 
Methods: A literature review was performed to indentify to clinical 
and radiological features of these rare category of lung tumours. 
A management approach was identifed with the treatment options 
available.
Results: Presenting symptoms of inflammatory myofibroblastic 
tumours include cough, chest pain, dyspnea, haemoptysis, general 
fatigue, weight loss, low fever and arthralgias. It appears most com-
monly in children and young individuals with a prevelance of 0.7%. 
Microscopic analysis demonstrates a mixture of inflammatory, 
myofibroblastic spindle cells. Treatment options include complete 
surgical resection. Chemotherapy agents have been also applied 
with minimal effect such as Paclitaxel and Carboplatin. The recur-
rence is very rare after complete resection. Overall prognosis is 
satisfactory with a reported 10-year survival of just under 80%.
Conclusion: It is not quite certain whether inflammatory myofibto-
blastic tumour is a reactive lesion or true neoplasm. Surgical resec-
tion is the gold standard treatment option.
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PREVALENCE OF MET EXPRESSION IN EARLY STAGE 
LUNG CANCER. EXPERIENCE OF A THORACIC HOSPITAL 
IN ARGENTINA.
Claudio Martin1, Ana Karina Patané2, Gabriela Guma3, Atilio Regi-
natto3, Patricia Vega4, Mercedes Rayá3, Guillermo Menga5, José 
Morero5  
1Hospital De Rehabilitacion Respiratoria Maria Ferrer, Oncologia, 
Buenos Aires/ARGENTINA, 2Hospital De Rehabilitación Respira-
toria María Ferrer, Thoracic Surgery, Buenos Aires/ARGENTINA, 
3Hospital De Rehabilitación Respiratoria María Ferrer, Pathology, 
Buenos Aires/ARGENTINA, 4Hospital De Rehabilitación Respira-
toria María Ferrer, Medical Oncology, Buenos Aires/ARGENTINA, 
5Hospital De Rehabilitación Respiratoria María Ferrer, Pulmonology, 
Buenos Aires/ARGENTINA
Background: MET signal is correlated with poor prognosis in non 
small cell lung cancer. Also it was proposed as predictive factor for 
benefit with MET inhibitors. Prevalence of met expression in early 
lung cancer was not clearly defined. We evaluated MET expression 
in lung cancer stages I-IIIa. 
Methods: Archival biopsy tumor specimens were evaluated MET 
expression using MET IHC staining with Anti-total c-MET(SP44)
Rabbit Monoclonal Antibody. Clinical Score was established and a 
Clinical Diagnosis of Negative was assigned to cases with Clinical 
Scores of 0 and 1+. Cases with Clinical Scores of 2+ or 3+ was as-
signed as Positive Clinical Diagnosis.Patient who went on surgery in 
our institution from January 1990 to December 2013 and had stage 
I to III was included.
Results: 122 tumor tissue samples were evaluated for MET ICH 
expression. 88 (72%) males and 24 (28%) females. Median age was 
63 +/- 9 years. 87 (71,31%) were current smokers at the time of di-
agnosis, 3 (2,46%) ex smokers and 10 (8.2%) never smokers, without 
data in 22 (18,03%) patients. 35 were Stage Ia (29%), 34 Ib (28%), 25 
IIa (20%), 18 IIb (15%) and 10 (8%) IIIa. 71 (62,28%) were adenocarci-
noma, 27 (32,46%) squamous carcinoma, 4 ( 3,51%) large cell carci-
noma, 1 (0,88%) Large cell neuroendocrine carcinoma and 1 (0,88%) 
NOS. For the population of study, MET were classified as positive in 
10 patients (8 %) and negative in 112 (92%). MET expression was pos-
itive in 5/70 (7.1%) adenocarcinomas and 4/37 (10.81%) squamous 
carcinomas. According to the 7th Edition of TNM classification, 2 
cases were Ia, 3 Ib, 2 IIa and 3 IIb. 8/10 patients MET + was current 
smokers, 1 No Smoker and in 1 case no data was available.
Conclusion: The prevalence of met expression in the population 
of study was similar to other series
Keyword: c-met overexpression and lung cancer
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1ST LINE TREATMENT WITH ERLOTINIB IN ADVANCED 
NON SQUAMOUS ,NON SMALL CELL LUNG CANCER ( 
NSCLC) WITH OUT EGFR TESTING
Ravi Mohan Pedapenki1, Satyaprasad Valluri2, Sambu Naik Banavatu3  
1Rims Government Medical College And King George Hospital, Medicine And 
Oncology, Srikakulam/INDIA, 2Rangaraya Medical College, Medicine, Kakinada/
INDIA, 3Anil Neerukonda Medical College, Medicine, Visakhapatnam/INDIA
Background: Majority of the lung cancers are diagnosed late and 
in advanced stages in India. As these are initially treated as tuber-
culosis and later diagnosed to have advanced malignancy. Diagno-
sis is established in a large majority of the patients by Fine needle 
aspiration cytology ( FNAC) or by pleural aspiration cytology by 
the community physicians and seldom by a Biopsy. EGFR testing 
cannot be done on these cytology specimen. Majority of these 
patients were against a re-biopsy. Inject able chemotherapies are 
unpopular with their side effects and cost. In such a back ground, 
Oral cheap generic Erlotinib is studied in these non squamous 
NSCLC in former and non smokers. We studied , 1st line treatment 
with Erlotinib in advanced non squamous NSCLC in former and 
non smokers with out Epidermal Growth Factor Receptor (EGFR) 
testing. 
Methods: All the patients attending to our outpatient department 
from January 2012 to June 2013, non smokers and former smokers, 
quit smoking five years earlier, with a FNAC diagnosis of non squa-
mous pathology (Undifferentiated, poorly differentiated, adeno , 
large cell or Bronchoalveolar carcinomas ), unwilling for Chemo-
therapy and EGFR testing with normal hematological, liver and 
renal function were included in this study after informed consent. A 
total of 86 patients with a performance status of 0 to 2 were treat-
ed with oral Erlotinib with a Dose of 100mg for < 45 Kg or 150mg 
for >45 Kg per day, for a minimum period of 3 months ( range 3-14 
months) and followed up for a minimum of 6 months( range 6-14 
months)
Results: Age 23 to 78 years, Male : Female is 59:27, Performance 
status 0-11, 1-61, and 2-14 Non smokers 72 and Past Smokers 14 
Histopathology: Poorly differentiated carcinoma -33, Undifferen-
tiated carcinoma -29, Adenocarcinoma -17, large cell carcinoma -5 
and Bronchoalveolar carcinoma- 2 Stage III B -32 and Stage IV -54 
Dose of Erlotinib 100mg -35 and 150mg -51 Median follow up was 
8 months (range 6-14 months) Evaluable patients were 69 and non 
evaluable were 17 as they have not completed 3 months of treat-
ment or lost for follow up Median survival was 8.2 months Adverse 
events Grade I & II diarrhea 28% Grade I & II skin lesions and rash 
22%. No Grade III or IV or hematological adverse events All the 69 
patients were evaluable, responded well with a median survival of 
8.2 months , which is comparable to standard platinum based che-
motherapy in the absence of EGFRstatus. Tolerance to treatment 
was good with out undue toxicity, particularly in patients with poor 
performance status. Upfront treatment with generic Erlotinib is 
cheap and effective . 30 tablets of generic Erlotinib costs about US 
$ 80 (Exchange rate of US$ 1 = 62 Indian Rupees)
Conclusion: 1st line generic Erlotinib is a reasonably cheap alter-
native to chemotherapy in resource poor setting where facilities 
for biopsy and or EGFR testing is not possible or costly, in advance 
non squamous NSCLC among non or past smokers , with good 
tolerance with out undue toxicity .
Keyword: Non-Squamous, NSCLC, EGFR, Erlotinib
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DIAGNOSIS OF THE ALK-EML4 TRANSLOCATION WITH 
FISH, IMMUNOHISTOCHEMISTRY, AND REAL TIME-POLY-
MERASE CHAIN REACTION IN PATIENTS WITH NON-
SMALL-CELL LUNG CANCER.
Oscar Arrieta1, Graciela Cruz-Rico1, Vicente Morales-Oyarvide2, 
Alejandro Aviles-Salas3, Ana María Espinosa-García4, Vilma Mal-
donado-Laguna5, Carlos Rojas-Enriquez6, Andrés Felipe Cardona 
Cardona7  
1Instituto Nacional De Cancerologia, Experimental Oncolgy Lab, Mexico City/
MEXICO, 2Instituto Nacional De Cancerologia, Clinic Of Thoracic Oncology, 
Mexico City/MEXICO, 3Instituto Nacional De Cancerologia, Departament Of 
Pathology, Mexico City/MEXICO, 4Hospital General De México, Genomic Med-
ice Lab, Mexico City/MEXICO, 5Inmegen, Epigenetica, Mexico City/MEXICO, 
6Instituto Nacional De Cancerologia, Departament Of Radiology, Mexico City/
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MEXICO, 7Institute Of Oncology, Fundacion Santa Fe De Bogota, Bogota/CO-
LOMBIA
Background: Anaplastic lymphoma kinase (ALK) rearrangements 
are found in 2-7% of non-small-cell lung cancers (NSCLC) and 
predict response to ALK-tyrosine kinase inhibitors. Fluorescence 
in-situ hybridization (FISH) has been the method of choice for de-
tection of ALK-rearrangements in NSCLC; however, this test pres-
ents technical and financial limitations. In this study we evaluate the 
value of ALK immunohistochemistry (IHC) with the 5A4 antibody 
and real-time polymerase chain reaction (RT-qPCR) in the diagno-
sis of ALK-rearranged NSCLC in the Mexican population. 
Methods: 170 advanced NSCLC were evaluated by FISH. De-
mographic and clinicopathologic characteristics were analyzed. 
Additional IHC and RT-qPCR (variants 1-5) was done in 63 and 
48 patients, respectively. Performance characteristics of IHC and 
RT-qPCR were calculated.
Results: 18 (10.5%) patients were positive for ALK-rearrangements 
(ALK+) by FISH. ALK+ patients were significantly younger at the 
time of diagnosis compared with ALK-negative patients (46 vs. 58 
years, P = 0.02), and had a lighter smoking history. We found no 
significant differences in terms of sex, wood smoke exposure, his-
tologic type, carcinoembryonic antigen, or clinical stage at presen-
tation. When we compared IHC with FISH, using an IHC cutoff of 
1+ staining, there were 15 true positive (TP) cases, 3 false positives 
(FP), 3 false negatives (FN), and 42 true negatives (TN), yielding a 
sensitivity and specificity of 83% and 93%, respectively. Compared 
with FISH, RT-qPCR identified 5 TP cases with variant 1, no FP, 4 FN 
for variants 1-5, and 39 TN, yielding a sensitivity and specificity of 
55% and 100%, respectively.
Conclusion: This is the first report of ALK-rearranged NSCLC in 
Latin America. The high prevalence of ALK+ patients found in our 
study reflects a clinically enriched patient population. Our results 
show that ALK+ patients in Mexico are younger than ALK-negative 
patients and have a lighter smoking history. Our findings suggest 
that IHC with 5A4 clone is relatively sensitive for the detection of 
ALK+ NSCLC and may help select patients to undergo FISH test-
ing.
Keywords: Adenocarcinoma, Immuohistochemistry, Real Time 
Polymerase Chain Reaction, Anaplastic Lymphoma Kinase
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A SCALP LUMP AS THE SOLE PRESENTATION OF  
SQUAMOUS CELL CARCINOMA OF THE LUNGS:  
A CASE REPORT.
Simant Singh Thapa, Rashmey Pun Gurung  
National Hospital And Cancer Research Center, Kathmandu/NEPAL
Background: The solitary scalp metastasis from bronchogenic 
carcinoma as the only presenting feature is not frequently seen 
in the clinical practice. Here we present a case with scalp lump as 
the only initial presentation of the quiescent primary lung cancer 
making such cases formidable diagnostic challenge. Identification 
of such cases as a possible link to underlying visceral malignancy is 
important as early detection makes it possible to diagnose prompt-
ly and ensure timely treatment. A 63 years old female presented to 
us with complain of solitary, painless scalp lump that she noticed 
since past 2 months which was progressively increasing in size. 
The patient denied of having any other symptoms or head trauma. 
Initially her lump was diagnosed as benign cyst in the primary care 
center. On presentation she had normal performance status with 
stable vitals. Local examination of the lump revealed 6*5 cm hard, 
non-tender, non-pulsatile, non-mobile mass over left parietal scalp 
area with local rise in temperature. Fine needle aspiration cytology 
of the lump was done which was suggestive of malignant tumor. 
MRI of the brain revealed subgaleal lesion in the left parietal re-
gion with normal study of the brain parenchyma. Non contrast CT 
scan of the chest showed moderate enhancing mass in the right 
lower lobe with multiple nodules in both the lungs. CT scan guided 
right lower lobe lung mass biopsy was positive for squamous cell 
carcinoma. Whole body skeletal scan was consistent with multiple 
skeletal metastasis. She received 4 cycles of first line palliative 
chemotherapy with Gemcitabine and Cisplatin. Radiological eval-
uation showed disease progression therefore she received second 
line chemotherapy (Taxol based) plus palliative radiation therapy 
for vertebral metastasis. 
Methods: Not applicable.
Results: Not applicable.
Conclusion: Aim of this case is to highlight that the patient may 
sometime present only with solitary scalp lump as the initial pre-
senting symptom even in underlying advanced lung cancer. The 
patient may be under evaluated and remain undiagnosed until 
clinically suspected. As lung carcinoma is among the commonest 
cancer and its incidence is raising yearly worldwide, whenever un-
usual cutaneous metastases are found in the absence of a primary 
tumor, a high index of suspicion is must and lung cancer should be 
considered in the list of differential diagnosis for the early detec-
tion and prompt treatment of such cases.
Keywords: Scalp, Diagnosis, Differential, Lung neoplasm
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EGFR MUTATION AND OUTCOMES IN PATIENTS WITH 
METASTATIC NSCLC  TREATED WITH ERLOTINIB AT INSTI-
TUTO ONCOLOGICO NACIONAL. PANAMA
Omar Castillo-Fernandez, Erick Arauz, Angela Cabreja, Yong Loo, 
Ignacio Veliz, Mario Guardia, Ivette Rodriguez  
Instituto Oncologico Nacional, Medical Oncology, Panama/PANAMA
Background: About 80% of lung cancer are non small cell histol-
ogy (NSCLC) and most cases are diagnosed in advanced stages 
(III,IV). Overal survival at 5 years is only 14%. Mutation in EGFR is a 
predictive factor in metastatic patients treated with tirosin kinase 
inhibitors. 
Methods: We conducted a retrospective review of patients with 
metastatic NSCLC addressed for EGFR mutation in our institution 
between january 2010 to march 2013 and treated with Erlotinib. 
Overall survival and progression free survival was evaluated using 
Kaplan Meier method.
Results: 125 patients were evaluated. 64 (51%) female 61 (48%) 
male. Stage IV 102 pts (81%) non smokers 65 (52%). 112 (93%) Ad-
enocarcinoma. 31 patients (24.8%) had mutation in EGFR, 18 pts 
(58%) exon 19 deletion, 9 pts (29%) exon 21 L858R, 2pts (6.6%) 
complex mutation L858R/S7681, 1 pt (3.2%) exon 18, 1 pt (3.2%) 
exon 20 T790M. Partial response was reported in 70%. Overall 
survival in mutated patients was 26.4 months (CI 95% 4.2-48.5)
Conclusion: Panamanian patients harboring a EGFR mutation 
have an increased response to Erlotinib and a prolonged survival 
compared with reported in clinical trials
Keywords: EGFR mutation, erlotinib, mutation, hispanics
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EGFR MUTATION PREVALENCE IN AN ACCESS PROGRAM 
IN BRAZIL.
Gilberto Lopes1, Luciola Pontes2, C Bacchi3, Em Queiroga4, T Piha4, 
Pa Miranda4, S Freire4, J Tabacof5, Clarissa Mathias6  
1Centro Paulista De Oncologia E Hcor Onco, Membros Do Grupo Oncoclinicas 
Do Brasil, São Paulo/BRAZIL, 2Hcor Onco, São Paulo/BRAZIL, 3Laboratórios 
Bacchi, Sao Paulo/BRAZIL, 4Astra Zeneca, Sao Paulo/BRAZIL, 5Centro Paulista 
De Oncologia, Membro Do Grupo Oncoclinicas Do Brasil, São Paulo/BRAZIL, 
6Nucleo De Oncologia Da Bahia, Membro Do Grupo Oncoclinicas Do Brasil, São 
Paulo/BRAZIL
Background: Epidermal growth factor receptor (EGFR) mutation 
testing allows for optimal selection of therapy with tyrosine kinase 
inhibitors in patients with non-small-cell lung cancer (NSCLC). Pre-
vious studies have shown a variation in EGRF genotype according 
to ethnic background, with scarce data about EGFR mutation sta-
tus among Brazilian patients with NSCLC. We aimed to study the 
prevalence of EGFR mutations and specific mutation distribution in 
a large sample of Brazilian patients. 
Methods: We had access to a de-identified patient database of 
samples collected between 2011 and 2013, as part of an EGFR mu-
tation testing program sponsored by a pharmaceutical company in 
Brazil. Tumor samples of patients with advanced stage, IIIb/IV, NS-
CLC were submitted, at the discretion of the attending physicians, 
for EGFR mutation testing. All analyses were performed at two 
reference laboratories, as follows: after microdissection, DNA was 
isolated from serial sections of formalin-fixed, paraffin-embedded 
tumor tissue to obtain at least 70% tumor cells. EGFR gene Exons 
18, 19, 20 and 21 were analysed using Sanger sequencing. EGFR 
mutation rate was calculated and its frequency compared between 
clinical subgroups using chi-square test. Data about smoking status 
was incomplete and thus not included in this analysis.
Results: Median age was 66 years for patients tested (range: 18-
97); and also for those with a positive test (range: 28-95). An EGFR 
mutation was seen in 25.5% of samples (857/3364). No increases 
in the frequency of EGFR detection were seen between the first 
500 analyzed samples and the last 500, decreasing the possibil-
ity of phenotypic selection bias by physicians‘ referral (p>0.05). 
We did not detect any differences in the rate of mutation across 
different regions in Brazil. For the patients who tested positive, 
300 were men and 557 were women. Data on histologic subtypes 
was available for 1472 samples, as follows: 1086 (74%) had adeno-
carcinomas; 386 (26%) had carcinomas, not otherwise specified 
(NOS). No patients had squamous cell carcinoma. EGFR mutations 
were more common in patients with adenocarcinoma (30.5%) vs. 
carcinoma NOS (10%) (p<0.05), and women (30.2%) vs. men (19%) 
(p<0.05). No differences in EGFR mutation frequency were found 
between age groups. 
Conclusion: To the best of our knowledge, this is the largest study 
to assess EGFR mutation status in Latin America and in Brazil. 
Our findings suggest that the frequency of EGFR mutation in this 
cohort was lower than that found in Asia, but higher than in Cauca-
sian populations, confirming findings seen in other Latin American 
countries.
Keywords: EGFR mutation, Brazil, Latin America
POSTER SESSION 2 - August 23, 2014 09:00-18:00 
Topic: Advanced NSCLC
P2.22
PREDICTIVE VALUE OF PRE-TREATMENT INFLAMMATORY 
MARKERS IN ADVANCED NON-SMALL-CELL LUNG CAN-
CER (NSCLC) (CLICAP)
Carlos Vargas1, Andrés Felipe Cardona Cardona1, Hernán Carran-
za1, Oscar Arrieta2, Leonardo Rojas3, Claudio Martín4, Jorge Otero1, 
Mauricio Cuello1  
1Institute Of Oncology, Fundacion Santa Fe De Bogota, Bogota/COLOMBIA, 2In-
stituto Nacional De Cancerologia, Experimental Oncolgy Lab, Mexico City/MEX-
ICO, 3Hospital Universitario San Ignacio; Centro Javeriano De Oncología, Medical 
Oncology, Bogotá/COLOMBIA, 4Instituto Fleming, Buenos Aires/ARGENTINA
Background: Accurate prediction of outcome in advanced Non-
small-cell lung cancer (NSCLC) remains challenging. Even within the 
same stage and treatment group, survival and response to treatment 
vary. We set out to determine the predictive value of inflammatory 
markers C-reactive protein (CRP), D-dimer (DD), ceruloplasmin (Cp) 
and serum albumin (SA) in patients with advanced NSCLC. 
Methods: Retrospective, single-institutional study, comprising 
a cohort of patients with NSCLC stage IIIB/IV and World Health 
Organization performance status (PS) 0-2 who started first-line 
chemotherapy between January 1, 2011, and January 31, 2013. Pa-
tient records were reviewed to obtain level of pre-treatment inflam-
matory markers and at the time of response assessment or clinical 
progression. Basal levels of CRP, DD, Cp and SA and their variation 
were correlated with treatment response, progression-free surviv-
al (PFS) and overall survival (OS). The value of a combined index 
(CRP+SA) and a multivariate analysis using Cox‘s proportional haz-
ards model was to assess prognosis.
Results: The study included 98 patients with a mean age of 65 
years (SD ± 11), 79% were females, 83% had adenocarcinoma, 47% 
had more than two organs involved by metastases, and 89% had 
a KI >70%. At onset of chemotherapy, 52%, 43%, 53%, 34% had 
abnormal levels of Cp, DD, SA and CRP respectively. Patients with 
low SA (p=0.004), and high DD (p=0.012) and CRP (p=0.040) had 
a worse overall response rate to first line chemotherapy. On univar-
iate analysis, patients with elevated CRP (HR 1.67, 95%CI 1.28-2.69, 
p=0.008) and DD (HR 2.56, 95CI 1.5-3.4, p=0.006) had inferior 
PFS and patients with high PCR (HR 1.9, 95CI 1.4-2.1, p=0.04) and 
low albumin (HR 2.9, 95CI 2.1-4.6, p=0.03) levels had worse OS. 
On multivariate analysis, both albumin and PCR were independent 
negative prognostic factors for survival.
Conclusion: CRP and albumin levels are independent prognostic 
factors for survival in patients with advanced NSCLC receiving 
first-line chemotherapy and provide additional information to es-
tablished main outcomes.
Keywords: prognosis, D dimer, Protein C reactive, albumin
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QUALITY OF LIFE AFTER CHEMOTHERAPY FOR AD-
VANCED NON-SMALL CELL LUNG CANCER
Jefferson Luiz Gross1, Aldo Lourenço Abadde Dettino2, Barbara M. 
S. Cruz3  
1Ac Camargo Cancer Center, Thoracic Surgery, Sao Paulo/BRAZIL, 2Ac Camargo 
Cancer Center, Clinical Oncology, Sao Paulo/BRAZIL, 3Ac Camargo Cancer 
Center, Post Graduation, Sao Paulo/BRAZIL
Background: Most lung cancer patients are diagnosed with ad-
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vanced disease and have no curative treatment options. The main 
purpose of therapeutic approaches in non-small cell lung cancer is 
palliative, and it should prolong survival and improve quality of life. 
The aim of this study is to evaluate if chemotherapy could improve 
quality of life in patients with advanced non-small cell lung cancer. 
Methods: This is a prospective, single center, cross sectional study. 
Institutional review board approval and written informed consent 
was provided by all patients. Patients with advanced (Clinical Stage 
IIIB/IV) non-small cell lung cancer receiving conventional che-
motherapy were included. Quality of life (QoL) were assessed by 
three questionnaires (EORTC QLQ-C30 / EORTC LC13 and Saint 
George Respiratory Disease Questionnaire (SGRD). The instru-
ments were completed in the day that chemotherapy was started, 
and were reapplied 30 days after the end of the treatment. Beyond 
these three questionnaires, all included patients were asked the 
following question: “How is your quality of life today?” at the first 
day and 30 days after chemotherapy. The answers were scored on 
a scale ranging from zero to ten.
Results: From February 2011 to May 2012, one hundred patients 
were included. Fifteen were excluded − eight died before finishing 
treatment, and seven did not answer questionnaires after had fin-
ished chemotherapy. The analysis was performed in the remaining 
85 patients. The median age was 60 years old, ranging from 31 to 
79 years old. Fifty-one (60%) were men, and 70.8% had stage IV 
NSCLC. Most of the patients received different lines of platinum 
based regimen of chemotherapy. In EORTC QLQ-C30 role, phys-
ical and social functioning significantly improved after chemother-
apy. In the other hand, we observed that fatigue, nausea/vomiting, 
dyspnea, appetite and global health deteriorated. In EORTC LC-13 
dysphagia, neuropathy and alopecia significantly deteriorated after 
chemotherapy, and nothing improved in the remaining items. In 
SGRD questionnaire we observed that the total score had deteri-
orated after chemotherapy. Analysis of the score to the question 
“how is your quality of life today?” showed worst quality of life after 
chemotherapy.
Conclusion: In the present study we did not observe improvement 
in quality of life in early assessment after chemotherapy for ad-
vanced NSCLC.
Keywords: Lung Cancer, Quality of life, chemotherapy
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IDENTIFY: CASE  AND CONTROL  STUDY ON DIAGNOSIS 
AND TREATMENT STRATEGIES IN PATIENTS WITH NSCLC 
WITH OR WITHOUT EGFR MUTATIONS
Claudio Martín1, Martin Plotquin2, Javier Toibaro3, Romina Yapur4, 
Mariana Trigo5, Nora Giacomi6, Gustavo Jankilevich7, Cesar Bla-
jman8, Sandra Mercurio2  
1Instituto Alexander Fleming, Buenos Aires/ARGENTINA, 2Astrazeneca, Medical 
Department, Buenos Aires/ARGENTINA, 3Hospital Gral De Agudos Jm Ramos 
Mejia, Comité De Farmacología, Buenos Aires/ARGENTINA, 4Hospital Gral.Roca, 
La Pampa/ARGENTINA, 5Hospital De Clínicas Jose De San Martín, Servicio De 
Oncología, Buenos Aires/ARGENTINA, 6Clínica Breast, Buenos Aires/ARGENTI-
NA, 7Hospital Carlos A. Durand, Servicio De Oncología, Buenos Aires/ARGENTI-
NA, 8Clinica Isis, Santa Fe/ARGENTINA
Background: There is no information available in Argentina about 
the behavior of patients with locally advanced or metastatic NS-
CLC, with EGFR mutations and treatment with the inhibitors of the 
kinase activity of the EGFR. Our objective is to review the evolu-
tion of patients receiving first line treatment for IIIb/IV NSCLC by 
comparing those patients who were requested to test for EGFR 
mutation status as part of this study with a historical control group 
who were untested. 
Methods: Cases and controls retrospective study. We included 
patients under 1st line treatment for IIIb/IV stage lung adenocar-
cinoma. The Cases were defined as patients diagnosed with lung 
adenocarcinoma under first line treatment, who were requested 
(2010) the test to detect EGFR mutations as part of diagnosis and 
treatment strategy; and Historical Controls were defined as pa-
tients diagnosed with lung adenocarcinoma (between 2008 and 
2010) under first line treatment, who were not requested the test 
to detect EGFR mutations. We obtained data of demographic and 
clinical characteristics, and clinical outcome after 12 months follow 
up. Controls have been paired by sex, age and site of oncologic 
treatment received We used chi 2 test or Fishers test for categorical 
variables and t test for continuous variables while for measures of 
association we used odds ratio and 95% confidence interval.
Results: General characteristics and baseline clinical features of 
cases and controls were similar (table 1). In the follow up we ob-
served higher mortality (p<0.05) in the controls group compared 
with the cases (Table 2). 
Table 1. Baseline characteristics and treatment of patients with diagnose 
of IIIb/IV stage lung adenocarcinoma with (cases) or without (historic 
controls) EGFR test as part of a diagnosis and treatment strategy.
Cases n=106 Controls n=168 p
Males % (n/n) 38.6 (41/106) 42.3 (71/166) 0.55
Smokers/past 
smokers 67.6 (71/105) 74.09 (123/166) 0.24
Oriental race % 
(n/n) 1.9 (2/106) 0.6 (1/161) 0.56
Media age (SD) 63.3 (10.61) 63.96 (10.6) 0.54
ECOG 0 % (n/n) 29.2 (31/106) 31.5 (53/168) 0.68
ECOG 1 % (n/n) 55.6 (59/106) 46.4 (78/168) 0.13
ECOG 2 % (n/n) 14.1 (15/106) 18.4 (31/168) 0.35
ECOG 3 % (n/n) 0.9 (1/06) 2.3 (4/168) 0.65
ECOG 4 % (n/n) 0 (0/106) 1.1 (2/168) ------
Stage IIIb % (n/n) 22.1 (23/104) 24.5 (41/167) 0.38
Stage IV% (n/n) 77.8 (81/104) 75.4 (126/167) 0.38
Gefitinib % (n/n) 15.0% (16/106) --------------------
Carboplatin % 
(n/n) 43.3% (46/106) 53.2% (89/167)
Paclitaxel % (n/n) 36.7% (39/106) 41.9% (70/167)
Pemetrexed % 
(n/n) 19.8% (21/106) 8.3% (14/167)
Gemcitabine 
(n/n) 9.4% (10/106) 23.3% (39/167)
Vinorelbine (n/n) 11.3% (12/106) 14.3% (24/167)
Docetaxel (n/n) 0.9% (1/106) 1.7% (3/167)
Cisplatin (n/n) 11.3% (12/106) 29.9% (50/167)
Table 2. Clinical progression of control and cases after one year diag-
nosed of IIIb/IV stage lung adenocarcinoma
Cases Controls OR (IC95%) p
Mortality rate 
% (n/n) 33.7 (35/104) 46.1 (76/165)
0.59 (0.35-
0.98) 0.044
Disease pro-
gression % 
(n/n)
69.3 (70/101) 66.03 (106/159) 1.13 (0.66-1.93) 0.65
Complete 
response % 
(n/n)
4.1 (5/103) 1.3 (1/75) 3.13 (0.36-27.37) 0.41
Partial re-
sponse % (n/n) 13.92 (11/79) 14.51 (18/124)
1.05 (0.46-
2.35) 0.90
Stable disease 
% (n/n) 38.6 (17/74) 20.9 (26/124)
0.89 (0.44-
1.77) 0.74
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Table 2. Clinical progression of control and cases after one year diag-
nosed of IIIb/IV stage lung adenocarcinoma
Cases Controls OR (IC95%) p
Hospitalization 
% (n/n) 45.2 (48/106) 39.8 (65/163)
0.80 (0.48-
1.31) 0.38
Hospitalization 
due to onco-
logic medica-
tion % (n/n)
11.4 (45/79) 12.9 (14/108) 1.15 (0.47-2.82) 0.74
Hospitalization 
due to base-
line disease % 
(n/n)
56.9 (45/79) 52.2 (57/109) 0.82 (0.46-1.48) 0.52
Number of 
hospitaliza-
tions. Median 
(IQR)
1 (0-2) 1 (0-3.4) --------------- 0.47
Conclusion: This study shows, in patients with IIIb/IV stage lung 
adenocarcinoma, the testing practice to detect EGFR mutations as 
part of the diagnosis and treatment strategy has an impact on the 
mortality rate at one year follow up when compared with patients 
of similar characteristics to whom the test had not been performed.
Keywords: NSCLC, EGFR, test
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KEYNOTE-042: PHASE 3 STUDY OF PEMBROLIZUMAB 
(MK-3475) VERSUS PLATINUM DOUBLET CHEMOTHER-
APY AS FIRST-LINE THERAPY FOR PD-L1-POSITIVE NON-
SMALL CELL LUNG CANCER
Gilberto Lopes1, Patricia A. Watson2, Jin Zhang2, Reshma Rangwa-
la2, Tony Mok3  
1Centro Paulista De Oncologia E Hcor Onco, Members Of The Oncoclínicas 
Do Brasil Group, São Paulo/BRAZIL, 2Merck & Co., Inc., North Wales/UNITED 
STATES OF AMERICA, 3The Chinese University Of Hong Kong, Hong Kong/
HONG KONG
Background: The standard of care (SOC) for patients with ad-
vanced non-small cell lung cancer (NSCLC) without genetic 
aberrations is platinum-based chemotherapy. The programmed 
death 1 (PD-1) pathway plays a critical role in tumor immunity and is 
frequently altered in cancer. Pembrolizumab (MK-3475) is a highly 
selective, humanized monoclonal IgG4 anti-PD-1 antibody de-
signed to block the interaction between PD-1 and its ligands PD-L1 
and PD-L2. In the phase 1 KEYNOTE-001 study, pembrolizumab 
showed acceptable safety and antitumor activity in patients with 
advanced NSCLC, with greater activity observed in patients with 
higher tumor PD-L1 expression. In treatment-naive patients with 
PD-L1+ NSCLC enrolled in KEYNOTE-001 and as assessed by 
RECIST v1.1, pembrolizumab was associated with a 26% response 
rate (47% by immune-related response criteria [irRC]) and 27-week 
median progression-free survival (PFS) (37 weeks by irRC). 
Methods: In this open-label, multicenter phase 3 study, adults with 
previously untreated, EGFR wild-type, ALK− advanced NSCLC that 
expresses PD-L1 will be randomized 1:1 to pembrolizumab or SOC 
(investigator’s choice of carboplatin + paclitaxel or carboplatin + 
pemetrexed [Alimta®]). Randomization will be stratified by ECOG 
performance status (0 vs 1), histology (squamous vs nonsquamous), 
geographic region (East Asia vs non-East Asia), and PD-L1 expres-
sion status (strong vs weak; determined by immunohistochemistry 
at a central laboratory). Pembrolizumab will be continued until pro-
gression, intolerable toxicity, investigator decision, or completion 
of 35 cycles; pembrolizumab discontinuation may be considered 
for patients who experience complete response. Chemothera-
py will be continued for a maximum of 6 cycles and followed by 
optional pemetrexed maintenance therapy in patients with non-
squamous histology. Response will be evaluated every 9 weeks 
by RECIST v1.1 by independent central review. Adverse events will 
be monitored and graded according to NCI CTCAE v4.0. The 
primary end point is overall survival (OS) in the PD-L1 strong-pos-
itive population. Secondary end points include PFS in the PD-L1 
strong-positive population, OS and PFS in the overall population, 
and safety. Exploratory end points include OS and PFS in the PD-L1 
weak-positive population and objective response rate and duration 
of response in the PD-L1 strong- and weak-positive and overall 
populations. Planned enrollment is approximately 1240 patients.
Results: KEYNOTE-042 is expected to begin enrollment in No-
vember 2014.
Conclusion: KEYNOTE-042 is expected to provide data on the 
efficacy and safety of pembrolizumab compared with SOC plat-
inum doublet as first-line therapy for PD-L1-positive, EGFR wild-
type, ALK− advanced NSCLC.
Keywords: NSCLC, PD-L1, MK-3475, pembrolizumab
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INCIDENCE OF DRIVEN MUTATIONS IN ADVANCED 
NSCLC USING AN EXTENDED BIOMARKER PANEL AND 
THEIR CO-EXISTENCE ASSOCIATION. 
Edgardo S. Santos  
Lynn Cancer Institute, Boca Raton/UNITED STATES OF AMERICA
Background: EGFR mutation and EML4/ALK and ROS-1 transloca-
tion have become standard genetic tests for patients with advanced 
adenocarcinoma of the lung. Other driven mutations and genetic 
abnormalities are still investigational including c-Met expression. 
C-met overexpression has shown to confer resistance to EGFR TKI. 
By targeting c-Met, studies suggest that lung cancer cells may re-
spond again to EGFR TKI. The incidence of c-Met in NSCLC is not 
clear yet as well as how it may relate to other biomarkers. 
Methods: A retrospective study of 43 consecutive biomarker pro-
file tests from pts. with either unresectable or stage IV chemonaïve 
adenocarcinoma of the lung were analyzed. We adopted a compre-
hensive biomarker panel as part of a common decision made from 
a lung cancer consortium. All pts’ samples were sent to Response 
Genetics Inc (RGI) with an order to perform a panel of 9 biomarkers. 
We report the incidence of c-MET expression and its co-existence 
with other biomarkers. During the collection data period, 2 more 
genetic tests were added (RET and B-Raf), thus, we have been using 
the so-called “academic panel” from RGI order form. Herein, we 
report the incidence of c-MET expression and its co-existence with 
EGFR, K-Ras, and PI3K mutations as well as EML4/ALK translocation 
and ROS-1 rearrangement. EGFR mutations (T790M, L858R, L861Q, 
G719X, S768I, exon 19 deletion, and exon 20 insertion) and K-Ras 
mutations in codon 12 and 13 were analyzed by allele-specific PCR; 
EML4/ALK translocation was tested by Vysis® ALK Break Apart 
FISH probe kit; ROS-1 rearrangement was tested via FISH using two 
single stranded DNA break-apart probes; PI3K mutations (H1047R, 
H1047L, 545K, Q546K, E542K, E545A, E545G) were tested via 
dye-terminator sequencing. 
Results: The tumor sample of 43 pts. with unresectable or stage 
IV chemonaïve adenocarcinoma of the lung were analyzed. All 
pts. were Caucasian; gender: 25 females/18 males; median age: 
79 (range, 58-89); distribution of staging was: stage I: n=5, stage 
II: n=1, stage III: n=7 and stage IV: n= 30 patients. c-MET was or-
dered in 37 patients: 9 pts. had c-MET overexpressed (24%), 16 had 
low-expression (43%); 12 had no enough tissue for the test. None 
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of the c-MET high expression pts. had EGFR mutation. 7/40 (18%) 
specimens had EGFR test result positive for mutation (3 had exon 
19 deletion, 3 L858R, and 1 exon 20 deletion); 3 pts. did not have 
enough tissue for testing. In this cohort, we had 38 specimens with 
EML4/ALK results; 9 pts. had this translocation (24%). Two pts. 
with EML4/ALK translocation also had high c-MET expression; in 
3 EML4/ALK pts., there was not enough tissue to report c-MET 
status. The presence of K-Ras (36 tumor samples tested), PI3K (36 
tumor sample tested), and ROS-1 (37 tumor samples tested) muta-
tions were 14/36 (39%), 1/36 (3%), and 0/37, respectively. 
Conclusion: To date, not too much is known about c-MET over-
expression in chemonaïve pts. and how these biomarkers interact 
with other driver mutations in lung cancer. Some new clinical trials 
propose a double target approach on the basis of overexpression 
or driven mutations present in tumor tissue. Hence, it is important 
to know the co-incidence of these biomarkers in the same tumor 
specimen. Our small cohort reveals that c-Met overexpression is 
common in chemonaive pts, but its co-existence with other mark-
ers is low. Interestingly, although EML4/ALK has a low incidence 
in NSCLC, 2 out of 2 pts (with all biomarkers reported) had c-Met 
overexpression. K-Ras mutation has a high incidence in advanced 
NSCLC and PI3K seems to be a rare genetic phenomenon.
Keywords: C-MET, EGFR, ROS-1, EML4/ALK
POSTER SESSION 2 - August 23, 2014 09:00-18:00 
Topic: Advanced NSCLC
P2.27
COMPLETE RESPONSE OF LUNG ADENOCARCINOMA 
BRAIN METASTASES (MTS) IN A PATIENT TREATED WITH 
AFATINIB (BIBW 2992) 
Silvia Alejandra Bogado1, Carolina Fontana1, María Cecilia Carraro1, 
Susana Goncalves2, Daniel Campos3, Silvia Carraro1  
1Imai Research, Buenos Aires/ARGENTINA, 2Boehringer Ingelheim, Buenos 
Aires/ARGENTINA, 3Fundacion Multidisciplinaria De Oncologia, Buenos Aires/
ARGENTINA
Background: Afatinib is a member of a second generation irre-
versible tyrosine kinase inhibitors of ErbB Family OBJECTIVE: To 
show complete response of brain metastases
Methods: A 71 year old female, ECOG PS 1, no smoking, type II 
diabetic, hypertensive, with stage IV lung adenocarcinoma, with 
a L858R mutation. At baseline, the patient was asymptomatic 
and had, according to RECIST 1.1, the following target lesions: LSI 
pulmonary nodule and a sub-carinal adenopathy; and non-target: 
multiple pulmonary nodules, pleural effusion and thickening, me-
diastinal and bilateral hilar lymphadenopathy and brain metastases. 
Evacuation and sealing of pleural effusion prior to the start of ther-
apy was performed. Toxicity assessments every 21 days and evalu-
ation of tumor response were performed every 6 weeks.
Results: The patient received treatment in the context of a clinical 
research study with Afatinib 40 mg / day, orally, from 01-2011 to 
08-2011 (11 courses). Tumor response: partial response was ob-
served from week 6. She had complete response of brain MTS 
from 05-2011 until 08-2011 when she left the study due to brain 
MTS progression. She received brain radiotherapy (3000 cGy) in 
09-2011,Gefitinib from 11-2011 to 06-2012, Erlotinib from 08-2012 
to 09-2012 when she died because of pneumonia and decompen-
sated diabetes. Toxicity: diarrhea grade I and cutaneous grade III.
Conclusion: Kim JE et al. reported 16/23 partial responses 
and 3/23 stable disease with EGFR TKI as first-line treatment in 
non-smoking patients with brain metastases from lung adenocarci-
noma.As for our patient, Afatinib demonstrated effectiveness, not 
only in terms of brain metastases (initially non-irradiated without 
corticosteroid therapy), but also on the extra-cranial level with a 
manageable toxicity profile.
Keywords: Tirosine kinase inhibitors, Afatinib, Brain metastases, 
Lung Adenocarcinoma
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NON SQUAMOUS LUNG CANCER IN ELDERLY PATIENTS: 
FEASIBILITY OF TREATMENT WITH CARBOPLATINO 
- PEMETREXED FOLLOWED BY MAINTENANCE PEME-
TREXED.
Luis Mas, Mivael Olivera Hurtado De Mendoza, Rossana Ruiz, 
Karin Veliz, Andrea Guzman, Henry Gomez  
Instituto Nacional De Enfermedades Neoplasicas, Medical Oncology, Lima/PERU
Background: Lung cancer is frequent in patients over 70 years old. 
Many of these have comorbidities which limit their activity, per-
formance status and therefore their treatment options. It has been 
stablished that patientes with a good physical condition and status 
performance benefit from treatment with combo based platinum 
salts. Maintenance therapy with pemetrexed is the standard of crae 
for patients with non-squamous lung cancer. We treated patients 
older tan 70 years old with a regimen containing Carboplatin + 
Pemetrexed folowed by pemetrexed as maintenance 
Methods: We assesed the clinical files of patients older than 70 
years who were treated with carboplatin AUC (5-6) and Peme-
trexed 500 mg/m2 every three weeks for four cycles followed by 
Pemetrexed 500 mg/m2 every three weeks as maintenance, until 
progression or unacceptable toxicity. We reported the toxicity 
profile and tolerance.
Results: Between May 2013 to May 2014, we treated 42 eldelrly 
patientes. 35 were evaluable for toxicity and tolerance. Male: 26 
and Female: 16. Median age: 75 years. Range: 70 - 86. Perfor-
mance status, ECOG 1: 36 , ECOG 2: 7. we administred 237 cycles 
of chemotherapy, Carboplatin + Pemetrexed: 116, Pemetrexed: 121. 
The toxicity reported most important was hematological. Anaemia 
grade 1: 16 %, 2: 15 %, 3-4:1%; Plaquetopenia grade 1: 3 %, 2:3%, 
3-4:2%; Neutropenia grade 1: 3%, 2: 9 %, 3-4: 6%, febrile neutro-
penia: 6%, Nausea and vomiting grade1: 1%, 2: 1 %, 3-4:1 %, Hyper-
trasmainasemia grade 4: 1%, mucositis grade 1-2: 2% . there were 
two treatment-related deaths, both febrile neutropenia and sepsis 
Conclusion: Elderly patients with good status performance and 
controlled comorbidities, adequately tolerate pemetrexed treat-
ment, either alone or in combination with platinum salts as is shown 
in our study. Age by itself should not preclude cytotoxic tratments. 
Geriatric assesment scales should be integrated in daily clinical 
practice as an important tool for therapeutic desicions.
Keywords: elderly, chemotherapy
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EXPERIENCIA INSTITUCIONAL EN LA OBTENCIóN DE 
BIOPSIAS EN PACIENTES CON CáNCER DE PULMóN.
Eduardo Richardet, Martin Richardet, Matias Molina, Matias 
Cortes, Maria Eugenia Pacher, Romina Brombin, Luciana Acosta, 
Patricia Hernandez, Aldo Riso, Pablo Companys  
Ionc, Cordoba, Cordoba/ARGENTINA
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Background: Las únicas pruebas moleculares con nivel de eviden-
cia para determinar el valor predictivo y pronóstico en cáncer de 
pulmón no células pequeñas (CPNCP) son la mutación de EGFR y 
ALK. El objetivo principal de este estudio es evaluar la prevalencia 
de los distintos subtipos histológicos y del estado de EGFR en paci-
entes con CPNCP. Los objetivos secundarios son evaluar la met-
odología de obtención de material anatomopatológico; evaluar si 
el material obtenido por los diferentes métodos es suficiente para 
un correcto estudio de biología molecular; y determinar el tiempo 
que transcurre desde el envío de la muestra hasta la obtención del 
resultado. 
Methods: Estudio observacional retrospectivo en el cual se 
analizaron 270 historias clínicas de pacientes con diagnóstico de 
CPNCP en el Instituto Oncológico de Córdoba (IONC) desde 
Enero de 2005 hasta el 30 de Abril de 2014.
Results: En cuanto a la histología, de los 270 pacientes, 65,9% 
fueron adenocarcinoma, 1.85% carcinomas células grandes, 15.1% 
carcinomas epidermoides, 7.40% carcinomas indiferenciados, 1.11% 
carcinomas neuroendocrinos y en 7.03% pacientes no se pudo 
determinar el subtipo histológico. En 49 (18.1%) pacientes se realizó 
estudio del status del EGFR. 53% no presentaron ninguna mutación, 
31% material fue subóptimo para la realización del estudio y 16% 
pacientes presentaron distintas mutaciones. La mutación del exón 18 
estuvo presente en 6% de los pacientes, la mutación del 20 en 3%, 
y la mutación más frecuente fue la del exón 21, presente en el 9% de 
los casos. 6% presentaron más de 1 mutación. En cuanto al método 
para obtención de tejido, el más utilizado fue la punción guiada por 
TAC en 72% de los casos; seguida por punción por fibrobronco-
scopía en el 10%, y cirugía en el 18%. Desde el envío de la muestra 
hasta la recepción del informe pasaron 1.86 semanas en prome-
dio. En aquellas en las que la muestra fue suficiente el tiempo fue 
levemente mayor 2.23 semanas vs. 1.71 semanas para aquellas con 
muestra insuficiente o inadecuada. El tiempo desde el diagnostico 
hasta que se recibe el resultado del EGFR es de 11,85 semanas.
Conclusion: En el 95% de los casos se pudo determinar el subtipo 
histológico. El más frecuente fue el adenocarcinoma (68%), segui-
do por carcinoma epidermoide (23%). De los pacientes estudiados 
(49), en el 69% se pudo determinar el estado EGFR, 24% presen-
taron mutaciones. Nuestros resultados coinciden con las estadísti-
cas mundiales actuales en donde el adenocarcinoma es el subtipo 
predominante. La metodología más utilizada para la obtención 
de tejido tumoral fue la punción guiada por TAC (72%). El tiempo 
transcurrido desde el inicio de los síntomas hasta que el paciente 
comienza con un tratamiento es similar a los datos publicados; 
pero triplicamos el tiempo que transcurre desde que se realiza el 
diagnostico hasta conocer el informe de biología molecular. De-
beremos buscar los mecanismos para que los estudios puedan ser 
realizados en tiempos adecuados y que permitan al médico contar 
con todas las armas a la hora de tomar una decisión terapéutica sin 
necesidad de demorar la misma.
Keywords: NSCLC, EGFR, Biopsia
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ACTIVE IMMUNOTHERAPY IN ADVANCED NON-SMALL 
CELL LUNG CANCER
Elia Neninger1, Pedro Camilo Rodriguez2, Tania Crombet3  
1Hermanos Ameijeiras Hospital, Clinical Oncology, Havana/CUBA, 2Center Of 
Molecular Immunology, Havana/CUBA, 3Center Of Molecular Immunology, 
Clinical Research, Havana/CUBA
Background: CimaVax-EGF is a cuban therapeutic cancer vaccine 
composed by human recombinant Epidermal Growth Factor (EGF) 
conjugated to a carrier protein, P64K from Neisseria Meningiti-
des which induces antibodies against self EGF that would block 
EGF-EGFR interaction. In previous studies was demonstrated its 
safety and efficacy related to survival functions. Several clinical 
trials have been carried out, showing increase in anti-EGF anti-
body titers, decrease in plasma EGF concentration and survival 
advantage in vaccinated patients. This randomized phase III trial 
investigated the efficacy and safety of Cimavax EGF in advanced 
non−small-cell lung cancer (NSCLC) patients after first line therapy 
Methods: Patients with advanced NSCLC who achieved disease 
control after first line chemotherapy was randomly assigned to 
receive CIMAVAX 2.4 mg per vaccination bi-weekly in induction 
phase and monthly re-immunizations beyond progression. Control 
arm received the best supportive care. Randomization was1:2 (Favor-
ing Vaccine arm). Overall Survival, immunogenicity and safety were 
the principal objectives sin this study. During the time of recruitment 
405 stage IIIB/IV non-small-cell lung cancer patients were random-
ly assigned (control n=135); (vaccinated n=270). 
Results: By Intent to Treat Analysis OS was 10.37 vs 8.93 months 
favored to vaccinated arm (p= 0.043 HR); patients with Basal se-
rum EGF concentrations as predictor biomarker (threshold >900 
pg/mL) showed higher survival in experimental arm: 13.56 vs 6.9 
months (p=0.0001 HR 0.41). Five years Survival rate was superior in 
vaccinated patients than controls (23 % vs 0%). The most frequent 
adverse events for vaccinated patients were grade 1 or 2 injection 
site reactions, fever, headache and vomiting. Conclusions: Cimavax 
egf works efficiently in advanced non-small cell lung cancer. High 
serum EGf concentration is a biomarker than can predict survival 
benefit after first line chemotherapy in this setting 
Methods: Patients with advanced NSCLC who achieved disease 
control after first line chemotherapy was randomly assigned to 
receive CIMAVAX 2.4 mg per vaccination bi-weekly in induction 
phase and monthly re-immunizations beyond progression. Control 
arm received the best supportive care. Randomization was1:2 (Fa-
voring Vaccine arm). Overall Survival, immunogenicity and safety 
were the principal objectives sin this study. During the time of 
recruitment 405 stage IIIB/IV non-small-cell lung cancer patients 
were randomly assigned (control n=135); (vaccinated n=270). 
Results: By Intent to Treat Analysis OS was 10.37 vs 8.93 months 
favored to vaccinated arm (p= 0.043 HR); patients with Basal se-
rum EGF concentrations as predictor biomarker (threshold >900 
pg/mL) showed higher survival in experimental arm: 13.56 vs 6.9 
months (p=0.0001 HR 0.41). Five years Survival rate was superior in 
vaccinated patients than controls (23 % vs 0%). The most frequent 
adverse events for vaccinated patients were grade 1 or 2 injection 
site reactions, fever, headache and vomiting.
Conclusion: Cimavax egf works efficiently in advanced non-small 
cell lung cancer. High serum EGf concentration is a biomarker than 
can predict survival benefit after first line chemotherapy in this 
setting
Keywords: advanced NSCLC, Cancer vaccine, Serum EGF con-
centration
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LOCALLY ADVANCED THYMIC MALIGNANCIES TREATED 
WITH MULTIMODAL THERAPIES: AN OBSERVATIONAL 
STUDY
Rafael Caparica Bitton1, Leticia Lauricella2, Pedro Nabuco2, Ro-
drigo Canellas De Souza3, Cristiane Mesquita1, Ricardo Mingarini 
Terra2, Gilberto De Castro Jr1  
1Instituto Do Câncer Do Estado De São Paulo - Icesp, Clinical Oncology, São 
Paulo/BRAZIL, 2Instituto Do Câncer Do Estado De São Paulo - Icesp, Thoracic 
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Background: Thymic malignancies are rare. Treatment with cu-
rative intent is based on surgical resection. 30% of these patients 
(pts) present with locally advanced disease (Masaoka stages III-IVa). 
Neoadjuvant chemotherapy followed by surgery and adjuvant 
radiotherapy or definitive concomitant chemoradiotherapy are 
therapeutic options, but no clear superiority of one strategy over 
another does exist. In this study, we report our results on locally 
advanced thymic malignancies treated with multimodal therapies. 
Methods: It is a retrospective, observational, uninstitutional study. 
We reviewed medical records of all pts diagnosed with locally 
advanced thymic malignancies treated consecutively on our insti-
tution from 2010 to 2014. Neoadjuvant chemotherapy consisted 
of PAC regimen (cyclophosphamide 500mg/m2 d1, doxorubicin 
50mg/m2 d1, cisplatin 50mg/m2 d1) 3 − 6 cycles, or CP regimen 
(carboplatin AUC 6 d1, paclitaxel 200mg/m2 d1) followed by 
surgery. Radiotherapy was administered either as adjuvant after 
surgery (54 Gy), or as a definitive local modality treatment after 
chemotherapy (50 − 60 Gy). Response rates were evaluated using 
RECIST 1.1 criteria, and toxicities were classified using CTCAE v4.0. 
Overall survival (OS) and progression free survival (PFS) were cal-
culated using Kaplan-Meier method, and curves were compared 
using log-rank.
Results: Ten pts were included in this study: median age 55 y (37-
82), 7 male. Six pts were staged as Masaoka III, and 4 were Masa-
oka IVa. According to WHO classification, pts were classified as: 
1 AB, 3 B3, 3 C (thymic carcinoma) and 3 were unclassified. Nine 
pts were treated with neoadjuvant PAC, in a median of 4 cycles 
(range 3-6) and 1 pt with CP (4 cycles). Four pts (40%) obtained 
partial response, and 6 pts (60%) presented stable disease after 
neoadjuvant chemotherapy. No grade 4 toxicities were recorded, 
1 pt experienced grade 3 emesis, and 3 pts grade 3 neutropenia. 
Three pts (out of 3) underwent R0 surgical resections, with no 
major complications, and 2 pts will be submitted to surgery. Ra-
diotherapy was administered as adjuvant treatment in 2 pts, and as 
a definitive local modality treatment after chemotherapy in 4 pts. 
One pt received second-line chemotherapy (CP) after progressive 
disease. In a median follow up of 22.8 (2.9-37.5) months, 1 pt died 
and 2 pts presented disease progression. Median PFS and OS were 
not achieved. 2-year PFS was 77%, and 2-year OS was 90%. Inter-
estingly, median OS was not achieved in those 3 pts treated with 
radical surgery and it was 25.4 months among those pts treated 
with chemoradiation alone (p=0.184).
Conclusion: Neoadjuvant chemotherapy presented a high re-
sponse rate in this group of pts, with an acceptable toxicity profile. 
Overall, the prognosis of thymic malignancies is good, and surgery 
seemed to have a positive impact in survival outcomes. Cooper-
ative studies must be encouraged to better establish therapeutic 
strategies in this rare group of pts.
Keywords: Thymoma, Thymic carcinoma, Neoadjuvant
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EXTENSIVENESS OF DISEASE, PERFORMANCE SCORE 
AND EFFECT OF CHEMOTHERAPY ON SURVIVAL IN PA-
TIENTS WITH SMALL CELL LUNG CANCER
Erhan Sadik Turgut1, Murat Kocer2, Muruvvet Aybek3, Abdullah 
Sakin4, Ahmet Ali Usta3  
1Kanuni Sultan Suleyman Research Hospital, Pulmonology, Istanbul/TURKEY, 
2Suleyman Demirel University Hospital, Medical Oncology, Isparta/TURKEY, 3Su-
leyman Demirel University Hospital, Internal Medicine, Isparta/TURKEY, 4Kanuni 
Sultan Suleyman Research Hospital, Internal Medicine, Istanbul/TURKEY
Background: Small cell lung cancer (SCLC) is a disease which has 
high potential of early metastasis and short survival. The Eastern 
Cooperative Oncology Group (ECOG) performance score of the 
patient and the diseaase being in the limited- or extensive-stage 
at the time of diagnosis, and chemotherapy are considered to re-
markably affect survilal. The present study aimed to evaluate the 
effects of these parameters on survival in 70 patients with SCLC 
who were fallowed-up between 2009 and 2013. 
Methods: Medical records of 70 patients with SCLC, who were 
fallowed-up in the Medical Oncology Clinic of Suleyman Demirel 
University Medical Faculty between 2009 and 2013, were evalu-
ated retrospectively. Data regarding demographic characteristics, 
diagnostic procedures, accompanying comorbities and regions of 
metastasis of all patients were documented. Disease extend and 
the ECOG performance scores at the time of diagnosis, applied 
chemotherapies, and effects of these factors on survival were in-
vestigated.
Results: Of the patients, 98.57% was male and 1.43 was female. 
The mean age was 63 years (range, 45-84 years). At the time of 
diagnosis, 28.6% had limited-stage SCLC, whereas 71.4% had 
extensive-stage SCLC. At the time of diagnosis the ECOG scores 
were 0 in 10% of the patients, 1 in 30% of the patients, 2 in 31.4% 
of the patients, 3 in 21.4% of the patients, 4 in 7.2% of the patients. 
While 72.86% of the patients received chemotherapy during 
fallow-up, 58.6% of the patients received definitive or palliative 
radiotherapy. The mean overall survival was 391.4 days in the pa-
tients having limited-stage diseae, whereas it was 194 days in those 
having extensive-stage diseae (p<0.01). The mean overall survival 
was 321.4 days in he patients received chemotherapy, whereas it 
was 49.3 days in those who did not receive chemtherapy (p<0.01). 
Evaluation of the effect of chemotherapy on survival in the patients 
having limited-stage disease revealed that the mean survival in the 
patients received chemothapy was 438.3 days, whereas it was 17 
days in 1 patient who did not receive chemotherapy. In the patients 
having extensive-stage disease, the mean survival was 277 days 
in those received chemotherapy and 51.2 days in those who did 
not receive chemotherapy. Evaluation of the overall survival of the 
patients according to the ECOG scores at the time of diagnosis 
revealed that the mean survival was 407.7 days in those with ECOG 
score of 0, 324 days in those with ECOG score of 1, 261 days in 
those with ECOG score of 2, 114 days in those with ECOG score 
of 3, 20.5 days in those with ECOG score of 4. The mean overall 
survival of the group with ECOG score of 4 was found to be sig-
nificantly different than those of the groups with ECOG score of 0 
and 1 (p<0.01). 
Conclusion: Based on the examinations and statistical evaluations, 
disease extend and high peformance score at the time of diagnosis 
were observed to significantly and unfavorably affect survival in 
SCLC fallowed in our clinic. Morover, chemotherapy significantly 
contributed to survival, this effect being more noticeable in the 
limited-stage disease.
Keywords: small cell lung cancer, survival, performance score
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SURGICAL AND CLINICAL TREATMENT OF MALIGNANT 
PLEURAL MESOTHELIOMA: RETROSPECTIVE ANALYSIS 
OF 15 YEARS
Ricardo Mingarini Terra1, Benoit Jacques Bibas1, Priscila Berenice 
Costa1, Mauro Federico Luis Tamagno1, Teresa Yae Takagaki2, Ri-
cardo Beyruti1, Gilberto De Castro Jr3, Paulo Pego-Fernandes1  
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Background: Malignant pleural mesothelioma (MPM) is the most 
common primary cancer of the pleura. Its aggressiveness demon-
strated by the short survival is still troublesome. The objective of 
this study is to describe the overall survival rates of surgical and 
clinical treatment for MPM and to analyze possible predictors for 
mortality. 
Methods: Retrospective study with patients with MPM between 
December 1999 and April 2014. All patients were considered 
for multimodal therapy (neoadjuvant chemotherapy followed by 
extrapleural pleuropneumonectomy and adjuvant radiotherapy), 
unless contraindicated. Primary outcome was overall survival. Sec-
ondary outcomes were surgical morbidity and 30-day mortality. 
Kaplan-Meier estimate was used for survival analysis and logrank 
for difference between survival estimates. Multivariate analysis was 
done with Cox proportional hazards.
Results: Sixty-nine patients were included (55 M/ 14 F). Baseline 
characteristics are depicted in table 1. Mean age was 59 + 13 years. 
Surgical approaches were multimodal (neoadjuvant chemotherapy 
plus extrapleural pleuropneumonectomy plus adjuvant radiother-
apy) in 25 patients (96%), and decortication and adjuvant chemo-
therapy in 1 (4%). Complications occurred in 15 patients (57%), and 
30-day surgical mortality was 27%. Treatment in the non-surgical 
group was chemotherapy and radiotherapy in 11 (26%), or chemo-
therapy alone in 32 (74%). Medial overall survival was 10 months. 
Patients submitted to surgical treatment had a higher survival rate 
(14 vs 8 months; p=0.029) (Figure1). Multivariate cox proportional 
hazards revealed that surgery significantly increased survival (HR 
.366; p=0.012; IC95%.1674494 - .8026208) (Table 2). 
Table 1 
Surgery Clinical Treatment
N 26 43
Sex
Male 88% (23) 74% (32)
Female 12% (3) 26% (11)
Age 53 + 14.71 63.25 + 11.97 p= 0.002
Tobacco Exposure 42% (11) 48% (21)
Asbesto Exposure 38% (10) 44% (19)
Histhology
Epithelioid 73% (19) 79% (34)
Sarcomathoid 8% (2) 4% (2)
Biphasic 19% (5) 9% (4)
Desmoplastic - 7% (3)
Tumor Stage (TNM)
I 46% (12) 12% (5)
II 12% (3) 9% (4)
III 42% (11) 56% (24)
IV 23% (10)
Surgical Mortality (30 
days); n (%) 27% (7)
Surgical Morbidity 57% (15)
 
 
Figure 1 
A - Overall survival B - Group Comparison Table 2 
Haz. Ratio Std. Err. z P>|z| [95% Conf. Interval] 
Treatment 
(surgery x 
Clinical)
.3666038 .1465695 -2.51 0.012 .1674494 - .8026208
Age .9923824 .0118248 -0.64 0.521 .9694747 - 1.015831
Tobacco 
exposure 1.294.681 .3841834 0.87 0.384
.7237318 - 
2.316052
Asbesto 
exposure .8658022 .2564864 -0.49 0.627
.4844596 - 
1.547319
Histhology .7975542 .1211459 -1.49 0.136 .592196 - 1.074125
Tumor Stage .8701092 .1508053 -0.80 0.422 .6195059 - 1.222087
 
Conclusion: Treatment of MPM is still controversial. Extrapleural 
pleuropneumonectomy has high morbidity and mortality, but after 
adjustments to multivariate analysis, seems to improve survival 
rates when compared to chemotherapy and radiotherapy.
Keywords: mesothelioma, pleura, mortality, survival
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THE NOVEL SYNTHETIC PEPTIDE CIGB-300 AFFECTS 
SEVERAL SIGNALING PATHWAYS INVOLVED IN MALIG-
NANT PROGRESSION OF HUMAN AND MURINE LUNG 
TUMOURS.
Stéfano Cirigliano1, Inés Díaz Bessone1, Carolina Flumian1, Damián 
Emilio Berardi1, Silvio Perea2, Elisa Bal De Kier Joffé1, Hernán Fari-
na3, Laura Todaro1, Alejandro Urtreger1  
1“Ángel H. Roffo“ Hospital, Research Area, Ciudad Autónoma De Buenos Aires/
ARGENTINA, 2Center For Genetic Engineering And Biotechnology, Havana/
CUBA, 3Quilmes National University, Bernal/ARGENTINA
Background: CK2 is a serine/threonine kinase involved in cell 
growth, survival and apoptosis. CIGB-300 is a synthetic peptide 
capable of binding to CK2 substrates thus preventing enzyme 
activity. We have studied the effect of CIGB-300 on signaling 
pathways involved in tumour progression and spheroid growth, 
using a model of human and murine lung cancer cell lines. Previ-
ously, we have determined that CIGB-300 presented an inhibitory 
concentration 50 (IC50) of 119±2.4 µM in NCI-H125 human lung 
cancer cells. Through an Annexin V-FITC assay we determined 
that CIGB-300 is a potent apoptosis inductor since the treatment 
for 60 minutes induced apoptosis at a level comparable with that 
observed with etoposide. Concomitantly with cell death induction, 
we could observe caspase-3 activation and the decreased expres-
sion of c-myc, cyclin D1 and D2. In this work we analyzed whether 
CIGB-300 is able to alter the ability of lung cancer cells to grow 
in 3D and to modulate signaling pathways involved in tumour pro-
gression. 
Methods: Cell lines: the murine 3LL (Lewis lung carcinoma clone) 
and the NCI-H125 human non-small-cell lung adenocarcinoma 
were used. Cytotoxicity assays: the response to CIGB-300 was 
evaluated measuring cell viability by MTS. Nuclear factor қB (NF-
қB) Western blot (WB): to evaluate NF-κB expression levels, we 
performed the separation of nuclear and cytoplasmic fractions, 
following Abcam protocol. Wound healing assay: migration of 
3LL and NCI-H125 cells was evaluated in presence of CIGB-300. 
Apoptosis was assessed in cells treated with CIGB-300 or etopo-
side by fluorescence, using Annexin V/PI staining, according the 
Invitrogen protocol. Reporter genes assay was performed by trans-
fection with a plasmid containing the luciferase gene under reg-
ulation of a promoter containing NF-κB/RE. Multicellular tumour 
spheroids was done through the hanging-drop method.
Results: To analyze the effect of CIGB-300 on canonical Wnt sig-
naling, this pathway was initially activated by incubating NCI-H125 
cells with a conditioned media containing Wnt3a factor. This in-
cubation led to a significant increase in the levels of cytoplasmic 
β-catenin. By WB we could observe that treatment with CIGB-300 
blocked this increase, suggesting its role in the modulation of the 
Wnt canonical pathway. In order to analyze the NF-қB dependent 
pathway, this transcription factor was activated by a phorbol ester 
treatment. Short treatment with CIGB-300 induced an important 
reduction in nuclear NF-қB levels. However, this inhibition was 
reverted 24 h later as determined by WB and reporter gene assays. 
Next, we evaluated the effect of CIGB-300 in the modulation of 
3D growth capacity. NCI-H125 cells were able to developed stable 
spheroids in vitro. After 5 days of treatment, CIGB-300 induced 
a significant growth inhibition (volume: 4.07x107±0.70x107 µm3 in 
control spheroids vs 2.13x107±0.35x107 µm3 in spheroids treated 
with the IC50 p<0.05).
Conclusion: Our results indicate that treatment with CIGB-300 
strongly induces apoptosis and negatively modulates several 
signaling pathways involved in tumour development. Moreover, 
CIGB-300 would be involved in the reduction of lung cancer 
progression since it alters migratory and three dimensional cell 
growth, which resembles in vivo tumour growth conditions. Alto-
gether indicates that CIGB-300 may become a new strategy for 
treatment of lung cancer.
Keywords: CK2, CIGB-300, 3D Culture, Cell Signaling
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MODELING INFLAMMATORY MEDIATORS AND APOPTO-
SIS BY PLEURAL MESOTHELIAL CELLS EXPOSED TO TALC 
PARTICLES
Milena Marques Pagliarelli Acencio, Lisete Ribeiro Teixeira, Vera 
Luiza Capelozzi, Bruna Rocha Silva, Vanessa Adelia Alvarenga, 
Carlos Rocha Silva, Francisco Suso Vargas, Evaldo Marchi  
Pleura Laboratory, Pulmonary Division, Heart Institute (Incor), University Of Sao 
Paulo Medical School, Sao Paulo/BRAZIL
Background: Talc pleurodesis is the most used method to prevent 
recurrence of malignant pleural effusion. It is discussed the role of 
the inflammatory response produced by pleural mesothelial cells 
(PMC) and neoplastic cells and the relationship of these cells with 
the effectiveness of pleurodesis induced by talc. The aim was to 
determine the role of PMC and / or neoplastic cells in the initial 
phase and regulation of the acute inflammatory response after 
instillation of talc to evaluate the production of inflammatory medi-
ators and percentage of apoptosis. 
Methods: In this study we used cultures of human PMC extracted 
from transudative pleural fluid and adenocarcinoma cells (Lewis 
Lung Cells - LLC) divided into 5 groups: 100% of PMC, 100% of LLC, 
25% of PMC + 75% of LLC, 50% of each cell line and CMP + 75% of 
PMC + 25% of LLC. All groups were exposed to 48 mm / talc cm2 
for 48 hours and IL-6, TNF RI were measured along with the per-
centage of apoptosis. Statistical Analysis: One Way Anova, p< 0.05.
Results: The production of both IL-6 and TNF IR was highest in the 
culture of 100% CMP, diminishing proportionally with the reduc-
tion in the percentage of this cell type; the culture that contained 
only LLC had the lowest levels of these cytokines. Conversely, the 
percentage of apoptosis was most evident in cultures of 100% LLC.
Conclusion: The contact of talc with the mesothelium is pivotal to 
the initiation of the inflammatory process with production of medi-
ators that lead to inflammation and pleural fibrosis; besides that, talc 
acts selectively with higher rates of apoptosis in cancer cells. Meso-
thelial cells play a key role in the initiation and regulation of the acute 
inflammatory response in the pleural space after talc instillation. Talc 
induces apoptosis in tumor cells and inhibits angiogenesis as well as 
promoting less aggressive action in mesothelial cells, thus contribut-
ing to better control of malignant pleural effusion.
Keywords: pleurodesis, malignant pleural effusion, talc, Lung Cancer
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THE USE OF NEXT GENERATION SEQUENCING FOR THE 
ANALYSIS OF LUNG CANCER.
Christopher Parks1, Patricia Thompson2, Rabih Bechara1  
1Georgia Regents University/Cancer Treatment Centers Of America, Pulmonary, 
Newnan/UNITED STATES OF AMERICA, 2Cancer Treatment Centers Of Ameri-
ca, Medical Oncology, Newnan/UNITED STATES OF AMERICA
Background: Lung cancer cells undergo multuiple modificaions 
during the course of treatment. Historically there there have been 
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no methods for to detect individual mutations. Because individu-
alized cancer treatment is the ultimate goal for clinicians and their 
patients this type of analysis could prove helpful in determining 
additional available treatments We report the results of a next-gen-
eration sequencing assay in advanced lung cancer. 
Methods: A Prospective Cohort of patients with advanced non 
operable lung cancer was recruited. Tissue from their tumors was 
sent for next-generation sequencing 258 patients with advanced 
lung cancer patients were analysied.. 182 (70.54%) had tissue avail-
able for genomic testing with 182 yielding results. Overall median 
age was 57 yrs (range 28-78). Median number of prior chemother-
apy lines 2.
Results: Lung cancer types: Non-Small cell (NSCLC)/Adenocarci-
noma 134(73.62%), Squamous cell 21 (11.54%), Small Cell 11(6.04%), 
Large Cell 8 (4.40%), Adenosquamous 3 (1.65%), Lung Adenoid 
Cystic Carcinoma 2 (1.10%), Lung Sarcomatoid Carcinoma 2 
(1.10%), Lung Typical Carcinoid 1(0.55%) There were a total of 23 
genomic alterations detected ( 21 in adenocarcinoma, 14 in squa-
mous cell, 6 in small cell, 2 in large cell and 2 in adenosquamous . 
177 patients had at least 1 genomic alteration, 3 had no alterations 
and 2 failed test results. Alterations found: Adenocarcinoma 51/134 
(38.06%) had KRAS, Squamous Cell 8/21 (40%) had CDKN2A, 
Small Cell 5/11 (45.45%) had RB1, Large cell 2/4 (50%) had TP53, 
and Adenosquamous 3/3 had TP53. Of 177 test results 56 (31.64%) 
had at least 1 FDA approved treatment for patient’s tumor type, 132 
(74.58%) with at least 1 FDA approved treatment for another tumor 
type, 143 (80.79%) with at least 1 “actionable result” (FDA approved 
treatment to patient’s or another tumor type, 168 (93.78%) with at 
least 1 clinical trial for a targeted genomic alteration (in clinicaltrial.
gov).
Conclusion: In the majority of patients genomic testing revealed 
potential therapies using medications not traditionally used in the 
treatment of lung cancer. The role this plays in clinical practice 
warrants further investigation.
Keywords: Lung Cancer, chemotherapy, Genetic testing
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CO-EXISTING EGFR AND ALK ALTERATIONS IN NSCLC: 
IMPLICATIONS ON MOLECULAR DIAGNOSTIC ALGO-
RITHMS AND RESISTANCE TO TYROSINE KINASE INHIBI-
TORS
Angela Maria Takano1, Amit Jain2, W C Tan2, Ang Mei Kim2, C. K. 
Toh2, Tira Jing Ying Tan2, Quang Sing Ng2, Ravindran Kenasvaran2, 
Wu Meng Tan2, Anatham Devanand3, Ann Hsu3, Chian Min Loo3, 
Heng Nung Koong4, Chong Hee Lim5, Tse Hsien Koh1, Balram 
Chowbay6, Kam Meng Fong7, Kian Sing Chan1, Lynette Lin Ean 
Oon1, Sam Xiu Xiu1, Tse Hui Lim1, Alvin Soon Tiong Lim1, Darren 
Wan-Teck Lim2, Tony Kiat Hon Lim1, Eng Huat Tan2, Daniel Shao 
Weng Tan2  
1Singapore General Hospital Singhealth, Pathology, Singapore/SINGAPORE, 
2National Cancer Center Of Singapore, Medical Oncology, Singapore/SINGA-
PORE, 3Singapore General Hospital Singhealth, Respiratory And Critical Care 
Medicine, Singapore/SINGAPORE, 4National Cancer Center Of Singapore, 
Surgery, Singapore/SINGAPORE, 5National Heart Center Of Singapore, Surgery, 
Singapore/SINGAPORE, 6Duke-Nus Graduate Medical School, Clinical Sciences, 
Singapore/SINGAPORE, 7National Cancer Center Of Singapore, Cancer Infor-
matics, Singapore/SINGAPORE
Background: Epidermal Growth Factor Receptor (EGFR) muta-
tions and Anaplastic Lymphoma Kinase (ALK) rearrangements are 
widely regarded to be mutually exclusive molecular subtypes of 
non-small-cell lung cancer (NSCLC), leading to the practice of 
sequential testing in diagnostic laboratories. We sought to examine 
the prevalence of co-exisiting EGFR and ALK through concurrent 
testing in consecutive patients with newly diagnosed lung adeno-
carcinoma. 
Methods: Single-centre retrospective review of 512 consecutive 
NSCLC undergoing concurrent reflex diagnostic testing for EGFR 
mutation and ALK rearrangement between 7/2012−9/2013.
Results: 15 patients were found to harbour both alterations in three 
different clinical contexts. Patients harbouring dual EGFR-ALK al-
terations in the same specimen comprised of 2.5% of all adenocar-
cinoma, 5.2% of EGFR-positive and 27% of ALK-positive cohorts. 
Majority (13/15, 87%) had both mutations detected in the same 
specimen, one had EGFR mutation detected after failure of ALK-
TKI, another had EGFR and ALK alterations in separate synchro-
nous lung tumours. Immunostaining of consecutive sections re-
vealed co-expression of EGFR and ALK on the same tumour cells. 
In patients who received an EGFR TKI, response rate was 60% and 
median progression free survival 8.3 months (95% CI 4.3-12.2).
Conclusion: Co-existing EGFR and ALK alterations may have a 
higher prevalence than previously thought, particularly in East-
Asian NSCLC. There were 3 scenarios where dual EGFR-ALK 
alterations occurred; from the same specimen, separated in time 
after treatment failure post-TKI, and separated in space in different 
nodules.
Keyword: NSCLC, EGFR, ALK, TKI RESISTANCE
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BIM EXPRESSION AND POLYMORPHISMS IN EGFR-MU-
TANT NON-SMALL-CELL LUNG CANCER (NSCLC) PA-
TIENTS (PTS) TREATED WITH ERLOTINIB IN COLOMBIA 
(CLICAP)
Andrés Felipe Cardona Cardona1, Oscar Arrieta2, Niki Kara-
chaliou3, Ana Drozdowskyj3, Ana Giménez Capitan4, Miguel Angel 
Molina4, Hernán Carranza1, Carlos Vargas1, Jorge Otero1, Leonardo 
Rojas5, Rafael Rosell4  
1Instituto De Oncología; Fundación Santa Fe De Bogotá, Medical Oncology, 
Bogotá/COLOMBIA, 2Instituto Nacional De Cancerología De México (Incan), 
Medical Oncology, Mexico City/MEXICO, 3Pangaea Biotech, Barcelona/SPAIN, 
4Hospital Germans Trias I Pujol, Barcelona/SPAIN, 5Hospital Universitario San Ig-
nacio; Centro Javeriano De Oncología, Medical Oncology, Bogotá/COLOMBIA
Background: Tyrosine kinase inhibitors (TKIs) elicit high response 
rates among individuals with EGFR-mutated NSCLC. However, 
the extent and duration of these responses are heterogeneous, 
suggesting the existence of genetic modifiers affecting an indi-
vidual‘s response to TKIs. BIM is a pro-apoptotic member of the 
BCL2 family of proteins, and its upregulation is required for TKIs to 
induce apoptosis in kinase-driven cancers. Previous reports have 
linked BIM to response and progression-free survival (PFS), and its 
polymorphism was sufficient to confer intrinsic resistance in Asian 
population.
Methods: We study the impact of BIM mRNA expression on 
response and OS in 29 EGFR-mutant pts treated with erlotinib in 
Colombia.
Results: 55% of pts were >60 years old, 79% (n = 23) were wom-
en and overall response rate to TKIs was 58.6%. Response was 
70% for erlotinib-treated pts with high total BIM levels, compared 
to 52.9% with low/intermediate total BIM levels (p=0.4475). OS 
was 32.9-mo for pts with high and 18.1-mo for those with low BIM 
(p=0.23).
Conclusion: From our knowledge this is the first attempt to estab-
lish the relevance of BIM mRNA expression in patients with EGFR 
mutations in a LATAM population. The results define the potential 
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usefulness of this biomarker to predict the response to TKIs.
Keywords: BIM expression, EGFR-mutant, Non-small-cell lung 
cancer, erlotinib
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E-CADHERIN AND VIMENTIN AS CLINICAL OUTCOME 
BIOMARKERS AMONGST EGFR+ LUNG ADENOCARCI-
NOMA (LA) PATIENTS TREATED WITH ERLOTINIB (CLICAP)
Andrés Felipe Cardona Cardona1, Claudio Martín2, Oscar Arrieta3, 
Hernán Carranza1, Carlos Vargas1, Jorge Otero1, Mauricio Cuello4, 
Luis Corrales5, Pilar Archila6, July Rodríguez6, Guillermo Bramuglia7, 
Diana Torres6, Leonardo Rojas8  
1Instituto De Oncología; Fundación Santa Fe De Bogotá, Medical Oncology, 
Bogotá/COLOMBIA, 2Instituto Fleming, Buenos Aires/ARGENTINA, 3Instituto 
Nacional De Cancerología De México (Incan), Medical Oncology, Mexico City/
MEXICO, 4Hospital De Clínicas - Udelar, Montevideo/URUGUAY, 5Hospital Cen-
tral, San José/COSTA RICA, 6Fundación Para La Investigación Clínica Y Molecular 
Aplicada Del Cáncer - Ficmac, Bogotá/COLOMBIA, 7Fundación Investigar, Bue-
nos Aires/ARGENTINA, 8Hospital Universitario San Ignacio; Centro Javeriano De 
Oncología, Medical Oncology, Bogotá/COLOMBIA
Background: Epithelial-mesenchymal transition (EMT) has been 
known to play a key role in stromal invasion regarding lung adeno-
carcinoma (LA). Loss of E-cadherin (calcium-dependent adhesion) 
and vimentin gain represent two critical steps in EMT which are 
induced by Snail-1 and Twist upregulation associated with epi-
dermal growth factor receptor (EGFR) overexpression. However, 
EMT-related proteins’ roles in EGFR mutants have not been fully 
elucidated; this study was thus aimed at investigating EMT-related 
protein immunoexpression in EGFR-related LA to demonstrate 
their key roles in tumour progression. 
Methods: E-cadherin and vimentin expression was assessed in 84 
EGFR+ LA patients (pt) to determine whether such markers were 
able to predict erlotinib therapy outcome. The percentage of tu-
mour cells grades 0, 1, 2 or 3 membrane staining of E-cadherin and 
vimentin cytoplasmic staining was measured. A previously report-
ed ≥40% tumour cells having +2 and +3 staining cut-off point was 
selected for E-cadherin and ≥10% tumour cells with any staining 
cut-off for vimentin, thereby providing optimal stratification. Over-
all response (ORR), clinical benefit (CB), progression-free survival 
(PFS) time to progression (TTP) and overall survival (OS) rates were 
estimated, as were variables which influenced OS.
Results: Average age was 59.6 years (SD+/-13.1); 79.8% of the 
sample was female. 63%, 31% and 6% had EGFR exon 19, L858R 
and G719X point mutations, respectively. Vimentin expression was 
strong in 9.5% of the patients (n=8) and E-cadherin proved weak 
in 51.2%, moderate in 23.8% and strong in 23.8%. The greatest 
E-cadherin positivity was related to exon 19 deletion (p=0.001) but 
not to L858R (p=0.14) and strong vimentin reactivity was associ-
ated with a background of smoking (p=0.03). OS was 12.3 [10-14], 
27.0[23-31], 26.1 [20-32] and 33.5 months [30-36] when E-cadher-
in expression was negative, weak, moderate and strong, respec-
tively (p=0.05). OS regarding negative vimentin was 33 months [31-
35] and 8.2 months when positive [6-10] (p=0.001). Similar trends 
were observed for progression-free survival and response rate.
Conclusion: E-cadherin and vimentin were seen to be valuable 
predictive biomarkers for EGFR+LA patients. The above results 
suggest that further research is necessary regarding EMT in select-
ed populations exposed to erlotinib.
Keywords: Epithelial-Mesenchymal Transition, EGFR-mutations, 
Lung Adenocarcinoma, erlotinib
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INCREASED SUSCEPTIBILITY TO LUNG CANCER RELAT-
ED TO SMOKING IN WOMEN IS NOT EXPLAINED BY THE 
EXPRESSION OF DNA REPAIR GENES
Joseph Arturo Pinto1, Alexandra Prado1, Nadezhda Cárdenas1, Pris-
cila Valdiviezo1, Silvia Neciosup1, Alfredo Aguilar1, Gustavo Sarria2, 
Mayer Zaharia2, Claudio Jaime Flores1, Luis Mas1  
1Oncosalud -Auna, Lima/PERU, 2Radioncología, Lima/PERU
Background: Different studies have shown different susceptibility 
to smoking-induced DNA damage among male and female Lung 
cancer patients and an increased risk to lung cancer in women. 
Our aim was to evaluate differentially expressed genes involved in 
DNA repair. 
Methods: We studied a public dataset (GSE50081) with 181 non-
small cell lung cancer samples profiled with the Affymetrix Human 
Genome U133 Plus 2.0 Array. Tumors were in stages IA-IIB; 83 
patients (45.9%) were women; 57 (31.5%) were current smokers, 
79 (43.6%) ex-smokers, 24 (13.3%) never smokers and 11 patients 
(11.6%) have unknown status. We evaluated 99 genes involved in 
DNA repair and included in the U1332A platform. We evaluated 
differentially expressed genes between men and women with 
smoking status as the main cofounding factor.
Results: There were not differentially expressed DNA-repair 
genes between women and men. Differentially expressed genes at 
higher levels in never smokers than in current smokers (with P<0.05 
and False Discovery Rate <15%) were MGMT, XPC and RAD50. 
Genes differentially expressed at higher levels in current smokers 
than in never smokers were H2AFX, POLR2H, LIG3, UB2T, RFC2, 
MAD2L2, FANCG, POLR2J, POLE, FEN1 AND FANC1.
Conclusion: Our data doesn` t support a different susceptibility to 
smoking-related lung cancer mediated by patterns of expression 
of DNA repair genes. Expression of these genes is related to the 
smoking status.
Keywords: SMOKING, DNA repair genes, Cell lung cancer, mo-
lecular profiling
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PDL1 EXPRESSION IN METASTATIC NON-SMALL CELL 
LUNG CANCER PATIENTS FROM COLOMBIA (CLICAP)
Leonardo Rojas1, Andrés Felipe Cardona Cardona2, Oscar Arrieta3, 
Hernán Carranza2, Claudio Martín4, Jorge Otero2, Mauricio Lema5, 
Mauricio Cuello6  
1Hospital Universitario San Ignacio; Centro Javeriano De Oncología, Medical 
Oncology, Bogotá/COLOMBIA, 2Institute Of Oncology, Fundacion Santa Fe De 
Bogota, Bogota/COLOMBIA, 3Instituto Nacional De Cancerologia, Experimental 
Oncolgy Lab, Mexico City/MEXICO, 4Instituto Fleming, Buenos Aires/ARGEN-
TINA, 5Clinica Soma/Astorga, Medellin/COLOMBIA, 6Hospital De Clínicas - 
Udelar, Montevideo/URUGUAY
Background: Programmed cell death-1-ligand 1 (PD-L1) is involved 
in the ability of tumor cells to escape the host’s immune system. 
PD-L1 is selectively expressed in a number of tumors. The blockade 
of interactions between PD-1 and PD-L1 enhances the immune 
function in vitro and mediates antitumor activity in preclinical 
models. Recent studies have suggested that antibody-mediated 
blockade of PD-L1 induced durable tumor regression and pro-
longed stabilization of the disease in certain cancers including 
NSCLC. A recent study demonstrated that immunohistochemical 
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(IHC) analysis detected no objective response in PD-L1-negative 
patients. However, 36% of the patients with PD-L1-positive tumors 
had an objective response, although the sample number for IHC 
was small. 
Methods: PD-L1 was assessed by IHC (Dako MAb) in 76 NSCLC 
patients, considering as positive a staining intensity ≥ 2 in more 
than 5% of cells. The driver mutation epidermal growth factor 
receptor (EGFR) was examined by direct sequencing and allele 
specific PCR. The correlations of PD-L1 expression with major clini-
copathologic parameters and outcomes were analyzed.
Results: Mean age was 64.7 years (SD+/-11.7), 67% were females, 
84% had adenocarcinoma and 56.6% were former/current smok-
ers. Fourteen patients (18.4%) had mutations in the EGFR and 19 
(25%) were PD-L1+. PD-L1 positivity was significantly associated 
with presence of EGFR mutations (p=0.001), in tumors with a high-
er grade of differentiation (p=0.023) and in presence of vascular 
invasion (p=0.038). Patients with PD-L1+ had a longer progression 
free survival (PFS) (11.9 months vs. 5.0 months, p= 0.001) and overall 
survival (OS) (23.4 vs. 12.3 months; p=0.05).
Conclusion: Although the study sample is small, PD-L1 positivity 
correlates with PFS and OS. This results supports that PD-L1 might 
be a critical factor in cancer immunotherapy.
Keywords: immunotherapy, PD-L1, expression, Outcomes
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PROSPECTIVE STUDY OF MOLECULAR MARKERS IN PA-
TIENTS WITH ADVANCED LUNG ADENOCARCINOMA
Gonzalo Recondo1, Valeria Denninhoff2, Gonzalo Recondo (Jr)3, 
Constanza Llorene2, Martin Greco3, Maximo De La Vega3, Enrique 
Diaz Canton3, Florencia Perazzo3, Maria Teresa Cuello2, Mariana 
Dos Santos2, Silvana Nieto2, Alejandro Garcia2, Alejandra Avagnina2 
1Cemic, Medicine. Oncology, Buenos Aires/ARGENTINA, 2Cemic, Pathology, 
Buenos Aires/ARGENTINA, 3Cemic, Medicine, Buenos Aires/ARGENTINA
Background: Lung cancer is the 1st cause of cancer death around 
the world and adenocarcinomas represents actually the most 
frequent histology. Great advances have been done concerning 
several molecular abnormalities with current and future clinical 
relevance. 
Methods: The objective of this prospective study is to determine 
de frequency of KRAS, BRAF and EGFR mutation, by PCR and 
Sanger sequencing, and the expression of ALK and CMET by 
immunohistochemistry (IH) in patients with advanced adenocar-
cinoma candidates to therapy. Patients (pts) with advanced lung 
adenocarcinoma (Stage IIIb or IV) with tumor biopsy sampling, 
over 18 years old, who are candidates to treatment and signed an 
inform consent were included. Specific sites regarding each candi-
date genes were analysed for mutations: KRAS exon2 (G12X and 
G13X), BRAF exon 15 (V600E, D594G y K601E) and exon 11 (G469) 
and EGFR exon 18 to 21 (G719X exon 18, T790M and S768I exon 
20, L858R and L861Q exon 21, exon 19 deletion). IH for ALK was 
performed with the 5A4 Mo Ab and IH for CMET with the Mo Ab 
SP44. In both cases scores ranged from 0 to 3 and were consid-
ered positive 3+ for ALK and 2 and 3+ for CMET.
Results: 75 pts from May 2012 and December 2013 signed the 
inform consent. A total of 7 pts were excluded, 2 pts had been mis-
diagnosed on pathology revision and 5 had inadequate material 
for analysis. Median age was 57 years (31-82), male/female 35/33, 
smoker/ex-smoke/never smoker 24(32%)/33(44%)/11(14.6%). A to-
tal of 50 surgical and 18 imaging directed biopsy (IDB) either endo-
scopic or computed tomography-guided biopsies, were analyzed. 
Complete mutational and IH studies were performed in 42 of the 
68 pts (70,5 %). Incomplete mutational analyses were done in 14 
cases due to insufficient material, 11 cases were only suitable for 
IH analysis and 1 patient had incomplete molecular analysis. Com-
plete molecular testing was achieved in 66% of surgical and 35% 
of IDB samples. KRAS mutation was detected in 9 pts (15,7 %): 7 in 
codon 12 and 2 in codon 13. EGFR mutations related to EGFR thy-
rosine kinase sensitivity were detected in 4 cases (8.1%): 2 in exon 
21-L858R and 2 exon 19 deletion. A mutation related to EGFR re-
sistance, insertion in exon 20 (D770_N771), was detected in 1 case. 
No BRAF mutations were documented (V600E/K600E1/D594G 
in 55 and G469A in 45 samples). ALK was 3+ in 1 (1.5%) case and 
CMET was overexpressed in 35 (55.5%) pts (27 2+ and 8 3+). 
 
Conclusion: The study of molecular markers in advanced lung ad-
enocarcinoma in an academic institution at a developing country is 
feasible. Improvement in biopsy sampling by IGB is necessary. The 
frequency of molecular abnormalities in our pts is similar to other 
reports in Caucasian population. Next generation sequencing 
and FISH are being incorporated in our institution to improve and 
expand molecular studying to other genetic abnormalities and 
reduce sampling limitations.
Keywords: Molecular marques, adenocarcinoma, ademocarcinoma
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AN USEFUL EXPERIMENTAL MODEL OF MALIGNANT 
PLEURAL DISEASE INDUCED BY LEWIS LUNG CANCER 
(LLC) CELLS
Lisete Ribeiro Teixeira1, Milena Marques Pagliarelli Acencio1, Eval-
do Marchi1, Juliana Puka1, Juliana Sanchez Silva1, Ricardo Mingarini 
Terra2, Leila Antonangelo3, Francisco Suso Vargas1, Vera Luiza 
Capelozzi1  
1Pleura Laboratory, Pulmonary Division, Heart Institute (Incor), University Of Sao 
Paulo Medical School, Sao Paulo/BRAZIL, 2Thoracic Surgery, Heart Institute (In-
cor), University Of Sao Paulo Medical School, Sao Paulo/BRAZIL, 3Lim 03, Pathol-
ogy Department, University Of Sao Paulo Medical School, Sao Paulo/BRAZIL
Background: Malignant pleural effusion (MPE) is a poor prognosis 
factor in patients with advanced lung cancer. Its pathogenesis is 
still poorly understood and therapeutic options are limited. Ani-
mal models of MPE can help to show new aspects along with the 
pathobiological reasoning at the root of this condition. Stathopou-
los et al in 2006 described a model of MPE using 1.5 x105 Lewis 
lung cancer (LLC) cells placed directly into the pleural space of 
mice. They reported carcinomatosis which yielded pleural effu-
sions, pleural tumors, and 100% mortality after 17 days. The aim of 
this study is to establish a mouse model of MPE using Lewis lung 
carcinoma (LLC) that will promote disease while allowing for longer 
survival time, with purpose of future investigation in pathogenesis 
and therapy. 
Methods: Sixty C57BL/6 mice were divided into groups receiving 
intrapleural injections of 0.1, 0.5 or 1.5 x 105 of LLC cells or PBS 
control. Thirty animals were followed until death to develop a 
survival curve. Thirty mice were euthanized after 7, 14 or 21 days; 
weight (g), mobility (score 0-3), tumor presence in visceral pleura 
and pericardium (score 0-4), inflammatory cells or histological 
changes in lung parenchyma, kidney, liver and spleen (score 0-4) 
were evaluated. Statistical analysis: One Way ANOVA, Kaplan−
Meier curve, p<0.05.
Results: The lowest survival time was observed in the group that 
received the highest concentration of LLC cells (p<0.05; 1.5 x 105 
= 21 days, 0.5 x 105 = 26 days and 0.1 x 105 = 28 days). Twenty-one 
days after intrapleural injection of LLC cells, a significant weight 
reduction was observed in the 1.5 x 105 cell group (p<0.05). The de-
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crease of mobility was more evident in the highest concentration. 
Tumor presence in the visceral pleura was observed in all groups 
and was proportional to the concentration and time since LLC 
cell instillation (p<0.05). Metastasis to the pericardium was more 
evident in concentrations of 1.5 x 105 cells. Inflammatory cells of the 
pulmonary parenchyma and histological changes in the kidneys, 
liver and spleen were noted in all groups with the highest scores in 
groups of 0.5 x 105 and 1.5 x 105 cells.
Conclusion: A mouse model of lung cancer malignant pleural ef-
fusion was effectively established by injecting 0.5 x 105 of LLC cells 
lines into the pleural cavity, expressing similar neoplastic changes 
previously reported, but with a significant increase in survival time. 
The model can support dynamic observations of the biological 
behavior of tumor cells in the pleural cavity, It may be promise in 
investigation on advanced lung cancer as well as anti-tumor target 
therapy.
Keywords: malignant pleural effusion, Lewis Lung Cancer, Lung 
Cancer, experimental model of lung cancer
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CLINICALLY RELEVANT GENE SEQUENCING IN LUNG 
CANCER
Patricia Thompson1, Navneet Dhillon1, Rabih Bechara2, Christopher 
Parks2, Terri Redmond1, Bruce Gershenhorn3  
1Cancer Treatment Centers Of America, Medical Oncology, Newnan/UNITED 
STATES OF AMERICA, 2Cancer Treatment Centers Of America, Thoracic On-
cology, Newnan/UNITED STATES OF AMERICA, 3Cancer Treatment Centers Of 
America, Medical Oncology, Zion/UNITED STATES OF AMERICA
Background: Individualized cancer treatment is the ultimate goal 
of clinicians and their patients. We report the results of a commer-
cially available next-generation sequencing assay in advanced lung 
cancer. 
Methods: We retrospectively analyzed all the reports of biopsies 
from advanced lung cancer which were sent for testing using a 
commercial next-generation sequencing platform from a network 
of five tertiary referral centers during the year 2013.
Results: 258 unique reports belonging to 258 patients with a 
diagnosis of advanced lung cancer were analyzed. Of these, 182 
(70.54%) formalin fixed paraffin embedded tissue were sent for 
genomic testing with 182 yielding reports. 177 reports had at least 
1 genomic alteration, 3 had no alterations and 2 failed test results. 
There were a total of 23 genomic alterations detected, 21 in Ad-
enocarcinoma, 14 in Squamous cell, 6 in Small cell , 2 in large cell 
and 2 in Adenosquamous. Overall median age of patients was 57 
years (range 28-78) having received a median of two prior lines of 
chemotherapy. Non-Small cell lung cancer (NSCLC) was present 
in all cases except 11 (6.04%) which were small cell lung cancer. Of 
the NSCLC, the reports were subdivided into Adenocarcinoma 134 
(73.62%), Squamous cell 21 (11.54%), Large cell 8 (4.40%), Adenos-
quamous 3 (1.65%) and Others (Lung Adenoid Cystic Carcinoma 
2 (1.10%), Lung Sarcomatoid Carcinoma 2 (1.10%), Lung Typical 
Carcinoid 1 (0.55%)) KRAS was most commonly mutated in Ade-
nocarcinoma 51/134 (38.06%), CDKN2A in Squamous Cell 8/21 
(40%), RB1 in Small Cell 5/11 (45.45%), Tp53 in Large Cell 2/4 (50%) 
and Adenosquamous 3/3 (100%). Of 177 reports, about one third 
56 (31.64%) had at least 1 FDA approved treatment for lung cancer, 
two thirds 132 (74.58%) had at least 1 FDA approved treatment from 
another tumor type. 143 (80.79%) reports had at least 1 “actionable 
result” (FDA approved treatment to patient’s or another tumor type) 
and 168 reports (93.78%) had at least one clinical trial for a targeted 
genomic alteration (in clinicaltrials.gov) in addition to FDA approved 
treatments in patients patients’ cancer or another malignancy.
Conclusion: Molecular profile based therapy represents a mile-
stone in the goal to develop personalized cancer therapies. We 
propose that future trials should address the molecular profile of 
each individual patient and treat each patient based on their mo-
lecular fingerprint.
Keywords: next-generation sequencing, advanced lung cancer
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CORRELATION OF ALK STATUS BETWEEN FISH AND IM-
MUNOHISTOCHEMISTRY IN LUNG CARCINOMA
Mercedes Liliana Dalurzo1, Paola Ximena De La Iglesia2  
1Hospital Italiano Buenos Aires, Pathology, Buenos Aires/ARGENTINA, 2Hospital 
Italiano Buenos Aires, Department Of Pathology, Buenos Aires/ARGENTINA
Background: AKL gene rearrangements are infrequent alterations 
in lung cancer and are present in approximately 3-5% of non small 
cell lung carcinomas (NSCLC). ALK status is an important pre-
dictive factor in NSCLC, as ALK rearranged tumors have shown 
sensitivity to Crizontinib treatment. FISH remains the gold standard 
for assessment of ALK status, however, it bears some disadvan-
tages such as availability, need for trained personnel and difficult 
evaluation in some cases. Detection of ALK protein by immuno-
histochemistry (IHC) is a much more affordable and widespread 
method. The use of new clones and highly sensitive methods has 
proved useful in the assessment of ALK status. 
Methods: We compared ALK rearrangement in 145 consecutive 
cases in our laboratory, of which 31 were not included due to poor 
cellularity or uninformative FISH result. The remaining 114 were 
evaluated by FISH and ultra sensitive IHC. FISH was performed on 
unstained 4 um formalin-fixed paraffin embedded tumor tissue 
sections using an ALK break-apart probe set (Vysis LSI ALK Dual 
Color, Break Apart Rearrangement Probe; Abbott Molecular) 
together with paraffin pretreatment IV reagent kit (Vysis, Abbott 
Molecular). Assays were performed following the manufacturer’s 
instructions. Positive and negative controls were present in each 
run. Sections were analyzed by a trained observer under a fluores-
cence microscope, using appropriate filters (Olympus BX51, Tokyo, 
Japan). Cases were considered ALK-FISH positive if ≥15% tumor 
cells showed split red and green signals (separation of 2 diameters 
or more) and/or single red signals. IHC were performed on an au-
tomatized Benchmark staining module (Ventana, Tucson, AZ) using 
monoclonal ALK antibody D5F3 (Cell Signaling Technology) on 
previously deparaffinized 4um tissue sections. For detection, Op-
tiView DAB IHC Detection Kit with signal amplification (Ventana, 
AZ) was used. Positive and negative controls were present in each 
run. IHC staining results were interpreted as either negative (weak 
or no staining present) or positive (strong staining present). 
Results: Of 114 cases, 110 were FISH negative and 4 FISH positive 
(prevalence of ALK rearranged cases 3.51%). Of FISH negative cas-
es, one case was IHC positive, and 4 out of 4 FISH positive cases 
were also IHC positive. Sensitivity and specificity for IHC testing 
was 100%, with a positive predictive value of 80% and a negative 
predictive value of 100%. 
Sensitivity 100% 
Specificity 100% 
Positive predicitive value 80% 
Negative predicitive value 100% 
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Conclusion: Even though our sample is small, other studies have 
shown similar results. IHC using sensitive antibodies and automa-
tized platforms appears to be a promising tool for screening of ALK 
rearrangements in NSCLC.
Keywords: ALK status, Immunohistochemistry, FISH
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CLINICAL CHARACTERISTICS AND TREATMENT RE-
SPONSE OF ACTIVE TUBERCULOSIS IN PATIENTS WITH 
LUNG CANCER
Kostas Nikolaos Syrigos, Antonis Christopoulos, Ioannis Gkiozos, 
Andriani Charpidou, E Merikas, Evangelos Sarris  
Sotiria General Hospital, Athens School Of Medicine, Oncology Unit Gpp, Ath-
ens/GREECE
Background: Lung cancer and anticancer treatment are both 
factors highly associated with increased risk of active tuberculosis. 
The aim of this paper is to elucidate the clinical characteristics and 
treatment response of tuberculosis (TB) in lung cancer patients. 
Methods: A systematic review of case-control studies and case se-
ries concerning tuberculosis in lung cancer patients was conducted 
in MEDLINE, PubMed, EMBASE and Medscape databases. 
Results: A total of 78 articles were retrieved. Ten case-control 
studies and four case series were eventually included involving a 
total of 354 cases of TB complicating lung cancer.
Conclusion: In most cases, tuberculosis already existed when lung 
cancer was diagnosed. The clinical/radiological characteristics of 
tuberculosis were similar to those found in lung cancer and lung 
cancer patients with active tuberculosis had poor survival rates 
compared to those free of tuberculosis. The efficacy of anti-tuber-
culosis treatment in lung cancer patients with active TB was almost 
comparable to that in patients without lung cancer.
Keywords: active tuberculosis, Lung Cancer, anticancer treatment, 
anti-tuberculosis treatment
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REDUCED MIGRATION OF COBRA FIDUCIAL MARKERS
Christopher Parks1, Patricia Thompson2, Rabih Bechara1  
1Georgia Regents University/Cancer Treatment Centers Of America, Pulmonary, 
Newnan/UNITED STATES OF AMERICA, 2Cancer Treatment Centers Of Ameri-
ca, Medical Oncology, Newnan/UNITED STATES OF AMERICA
Background: Fiducial markers have been shown to increase the 
accuracy and decrease the potential side effects of radiation deliv-
ered to central and peripheral lung lesions. The benefit is accom-
plished by assisting the radiation oncologist to overcome the respi-
ratory variation and target movement. Unfortunately, many tend to 
migrate, distally or proximally, after placement resulting in delay of 
initiation of treatment. In this manuscript, we demonstrate that the 
use of a new type of Cobra fiducial markers (superDimension, Inc. 
161 Cheshire Lane, Suite 100. Minneapolis, MN 55441-5433. USA) 
results in significantly less migration and decrease in the lag time 
between placement and simulation. 
Methods: 96 Cobra markers were placed in central and peripheral 
lung lesions using the I-Logic peripheral navigation system. The 
markers’ base allows spiral anchoring of the system to the tissues 
targeted. Immediately after insertion, simulation computerized 
tomography (CT) was performed for accurate verification of place-
ment location. Patients were then scanned one week after the 
initial placement and if no migration was demonstrated, radiation 
treatment was initiated per protocol.
Results: All procedures were performed without complications. All 
patients were discharged after markers placement was completed. 
At one, two, three and four-week follow-up, no expectoration 
of any maker was reported. In parallel, the CT scans obtained 
immediately after insertion and one week later did not show any 
significant migration. Importantly, the time from fiducial marker 
placement to treatment was shortened by fifty percent; instead of 
waiting for two weeks after placement to treat, patients were treat-
ed after one week.
Conclusion: In this manuscript, we showed that the use of Cobra 
fiducial markers results in significantly less migration, decrease in 
the lag time between placement and simulation, and importantly 
earlier initiation of treatment when compared to historical controls.
Keywords: Navigation, Radiation, Interventional
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ENDOBRONCHIAL INTERVENTIONS USED IN THE MAN-
AGEMET OF MALIGNANT CENTRAL AIRWAY OBSTRUC-
CIóN: INITIAL EXPERIENCE AT A REFERENCE CENTER 
Liliana Fernandez1, Mauricio Velasquez2, Luz Fernanda Sua3  
1Fundacion Valle Del Lili, Medicina Interna- Neumologia, Cali/COLOMBIA, 2Fun-
dacion Valle Del Lili, Cirugia De Torax, Cali/COLOMBIA, 3Fundacion Valle Del Lili, 
Patologia, Cali/COLOMBIA
Background: Central airway obstruction represents a great chal-
lenge to physicians who manage thoracic diseases. The 20-30% 
of patients with lung cancer are at some point in its evolution 
with obstruction of the airway by direct involvement or extrinsic 
compression, causing symptoms such as dyspnea, hemoptysis, 
post obstructive pneumonia, decreased quality of life and death. 
Acute management involves establishing an airway permeable to 
ensure gas exchange. Therapeutic bronchoscopy has proven to be 
highly effective in recanalization of the airway, relief of symptoms, 
improvement of quality of life and in some cases, improvement in 
survival. 
Our objective was to describe our initial experience with different 
techniques of interventional pulmonology in a reference center in 
Cali, Colombia 
Methods: We retrospectively reviewed consecutive cases with 
central airway obstruction by lung cancer or metastatic malignan-
cies, treated in Interventional Pulmonology Unit in a reference 
center in Cali, Colombia, Fundación Valle del Lili, from January 2011 
through January 2013
Results: We performed 47 procedures in 31 patients, 19 were 
women (61.3%) and 12 were men (38.7%). 24 (77%) patients had 
lung cancer and 7 (22%) had metastatic lesions. The procedures 
were, 11 (23.4%) rigid bronchoscopy and 36 (76.5%) therapeutic 
fiberoptic bronchoscopy. The most common presentation symp-
toms were, cough in 45 (95%), dyspnea in 39 (82%), hemoptysis 
in 28 (59.5%). Lesions were located in the trachea in 26 (55.3%) 
cases; involvement was the BFI in 21 (44%) and BFD in 29 cases 
(61.7%), some patients having more than one lesion. In 35 (74%) 
cases endoscopic electrocoagulation was used, in 28 (59%) cases 
argon plasma coagulation and in 31 (65%) cases tumor debride-
ment with forceps, in 9 (19%) cases tracheal or bronchial stent 
placed. After the procedure residual lesions were mild in most 
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patients. Examples of airway obstruction pre and post treatment 
in 2 patients with NSCLC are illustrated in Figure 1. Complications 
were, moderate bleeding in 2 patients, transient increase in the 
level of care in 2 cases, airway laceration in 1 patient, transient 
respiratory failure in 1 case, these complications were self-lim-
iting and non-fatal, initial symptoms improved in all patients. 
Conclusion: Several techniques are available for the management 
of malignant obstruction of the airway and current recommenda-
tions support a multimodality approach emphasizing the combina-
tion of several endobronchial interventions to achieve best results. 
These procedures may be safe, effective, and well tolerated; we 
present the experience in a reference center.
Keywords: Lung Cancer, interventional pulmonology, Central 
airway obstruction, metastatic malignancies
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ENDOBRONCHIAL RESECTION OF MUCOEPIDERMOID 
CARCINOMA (MEC) OF THE TRACHEA IN A PREGNANT 
WOMAN, CASE REPORT
Liliana Fernandez1, Luz Fernanda Sua2  
1Fundacion Valle Del Lili, Medicina Interna- Neumologia, Cali/COLOMBIA, 
2Fundacion Valle Del Lili, Patologia, Cali/COLOMBIA
Background: The (MEC) of the trachea is a rare tumor of low 
grade malignancy, with an incidence of 0.2%, its origin is in the 
tracheobronchial glands. It is more common in young people. The 
CME form polypoid lesions in the trachea, treatment is usually 
surgical. We report a case of a pregnant woman who presented 
with progressive dyspnea and chest pain, endoscopic resection of 
the lesion was performed with Argon Plasma Coagulation (APC) 
and electro coagulation 
Methods: We review the clinical history data
Results: This is a 22 year old with 17 wk of pregnancy with history 
of asthma, who consults several times to the emergency depart-
ment with progressive dyspnea, without improvement with inhaled 
bronchodilators, along with oppressive chest pain. In the physical 
examination found normal vital signs, had no alterations in the neck, 
no murmurs or gallops were found in the heart, had normal breath 
sounds without wheezing or crackles. His chest X-ray was normal. 
We think that she could have a pulmonary embolism by the clini-
cal picture, the chest x-ray without changes and pregnancy, then 
a CT angiography of the chest was made, identify endotracheal 
lesion occluding 80% of the tracheal lumen, which is management 
with endoscopic resection APC and electrocautery under general 
anesthesia with spontaneous ventilation without complications. 
The diagnosis was CME trachea, had complete relief of symptoms, 
continuing pregnancy without complications. Pathology: an ex-
pansive lesion, covered by squamous epithelium, composed of 
glands with mucin lakes. Positive expression for cytokeratin AE1/
AE3. Cell proliferation index assessed with the Ki-67 of 30%. 
 
Conclusion: Mucoepidermoid carcinoma of the trachea are rare 
lesions that require surgical resection as definitive management 
in this case a complete endoscopic resection is performed by 
electrosurgery and APC, the nature of low-grade and slow tumor 
growth monitoring conduct long-term
Keywords: interventional pulmonology, Mucoepidermoid carci-
noma, tracheal tumors, Argon Plasma Coagulation
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COMPARATIVE EFFICACY OF IBANDRONIC ACID VS. 
ZOLEDRONIC ACID IN LUNG CANCER  PATIENTS WITH 
SKELETAL METASTASES. DO THEY ALLEVIATE THE PA-
TIENT?
Ioannis A Dimitroulis, Agisilaos Dervas, Sofia Vasileiou, Meropi 
Panagiotarakou, Michalis Toumbis  
„Sotiria“Hospital For Thoracic Diseases, 6th Pulmonary Department, Athens/
GREECE
Background: Amino-biphosphonates are third-generation bi-
sphosphonates which act by inhibition of osteoclasts. We have 
presented at two previous ATS conferences (Dimitroulis I.A. et al 
2009, 2011), the role of each amino-biphosphonate separately. 
We set out to investigate the superiority or inferiority of Ibandronic 
acid (Ibandronate) over Zoledronic acid (Zoledronate), in terms of 
efficacy in reducing bone pain, and complications in patients with 
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skeletal metastases due to Lung Cancer. 
Methods: Within thee years, 110 patients with Skeletal Metastases 
due to Lung Cancer were enrolled, and were randomized on a 1:1 
basis to receive infusions of Ibandronate (55 pts) or Zoledronate 
(55 pts) intravenously, every 21 days. Infusion time for Zoledronate 
(4mg) was 15 minutes, and for Ibandronate (6mg) one hour. Patients 
(pts) were analysed for pain relief, skeletal-related events (SREs) and 
adverse events. All pts underwent dental and cardiac examination 
before enrollment, and completed blood tests every 21 days. Bone 
scan was performed every 6 months. Blood tests (including close 
monitoring of calcium levels and renal function) were performed 
before each amino-biphosphonate administration.
Results: Patients in both arms were well matched for their diagno-
sis, stage of disease, burden of skeletal disease, and performance 
status. Median follow-up was 28 months. Mean increase in British 
Pain Inventory pain scores were lower with Zoledronate compared 
to Ibandronate (0.45 vs 0.90 [p=0.02]). Analgesic use as defined 
by the 4 point analgesic scale was less with Zoledronate as com-
pared to Ibandronate. Incidence of SREs was not significantly 
different between two arms (34% for Zoledronate vs 37% for 
Ibandronate [p=0.2]). Median time to the first SRE was not reached 
in either arm. At 20 months of median follow up, percentages of 
patients with skeletal-related events were 40% in the Zoledronate 
arm vs 46% in the Ibandronate arm (p=0.05). Zoledronate caused 
fever in eight (14.5%) patients and hypocalcemia in two patients 
(3.6%). Ibandronate caused hypocalcemia in three patient (5.5%). 
No cases of jaw osteonecrosis, atrial fibrillation or renal failure 
(all of them possible side-effects of amino-biphosphonates) were 
observed.
Conclusion: Both these commonly used, third generation Ami-
no-biphosphonates are efficient. Zoledronate is the preferred 
amino-bisphosphonate for its shorter infusion time, availability and 
relative benefits. It is slightly better than Ibandronate in reducing 
bone pain and preventing skeletal-related events.
Keywords: Biphosphonates, Ibandronic Acid, Zoledronic Acid, 
Skeletal Metastases
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METHYLNALTREXONE BROMIDE IN THE TREATMENT OF 
OPIOID-INDUCED CONSTIPATION IN LUNG CANCER 
PATIENTS. IS IT EFFECTIVE?
Ioannis A Dimitroulis, Agisilaos Dervas, Sofia Vasileiou, Michalis 
Toumbis  
„Sotiria“Hospital For Thoracic Diseases, 6th Pulmonary Department, Athens/
GREECE
Background: Methylnaltrexone Bromide (MB) is a selective an-
tagonist of opioid binding at the mu-receptor. The ability of MB to 
cross the blood-brain barrier is restricted, allowing it to function as 
a peripherally acting mu-opioid antagonist in tissues such as the 
gastrointestinal tract, without impacting on opioid-mediated anal-
gesic effects in the central nervous system. Constipation is a quite 
common side effect in Lung Cancer patients receiving opioids 
for chronic pain, usually due to skeletal metastases. We set out to 
investigate if MB is effective in Lung Cancer patients who received 
opiods and complained for constipation. 
Methods: Thirty four patients with a life expectancy of at least 
three months receiving treatment for Lung Cancer in our depart-
ment, were recruited for our study after providing to us a written 
consent. All patients received fentanyl either as a transdermal 
patch or in its inhaled form. Patients were randomized (1:1) to four 
weeks of treatment with either MB 12mg/0.6ml (n=17) administered 
subcutaneously (sc) or placebo, on alternate days. We recorded 
the number of patients who had defecation within four hours from 
the MB or placebo injection, and the number of patients needing 
a second dose of MB or placebo within six hours from the first 
dose. Additionally, we recorded the side effects of this treatment. 
We required from the patients not to change their dietary habits or 
activities, and not to use other laxatives (mandatory).
Results: In the MB group after one injection, twelve patients (71%) 
had bowel movement within four hours compared with three 
placebo patients (18%), p=0.02. Five patients in the MB group 
had bowel movement after two or more doses of MB, raising the 
percentage of patients who responded to MB to 100%. The more 
severe the constipation, the higher the response with MB. The 
overall rate of adverse events was similar in the MB (41%) and pla-
cebo groups (40%). In the MB group, the most commonly reported 
adverse events were abdominal pain (15%), flatulence (15%), vomit-
ing (11%), and nausea (11%). Most treatment related adverse events 
were rated as mild or moderate by the patients. Discontinuation 
due to adverse events occurred in 5% and 6% of patients in the MB 
and placebo groups, respectively.
Conclusion: Methylnaltrexone Bromide has been shown to be 
superior to placebo in achieving defecation within a short time, in 
Lung Cancer patients with opioid-induced constipation, who were 
already being treated with a laxative regimen (but were required to 
refrain from it during the study). The more severe the constipation, 
the higher the response with MB. There were no serious adverse 
events. Methylnaltrexone Bromide is effective and safe.
Keywords: Methylnaltrexone Bromide, Opioids, Constipation, 
Fentanyl
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A NOVEL PLATINUM-CARBENE COMPOUND INHIBITS 
GROWTH OF LUNG AND NASOPHARYNGEAL CARCI-
NOMA XENOGRAFTS IN MICE AND DOWNREGULATES 
PROTO-ONCOGENES 
Ching Tung Lum, Taotao Zou, Raymond Wai-Yin Sun, Chi-Ming Che  
The University Of Hong Kong, Chemical Biology Centre, State Key Laboratory Of 
Synthetic Chemistry, And Department Of Chemistry, Hong Kong/HONG KONG
Background: Lung cancer is very common worldwide. We have 
synthesized a novel platinum-carbene compound, Pt-1a, which 
could significantly inhibit the growth of NCI-H460 lung cancer 
xenografts in nude mice by 55 ± 11% when applied at 3 mg/kg 
without death and significant body weight loss. In the present 
study, the safety pharmacological studies of Pt-1a were conducted 
using mice and rabbits. As nasopharyngeal carcinoma (NPC) fre-
quently metastasizes to lung we also investigated the efficacy of Pt-
1a in treating NPC. The molecular mechanisms through which Pt-1a 
exerts its effect in lung cancer and NPC were also investigated. 
Methods: NCI-H460 and SUNE1 cells were subcutaneously 
inoculated into the back flanks of nude mice. When the tumor 
volumes reached 50 mm3, the mice were randomly divided into 
solvent control or Pt-1a groups. Solvent control or 3 mg/kg Pt-1a 
was injected into the mice 2-3 times per week by intratumoral and/
or intraperitoneal injections. The safety pharmacological studies 
were conducted by a State Food and Drug Administration of Chi-
na-approved laboratory. To test the acute toxicity, KM mice were 
injected with 20 mg/kg Pt-1a by intravenous injection. To study 
the blood vessel stimulation response, Pt-1a was injected into the 
auricular veins of rabbits. To test the genotoxicity of Pt-1a, bone 
marrow micronucleus test was carried out in ICR mice. To deter-
mine the cytotoxicity and the ability of Pt-1a to inhibit migration 
of NCI-H460 and SUNE1 cells, cell viability and wound healing 
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assays were performed respectively. To determine the mRNA ex-
pression profiles, cancer drug targets qPCR arrays were employed.
Results: Pt-1a significantly reduced the growth of NPC xenografts. 
The average tumor volumes of mice treated with solvent control 
and 3 mg/kg Pt-1a were 785 ± 89 mm3 and 301 ± 92 mm3 respec-
tively, while the body weight of the mice was similar in both groups. 
No mouse died during the experiment. In the acute toxicity test, 
out of 20 mice, none died in the 14 days following intravenous 
injection of 20 mg/kg Pt-1a. In the blood vessel stimulation test, of 
4 rabbits injected with 0.5 mg/kg Pt-1a, no significant stimulation 
response was observed in the ear blood vessels and the adjacent 
tissues over the course of 14-day observation period after injec-
tion. In the bone marrow micronucleus test, 20 mg/kg Pt-1a did not 
increase the micronucleus rate in the polychromatic erythrocytes 
from the bone marrow of the mice, indicating that the compound 
was not genotoxic. Pt-1a dose-dependently reduced the viability 
and migration of both NCI-H460 and SUNE1 cells. Our prelimi-
nary data suggested Pt-1a downregulated the proto-oncogenes 
survivin (3.0-fold), K-ras (3.9-fold) and polo-like kinase 1 (3.4-fold), 
as well as thioredoxin reductase 1 (4.7-fold) in NCI-H460 cells, and 
downregulated Cathepsin S (6.2-fold) in SUNE1 cells. 
Conclusion: Pt-1a at 3 mg/kg was efficacious in treating lung 
cancer and NPC in mice while 20 mg/kg of Pt-1a did not cause 
death of mice. A large therapeutic window existed. The compound 
reduced viability and migration of lung cancer and NPC cells, and 
downregulated proto-oncogenes. Pt-1a might potentially be used 
clinically in cancer patients.
Keywords: platinum-carbene, mouse, xenografts, proto-oncogenes
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RELATIONSHIP BETWEEN THE SUCCESS OF BEDSIDE 
PLEURODESIS AND PLEURAL ELASTANCE IN RECURRENT 
MALIGNANT PLEURAL EFFUSION
Ricardo Mingarini Terra, Pedro Henrique Xavier Nabuco De Arau-
jo, Paulo Pego-Fernandes, Rodrigo Caruso Chate  
Thoracic Surgery, Heart Institute (Incor), University Of Sao Paulo Medical School, 
Sao Paulo/BRAZIL
Background: To investigate the relationships between pleural 
elastance and the acumulation of effusion, clinical effectiveness, 
quality of life, dyspnea, pain and complications in patientes with 
recurrent malignant pleural effusions (RMPEs) treated with bedside 
pleurodesis. 
Methods: Prospective study including patients with RMPEs candi-
dates for treatment with bedside pleurodesis recruited in our hos-
pital between June 2009 and September 2013. Pleural elastance 
was measure after insertion of pleural catheter (14 Fr pigtail) and 
analysed after emptying of 800 ml (E800) and at the ending of the 
effusion drainage (Total Elastance, TE). The pleural volume on CT 
was measured after effusion drainage and one month after that. 
We used the difference between them to calculate the accumu-
lation of effusion after the pleurodesis (radiological effectiveness, 
RE). Pleurodesis was considered successful when no additional 
pleural procedure was necessary. Life quality (analyzed in its var-
ious aspects), dyspnea and pain were evaluated before and 30 
days after pleurodesis. Complications were registered and graded 
according to the CTCAE3.0.
Results: A total of 119 patients were included. 39 were excluded 
(16 died before 30 days, 12 showed incomplete lung expansion, 5 
had effusion with less than 800 ml and 6 did not return). 80 cases 
were analysed (61 female, 19 males, mean age 60.5 years). The 
median Karnofsky Performance Status index was 60. The primary 
neoplasm was breast in 40 patients, lung in 20, ovary in 9, colon, 
prostate, kidney and indeterminate in 2 and thyroid, stomach and 
pancreas in 1. We did not find significant correlation between E800 
and RE (correlation coefficient -0,168, p=0,148), but we found it 
between TE and RE, however, it was a weak (or absent) correlation 
(correlation coefficient -0.224, p=0.047). There were no signif-
icant improvements in quality of life in every aspect reviewed. 
There were improvements in dyspnea and pain, but there were no 
significant correlation between both and E800 or RE. Successful 
pleurodesis was achieved in 71 patients (88.8%), but there were no 
significant correlation between it and E800 or TE. 5 patients had 
major complications and 8 had minor, there were no significant 
correlation between occurrence of major or minor complications 
and E800 or TE.
Conclusion: In this study, we did not find significant correlations 
between E800 or TE and radiological or clinical effectiveness of 
pleurodesis, quality of life, dyspnea, pain and complications. Pleu-
ral elastance could not predict clinical or radiological outcomes of 
bedside pleurodesis.
Keywords: pleurodesis, recurrent malignant pleural effusion, 
Chest CT, pleural elastance
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NUTRITIONAL STATUS, AND SARCOPENIA ARE ASSOCI-
ATED TO DOSE REDUCTION AND SEVERE GASTROINTES-
TINAL TOXICITY TO AFATINIB IN PATIENTS WITH NSCLC
Martha De La Torre1, Oscar Arrieta1, Diego López Macias1, David 
Orta1, Omar Macedo1, Vickie Baracos2  
1Instituto Nacional De Cancerología, Mexico City/MEXICO, 2University Of Alber-
ta, Department Of Oncology, Edmonton/CANADA
Background: The main reason for dose reduction of afatinib is 
gastrointestinal toxicity. In a phase II study we analyzed clinical, 
pathological, anthropometric, nutritional and biochemical factors 
associated with toxicity induced by afatinib. 
Methods: Patients diagnosed with NSCLC who progressed to 
platinum-based chemotherapy, received 40mg of afatinib. Prior 
treatment, nutritional status was assessed by Subjective Global 
Assessment (SGA) and skeletal muscle mass was determined by CT 
scan analysis using pre-stablished Houndsfield Unit thresholds for 
skeletal muscle (-29 to +150 HU), using the third lumbar vertebra 
(L3) as anatomic landmark for this measurement. Toxicity was ob-
tained during 4 cycles by CTCAE 4.0. Severe toxicity was defined 
as Grades 3 and 4, whilst, dose limiting toxicity (DLT) was defined 
as dose reduction due to adverse events.
Results: 84 patients were enrolled (Table 1). Severe diarrhea, 
mucositis and overall GI toxicity were present in 38.9%, 28.8% 
and 57.5% respectively. Fifty percent of patients developed DLT. 
ECOG greater than 2 (58.2% vs 100%, p=0.04), weight below the 
mean (73.2% vs 48.5%, p=0.03) and malnutrition (72.1% vs 48.4%, 
p= 0.04) were associated with severe gastrointestinal toxicity. 
Whereas, body surface less than 1.7m2 (67.3% vs 36.8%, p=0.02) 
and malnutrition (74.4% vs 38.7%, p= 0.002) where related to 
dose limiting toxicity. Moreover, Figure 1 shows the distribution 
of patients according to BMI and LBM/dose of afatinib (40mg). 
Patients with lower LBM and BMI (inside the box) developed more 
DLT than patients with higher LBM and BMI values (71.4% vs 18.8%, 
p=0.0017). 
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Table. 1. Baseline characteristics 
Variable n=84(%) 
Sex Female 59(70.2) 
Male 25(29.8) 
Age 59.3±1.6 
Histology Adenocarcinoma 79(94) 
Non-adenocarcinoma 5(6) 
Line of treatment 2nd line 45(53.6) 
>2nd line 39(46.4) 
Performance Status 
(ECOG) 0-1 77(91.7) 
2-3 7(8.4) 
Weight (kg) 58.6 (36-110)* 
Height (m) 1.54 (1.37-1.83)* 
BMI (kg/m2) 24.05(14.8-39.1)* 
Body surface (m2) 1.61±0.2 
Nutritional status 
(SGA) A 34(40.5) 
B 32(38.1) 
C 18(21.4) 
LBM (kg) 39.35 (24.1-64.3)* 
*Median (range) 
BMI=Body Mass In-
dex; ECOG= Eastern 
Cooperative Oncol-
ogy Group; LBM= 
Lean body mass 
 
Conclusion: Targeted therapies are usually administered under a 
flat dose indication; however, this does not take into account the 
nutritional status or the body composition of the patients. Mal-
nourished patients develop more severe GI toxicity than well-nour-
ished patients. Variation in weight and body composition variables, 
especially muscle mass, should be further studied to see if toxicity 
of targeted therapies could be reduced by adjusting the dose in 
patients with higher risk.
Keywords: NSCLC, toxicity, sarcopenia, nutritional status
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ANALGESIA REQUIREMENT FOLLOWING SINGLE PORT 
ACCESS VATS LUNG RESECTION − IMPROVING POST-OP-
ERATIVE EXPERIENCES
Melanie Anderson, Laura Socci, Alison Parnell  
Northern General Hospital, Sheffield/UNITED KINGDOM
Background: Following thoracic surgery, pain management is 
important to ensure the patient’s ability to participate in respiratory 
physiotherapy without discomfort.1 By using a single port approach 
the incision disrupts a single rib space, which may improve the 
efficacy of intercostal and paravertebral block efficacy.2,3 This unit 
uses a standardised postoperative analgesia regime with para-
vertebral catheter and patient controlled opiate analgesia for the 
acute postoperative period, aiming to move to oral analgesia on 
day 2 following surgery. 
Methods: Retrospective analysis of analgesia use and pain scores 
were made during the period June 2013 to April 2014. 39 patients 
underwent Single Port Access VATS Lung Resection during this 
period. 4 patients were excluded due to operative difficulty result-
ing in thoracotomy and a further patient was excluded as they had 
undergone a recent thoracotomy. 4 patients did not have com-
plete documentation to review. Local documentation uses a pain 
score of 0-3; where 0=pain free, 1=mild pain, 2=moderate pain 
and 3=severe pain. This is scored by the patient as nursing staff 
assess their vital signs, this was done hourly for the first 24 hours 
and reduced thereafter depending on the patients condition. Mor-
phine Sulphate - Patient Controlled Analgesia(PCA) useage in the 
immediate post operative period was also analysed. 
Results: Following surgery pain scores were low, with minimal 
requirement for PCA. 32 patients were analysed. 30 had postoper-
ative analgesia using paravertebral catheter, 2 had thoracic epidur-
al catheters due to possibility of chest wall resection. 28 patients 
had PCA use documented post-op. Pain scores and PCA use are 
shown in Table 1. Analgesia on discharge most commonly included 
paracetamol +weak opiate +/- topical lidocaine 12 and 3 patients 
respectively. 4 patients were discharged on paracetamol +/- topi-
cal lidocaine and 4 patients required strong opiates. Length of stay 
ranged from 2-13 days with a median of 4.  
Table 1.
Post-operative Day Median Pain Score (0-3) 
Median PCA Use (mg 
Morphine) 
0 0 9 
1 0 15 
2 0 12 
3 0 Stopped 
 
Conclusion: The experience of this unit is that using a combina-
tion of single port VATS approach with paravertebral catheters as 
primary analgesia we are able to achieve good pain control in the 
immediate post operative period. We are currently re-evaluating 
our practice to move to oral analgesia sooner, while maintaining 
use of paravertebral catheters. By introducing these changes 
alongside an enhanced recovery programme, we hope to improve 
patient experience and reduce length of stay.
Keywords: Pain, Uniportal, Analgesia
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WHOLE-BODY DIFFUSION-WEIGHTED MRI FOR STAGING 
NON-SMALL CELL LUNG CANCER PATIENTS
Jefferson Luiz Gross1, Marcos Duarte Guimarães2, Rubens Cho-
jniak3, Eduardo Nobrega Pereira Lima2  
1Ac Camargo Cancer Center, Thoracic Surgery, Sao Paulo/BRAZIL, 2Ac Camargo 
Cancer Center, Sao Paulo/BRAZIL, 3Ac Camargo Cancer Center, Radiology, Sao 
Paulo/BRAZIL
Background: Therapeutic decision and prognosis in non-small 
cell lung cancer (NSCLC) relies on accurate staging. Currently, 
Positron Emission Tomography/Computed Tomography (PET/CT) 
appears to have better efficacy, and is considered the gold stan-
dard method for staging lung cancer. Whole-body Magnetic Res-
onance Imaging (WB-MRI) with diffusion has become feasible and 
provides images with good resolution. Some investigators have 
suggested that WB-MRI could be used for assessment of primary 
tumor, lymph nodes and distant metastases in lung cancer. To date 
there are few data assessing WB-MRI for staging of NSCLC. The 
purpose of this study is to compare the role of WB-MRI and PET/
CT for staging NSCLC patients.
Methods: This is a prospective, single-center cross-sectional study. 
Institutional review board approval and written informed consent 
was provided by all patients. From May 2011 to September 2012, 
forty-eight patients with confirmed diagnosis of non-small cell lung 
cancer (NSCLC) were eligible including 36 (75%) patients with ade-
nocarcinoma and 12 (25%) patients with squamous cell carcinoma. 
Thirty (62.5%) were men and the mean age was 62 years old. PET/
CT and brain MRI was performed in all patients as a gold standard 
tools for staging work up. WB-MRI was performed as an alternative 
method for staging. Final stage in each patient was confirmed by 
pathological examination when available or through radiologic and 
clinical examinations/follow-up. Sensitivity, specificity, accuracy and 
the correlation of WB-MRI and PET-CT were evaluated.
Results: Patients with advanced staging (III-A, III-B and IV) were 
more common with 32 (66.7%) cases than patients with non-ad-
vanced staging (IA, IB, II-A and II-B) with 16 (33.3%) cases. The av-
erage lesion size was 48 mm + / - 24 mm in PET / CT and 50 mm 
+ / - 24 mm in WBMRI with no significant differences (p=0.39). 
Sensitivity, specificity, positive predictive value (PPV), negative 
predicitive value (NPV) and accuracy of WB-MRI were 96, 78, 91, 
81 and 84% for tumor assessment; 100, 71, 82, 100 and 86% for 
lymphonode assessment and 81, 93, 80, 95 and 83% for metastasis 
assessment, respectively. The overall correlation between WB MRI 
and PET/CT was 0,72 (0,52-0.96).
Conclusion: WBMRI demosntrates high correlation with PET/CT 
and satisfactory levels of sensitivity, specificity and accuracy in the 
NSCLC staging. These results emphasize that WBMRI can be in-
cluded as an alternative tool for NSCLC staging.
Keywords: Lung Cancer, Staging, MRI, PET-CT
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PLEURAL EFFUSION SIZE AS A PROGNOSTIC MARKER IN 
PATIENTS WITH MALIGNANT PLEURAL EFFUSION; A RET-
ROSPECTIVE CASE SERIES STUDY
Luis Ugalde Gamboa1, María Felicia Montero-Arias1, Jose Rojas 
Solano1, Allan Ramos-Esquivel2, Luis Corrales-Rodriguez3, Rodrigo 
Cartin-Ceba4  
1Hospital Mexico-Ccss, Division Of Pulmonology, San José/COSTA RICA, 2Univer-
sity Of Costa Rica, Department Of Pharmacology, San José/COSTA RICA, 3Hos-
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Background: Malignant pleural effusion (MPE) develops when 
tumor cells directly infiltrate the pleura and denote a reduced life 
expectancy. Palliative treatment options are based on tumor type, 
functional status, pleural apposition and expected survival. Multiple 
studies have attempted to define early predictors of mortality in 
these patients. However some controversies exist, some studies have 
found a correlation between biochemical parameters and survival 
while others have failed. Etiology and prognostic significance of 
clinical, biochemical and radiological features of malignant pleural 
effusions have not been yet evaluated in our population. 
Methods: 110 patients with malignant pleural effusion confirmed 
by pleural cytology or biopsy attended at Hospital Mexico, Costa 
Rica from January 2008 to July 2013 (5-year-period) were included 
in this retrospective cohort study. Clinical data, radiologic features 
and biochemical analysis were collected from the medical records. 
Patients were sub classified in 4 groups according to the size of ef-
fusion in a posterior-anterior-thorax-radiography (<25%, 25-50%, 
50-75%, and >75% or massive effusion).
Results: Of the total population, 65% were women and the mean 
age was 61±15 years (ranges, 18-86). Dyspnea (85%) and chest pain 
(45%) were the main symptoms experienced. All MPE were lym-
phocytic infiltrates with a mean glucose of 108±54mg/dL, LDH of 
515±580UL/mL, protein of 4.1±0.5 and pH ±0.2. Most frequent 
causes of MPE were lung cancer (36%) followed by breast cancer 
(31%), GU tumors (14%), lymphoma (6%), other tumors (5%) and 
unknown primary (4%). Mean survival of entire population was 8,3 
months (range 25-426 days) while median survival was 3 months. 
Using Kaplan-Meier method, no difference in survival based on 
tumor type was noted (p=0.812). There was no prognostic advan-
tage when patients were categorized by quartile distribution of 
age, pH and glucose. The only variable predictive of survival that 
achieved statistical significance was the size of pleural effusion. 
For each increase in size of 25%, mortality raised 1,78 times (con-
fidence interval of 95%, p<0.001). Patients with MPE < 50% had a 
significant better survival than those with MPE > 50%, with a medi-
an overall survival of 15,7 months compared to 5,7 months (HR: 1.71; 
95% CI=1.06-2.78; p=0.0026) (Figure 1).
Conclusion: Our study provides the one of the first analysis of 
MPE in a Latin American population, and demonstrates a signifi-
cant association between pleural effusion size and survival. There-
fore, chest Rx can be used as a predictive tool of survival in patients 
with MPE, especially in developing countries were a CT scan in 
not always available. This may aid clinicians in the decision making 
process in the management and treatment of MPE.
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